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Abstract
Information about cerebral blood flow (CBF) is valuable for clinical management of patients after severe brain
injury. Unfortunately, current modalities for monitoring brain are often limited by hurdles that include high
cost, low throughput, exposure to ionizing radiation, probe invasiveness, and increased risk to critically ill
patients when transportation out of their room or unit is required. A further limitation of current technologies
is an inability to provide continuous bedside measurements that are often desirable for unstable patients.
Here we explore the clinical utility of diffuse correlation spectroscopy (DCS) as an alternative approach for
bedside CBF monitoring. DCS uses the rapid intensity fluctuations of near-infrared light to derive a
continuous measure of changes in blood flow without ionizing radiation or invasive probing. Concurrently, we
employ another optical technique, called diffuse optical spectroscopy (DOS), to derive changes in cerebral
oxyhemoglobin (HbO2) and deoxyhemoglobin (Hb) concentrations. Our clinical studies integrate DCS with
DOS into a single hybrid instrument that simultaneously monitors CBF and HbO2/Hb in the injured adult
brain.
The first parts of this dissertation present the motivations for monitoring blood flow in injured brain, as well as
the theory underlying diffuse optics technology. The next section elaborates on details of the hybrid
instrumentation. The final chapters describe four human subject studies carried out with these methods. Each
of these studies investigates an aspect of the potential of the hybrid monitor in clinical applications involving
adult brain. The studies include: (1) validation of DCS-measured CBF against xenon-enhanced computed
tomography in brain-injured adults; (2) a study of the effects of age and gender on posture-change-induced
CBF variation in healthy subjects; (3) a study of the efficacy of DCS/DOS for monitoring neurocritical care
patients during various medical interventions such as head-of-bed manipulation and induced hyperoxia; and
(4) a first feasibility study for using DCS to study hemodynamics at high altitudes.
The work presented in this dissertation thus further develops DCS/DOS technology and demonstrates its
utility for monitoring the injured adult brain. It demonstrates the promise of this new clinical tool to help
neurocritical care clinicians make more informed decisions and thereby improve patient outcome.
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ABSTRACT
APPLICATIONS OF HYBRID DIFFUSE OPTICS FOR CLINICAL MANAGEMENT
OF ADULTS AFTER BRAIN INJURY
Meeri Nam Kim
Arjun G. Yodh
Information about cerebral blood flow (CBF) is valuable for clinical management of
patients after severe brain injury. Unfortunately, current modalities for monitoring brain
are often limited by hurdles that include high cost, low throughput, exposure to ionizing
radiation, probe invasiveness, and increased risk to critically ill patients when transportation
out of their room or unit is required. A further limitation of current technologies is an
inability to provide continuous bedside measurements that are often desirable for unstable
patients.
Here we explore the clinical utility of diffuse correlation spectroscopy (DCS) as an
alternative approach for bedside CBF monitoring. DCS uses the rapid intensity fluctuations
of near-infrared light to derive a continuous measure of changes in blood flow without
ionizing radiation or invasive probing. Concurrently, we employ another optical technique,
called diffuse optical spectroscopy (DOS), to derive changes in cerebral oxyhemoglobin
(HbO2) and deoxyhemoglobin (Hb) concentrations. Our clinical studies integrate DCS
with DOS into a single hybrid instrument that simultaneously monitors CBF and HbO2/Hb
in the injured adult brain.
vi
The first parts of this dissertation present the motivations for monitoring blood flow in
injured brain, as well as the theory underlying diffuse optics technology. The next section
elaborates on details of the hybrid instrumentation. The final chapters describe four hu-
man subject studies carried out with these methods. Each of these studies investigates an
aspect of the potential of the hybrid monitor in clinical applications involving adult brain.
The studies include: (1) validation of DCS-measured CBF against xenon-enhanced com-
puted tomography in brain-injured adults; (2) a study of the effects of age and gender on
posture-change-induced CBF variation in healthy subjects; (3) a study of the efficacy of
DCS/DOS for monitoring neurocritical care patients during various medical interventions
such as head-of-bed manipulation and induced hyperoxia; and (4) a first feasibility study
for using DCS to study hemodynamics at high altitudes.
The work presented in this dissertation thus further develops DCS/DOS technology and
demonstrates its utility for monitoring the injured adult brain. It demonstrates the promise
of this new clinical tool to help neurocritical care clinicians make more informed decisions
and thereby improve patient outcome.
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Chapter 1
Introduction
The overarching goal of the research described in this dissertation is to investigate the fea-
sibility of hybrid diffuse optics – a combination of diffuse optical spectroscopy (DOS) and
diffuse correlation spectroscopy (DCS) – as a method to quantitatively measure cerebral
hemodynamics in adults after severe brain injury. This introductory chapter will elaborate
on two types of severe brain injury that affected the majority of patients in our clinical stud-
ies, and it will also describe the modalities currently employed for neuromonitoring. The
remainder of the thesis includes a chapter on the theory of diffuse optics, i.e., DCS theory,
and a chapter that details the instrumentation and quality testing. The final four chapters
each describe successful studies in humans that explore and demonstrate the feasibility for
using hybrid diffuse optics on adult brain in practice, with an emphasis in problems related
to management of those with brain injury.
1
1.1 Traumatic Brain Injury
Traumatic brain injury (TBI) occurs when a sudden force on the head such as a bump, blow
or jolt, causes damage to the brain. The majority of TBIs that occur are mild forms such
as a concussion. The most common cause of TBI is falling, especially for children and the
elderly. Falls cause 50% of all TBIs for children younger than 14 years of age, and 61% of
all TBIs for those older than 65 [65]. Other causes include motor vehicle accidents, struck
by/against events, assault/violence, and blast injuries.
According to a report by the Centers for Disease Control and Prevention [65], there
are 1.7 million cases of TBI per year in the United States, with 275,000 requiring hospi-
talization, 80,000 causing permanent disabilities, and 52,000 causing death. The estimated
direct medical and indirect costs of TBI total about $60 billion dollars nationally (i.e., as
measured in 2000 [232, 68]). Worldwide, injury due to falls and traffic accidents is ranked
as the fourth-highest cause of life years lost due to both death and disability [162]. More
men suffer from TBI than women in all age groups [65], and males comprise about 75% of
all TBIs in young people [140].
TBI is classified by mechanism, clinical severity, and computed tomography (CT) as-
sessment of structural damage. Mechanism includes whether the injury is closed, e.g.,
when the skull remains intact, or penetrating. Clinical severity is typically indicated by the
patient’s post-resuscitation Glasgow Coma Scale score. The Glasgow Coma Scale (GCS)
was developed in 1974 by Graham Teasdale and Bryan Jennett, two professors of neu-
rosurgery at the University of Glasgow [229]. It was developed to assess the depth and
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Table 1.1: Glasgow Coma Scale
Eye opening Motor response Verbal response
Spontaneous 4 Normal 6 Normal conversation 5
To voice 3 Localized to pain 5 Disoriented conversation 4
To pain 2 Withdraws to pain 4 Words, but not coherent 3
None 1 Decorticate posture 3 No words, only sounds 2
Decerebrate 2 None 1
None 1
duration of impaired consciousness and coma, and it is currently used as the universal clas-
sification of TBI severity. However, the reader should be aware that a patient’s GCS score
can be easily confounded by medical sedation, paralysis, or intoxication [9, 222].
The GCS score ranges from 3 (comatose) to 15 (normal), and it is divided into three
independently measured aspects of behavior – eye opening, motor responsiveness, and
verbal performance (see Table 1.1). Mild TBI (typically a concussion) includes a post-
resuscitation GCS score of 13 to 15; even mild TBI has been found to cause longer term
effects like persistent headaches and memory issues [188]. If a patient has a GCS score of
9 to 13, as is usually found in stuporous or lethargic conditions, then he or she would be
classified as having suffered a moderate TBI. Lastly, severe TBI victims have a GCS of 3 to
8, and they are usually found comatose, i.e., unable to open their eyes or follow commands.
For instance, one of the severe TBI patients we studied was an 18 year old male pedestrian
who was hit by a car and thrown 100 ft; his GCS score at the scene of the accident was a 3,
the worst possible score.
Damage from the initial insult commonly includes shearing of white-matter tracts (bun-
dles of axons that connect different parts of the brain together), focal contusions (bruises
that cause swelling, bleeding, and destruction of brain tissue), hematomas (an expanding
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mass of blood in the brain), and torn blood vessels. Such injuries cause a cascade of reac-
tions by the body, including neurotransmitter release and inflammation, and these reactions
may inflict eventual secondary damage (see Section 1.3).
Thankfully, mortality from severe TBI has fallen drastically over the past 30 years [75].
In the 1970s, the mortality rate was at about 55%, and now it is at about 20 to 30%, in
part due to the advent of critical care, routine CT scanning, and monitoring of intracranial
pressure (ICP). Studies have shown that patient recovery typically depends on the severity
of initial and injuries, treatment received, and patient’s genotype [230].
1.2 Aneurysmal Subarachnoid Hemorrhage
Subarachnoid hemorrhage (SAH) is when bleeding occurs in the subarachnoid space of
the brain. There are three membranes that envelop the central nervous system – the dura
mater, the arachnoid mater, and the pia mater. The subarachnoid space is situated between
the arachnoid and pia mater. Bleeding in this space may arise from a ruptured cerebral
aneurysm or as a result of TBI, and is thus usually prefaced by ”aneurysmal” or ”traumatic.”
This section will focus on aneurysmal SAH only.
The vast majority of SAH – up to 85% – is caused by a ruptured saccular aneurysm at
the base of the brain [237, 241, 117, 238]. An aneurysm occurs when there is a weakened
area in a vessel wall that becomes a balloon-like structure. They develop in certain people
over the course of life, but not others; reasons for this are unknown [237]. However, risk
factors include hypertension, smoking, and alcohol abuse [231]. Also, women are 1.6 times
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Table 1.2: Hunt-Hess Scale
Category Criteria % Dead
Grade I Asymptomatic, or minimal headache 7/61 = 11%
and slight neck stiffness
Grade II Moderate to severe headache, neck stiffness, 23/88 = 26%
no neurological deficit other than cranial nerve palsy
Grade III Drowsiness, confusion, or mild neurological deficit 29/79 = 37%
Grade IV Stupor, moderate to severe hemiparesis, possibly early 25/35 = 71%
decerebrate rigidity and vegetative disturbances
Grade V Deep coma, decerebrate rigidity, moribund appearance 12/12 = 100%
more susceptible to SAH as men [224].
Aneursymal SAH has a high rate of death and complications. About 10% of deaths from
SAH occur before the patient can even receive medical attention, and 25% occur within 24
hours of the initial rupture [21]. The fatality rate for SAH is approximately 51%, with 40%
death within only one month of hospitalization, and one third of survivors needing lifelong
care [100, 198, 175].
Several classification systems exist for SAH: GCS, the Hunt and Hess scale, and Fisher
grade. GCS score (see Section 1.1), used for severe TBI, is also used to assess conscious-
ness in SAH patients. The Hunt and Hess scale (see Table 1.2) was intended to gauge sur-
gical risk and to decide the appropriate time after SAH at which the neurosurgeon should
operate [194, 104]. It is commonly used by the neurocritical care community, although it
has drawbacks, e.g., the terms used to define the grades are fairly vague and subjective. Ta-
ble 1.2 also shows the percentage of patients that died at each grade from Hunt and Hess’s
original study [104].
The Fisher grade (see Table 1.3) classifies patients by the amount of subarachnoid blood
detected by CT. Fisher et al. determined that the amount and distribution of subarachnoid
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Table 1.3: Fisher Scale
Grade CT Scan
1 No blood visualized
2 A diffuse deposition or thin layer with all vertical layers of blood < 1 mm thick
3 Localized clots and/or vertical layers of blood ≥ 1 mm in thickness
4 Diffuse or no SAH blood, but with intracerebral or intraventricular clots
blood after aneurysm rupture strongly correlates with the later development of vasospasm,
i.e., a condition in which blood vessels spasm and narrow [70]. The more blood, the higher
the risk of developing cerebral vasospasm. The danger of vasospasm lies in that it causes
the spasming artery to shut down, and the part of the brain supplied by that artery then can
become ischemic and die. Cerebral vasospasm typically develops between days 4 and 12
after injury, and is most likely due to an inflammatory reaction in the blood-vessel wall
[224].
1.3 Dangers of Secondary Injury
For both TBI and SAH patients, the secondary injury can be often as dangerous as the
primary injury. The primary injury is the initial insult, such as when a hard object strikes
the head for TBI or aneursym bursting for SAH. The secondary injury evolves after the
primary injury over hours and days, often while patients are under neurocritical care.
For TBI patients, complications usually arise due to brain swelling. It is the leading
cause of in-hospital deaths, post-TBI [143]. Swelling occurs due to a cascade of reac-
tions by the body after acute injuries, such as neurotransmitter release and inflammatory
response. For those suffering from SAH, complications due to the initial hemorrhage, cere-
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bral vasospasm and rebleeding are the biggest secondary injury dangers [163]. Vasospasm
and rebleeding each directly cause almost a quarter of deaths due to SAH [216].
Hemorrhaging and brain swelling due to the initial insult cause ICP to increase. ICP
is the pressure exerted by the cranium onto the brain tissue, cerebrospinal fluid and blood
volume. Cerebral perfusion pressure (CPP), defined as the difference between mean arterial
pressure (MAP) and ICP, is the net pressure driving flow of blood to the brain. When ICP
rises due to the increase of fluid within the skull, CPP drops. Or in the case of cerebral
vasospasm, the narrowing of the artery causes CPP to drop. This drop in CPP causes a
drop in cerebral blood flow (CBF), which in turn decreases the blood supply to the brain,
and can lead to ischemia and tissue death.
The main principles of ICP [6] are the following:
• The brain is enclosed in a non-expandable case of bone.
• The brain’s grey and white matter is nearly (but not perfectly) incompressible.
• The volume of blood that can occupy the cranial cavity is nearly constant.
• Continuous outflow of venous blood from the cranial cavity is required to make room
for continuous incoming blood.
A non-linear pressure-volume model describing the relationship between ICP and in-
tracranial volume has been determined, pictured in Figure 1.1 [221]. In the flat regime, at
lower intracranial volumes, ICP is low and stable with good compensatory reserve; in this
scenario, some cerebrospinal fluid and intracranial blood are able to leave the cranium if
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Figure 1.1: Intracranial pressure-volume curve. A normal intracranial pressure (ICP)
ranges from 0-10 mmHg (flat regime) for an adult human, while 15-25 mmHg marks the
point at which treatment should begin to reduce ICP (upward regime). Any higher than 25
mmHg marks the plateau regime where the cerebral arterial bed begins to collapse.
need be. This regime is the typical condition for a healthy individual at rest. The rapidly
rising upward regime is where that compensatory reserve begins to be spent, resulting in
a sharp rise in ICP even with a small increase in intracranial volume. Lastly, the curve
plateaus at the so-called ”critical pressure.” In this regime, the compensatory reserve is
completely spent, and at this point, the cerebral arterial bed will collapse and blood is
unable to reach tissues. This last regime is the zone wherein most severely brain-injured
patients reside, and this regime is a signal for increased danger due to secondary injury.
Methods for monitoring ICP are described in Section 1.4.2. A normal ICP ranges from
0-10 mmHg, while 15-25 mmHg marks the point at which treatment should begin to reduce
ICP [75]. The first line of defense against high ICP is draining cerebrospinal fluid (CSF),
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the fluid that occupies the subarachnoid space that acts as a cushion for the cortex. If
draining isn’t enough, clinicians will sometimes use hyperventilation. By increasing the
patient’s ventilator breath rate, hyperventilation will cause vasoconstriction, a drop in CBF,
and thus lower ICP. However, there is a risk, in this case, of worsening ischemia. Another
technique to manage high ICP is osmotherapy, which is a method of inducing dehydration
usually via drugs, in order to reduce accumulated fluid in the brain. The last resort is
decompressive craniotomy; this procedure involves removing a substantial portion of the
cranium and opening the dura in order to allow the brain’s volume to increase against
”atmospheric pressure” and thus relieve pressure. Figure 1.2 shows CT scans from an
SAH patient who participated in one of our studies that required a craniotomy. Notice the
large portions of skull (bone shows up as white in CT) that are missing from the patient,
suggesting that major intervention was required to prevent further crushed brain tissue.
1.4 Imaging and Monitoring the Injured Adult Brain
The patients residing in the neurocritical care unit have a wide range of injuries. Even
within a single injury category, patient population can be very heterogenous. For instance,
those with TBI have only one unifying factor among them, i.e., brain damage resulted from
external forces. This reason is often cited for the numerous failed randomized clinical
trials; none in the last 25 years has convincingly shown efficacy, as in they have shown no
significant improvement in patient outcomes [164]. Even though standardized treatment
protocols exist [19, 75], individualized approaches determined by monitoring are being
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Figure 1.2: CT scans from an aneurysmal subarachnoid hemorrhage patient who had a
decompressive craniotomy. Bone shows up as white in the CT, while brain tissue is a light
grey. Note the large amount of skull that has to be removed in this case, suggesting that a
major (and probably last resort) intervention was required to prevent crushed brain tissue
from elevated ICP.
explored as a better alternative to improve outcomes [140].
Neuromonitoring of 30 or 40 years ago would generally only alert clinicians of a pa-
tient’s deteriorating condition when it was irreversible. Today, clinicians know the broad
strokes of management to try to prevent occurrences of high ICP, etc. Neuromonitoring of
the future should be even more proactive and goal-oriented for each patient [247].
This section focuses on current neuromonitoring techniques used for those patients who
have suffered from severe brain injury. I describe the most common modalities employed
by clinicians in the neurocritical care unit, both to assess initial injury and for following the
dynamic progression of a patient’s condition. The section is divided into parameters mea-
sured, with details of the various options available under each subsection: neuroimaging
for structural damage/changes, intracranial pressure, cerebral perfusion pressure, cerebral
blood flow, and cerebral oxygenation.
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1.4.1 Neuroimaging
The most common type of neuroimaging performed on brain-injured patients is structural,
i.e., rather than functional. Structural imaging probes the morphological details of the
structures of the brain, while functional imaging probes actual cerebral processes.
CT uses X-rays to produce high-resolution structural images of the body, with contrast
provided by the degree of X-ray attenuation. Imaging with CT is quick and easy, both
beneficial for scanning patients that are agitated and/or unstable [38]. CT scanning is typ-
ically one of the first studies performed on patients with severe TBI or suspected SAH.
For TBI, patients that have been stabilized are typically examined by CT to identify mass
lesions such as hematomas that need to be dealt with surgically. For example, the removal
of such lesions soon after initial injury can have a profound improvement on mortality, thus
reinforcing the importance of CT imaging [205, 91].
CT, however, cannot detect lesions at the microscopic level. For example, it cannot
detect diffuse axonal injury (DAI). DAI is damage that has occurred over a widespread
area due to shearing of tissues in the white matter. DAI thus affects the neuronal axons.
Magnetic resonance imaging (MRI) can detect white matter abnormalities better than CT,
but MRI is not commonly used in the acute phase due to various logistical complexity
[38]. Repeated CT radiation exposure plagues CT, and is said to be responsible for 2%
of all cancer cases in the United States [20]. Also, both MRI and most CT requires the
patient to be taken from their room into an imaging suite, a process which puts the patient
at additional risk [248].
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CBF is the blood supply to the brain in a given time, and is typically given in units of
mL per 100 g per minute. It can be measured with modified methods using MRI and CT,
such as arterial spin-labeled perfusion MRI and stable xenon-enhanced CT (XeCT). Stable
non-radioactive 131Xe is radio-opaque, highly lipid-soluble, and diffusive tracer capable of
traveling through the blood-brain barrier [176, 258]. It provides a quantitative measure of
blood flow based on a modification of the Fick principle, which states that the amount of
oxygen uptake of each unit of blood as it passes through the lungs is equal to the oxygen
concentration difference between the arterial and mixed venous blood [119]. The patient
inhales a xenon + oxygen mixture, and the increase seen in CT contrast relates to the
increase of xenon concentration in the tissue, an effect which permits estimation of blood
flow. End-tidal xenon concentration is assumed to be proportional to arterial concentration.
The results are six CBF maps, each from a different slice of brain; Figure 1.3 shows two
slices from the same patient, before and after a blood pressure manipulation that decreased
perfusion. More details about XeCT can be found in Chapter 4, where we validate DCS
against XeCT measurements of CBF.
All neuroimaging techniques have the prominent drawback of only capturing momen-
tary snapshots of the patient’s condition. Because severe brain injury is such a dynamically
evolving process, it is desirable for clinicians to have continuous feedback in order to decide
on the best methods of treatment. Thus, the term ”multimodal monitoring” has gained trac-
tion in the neurocritical care community to describe continuous monitoring of numerous
parameters and thus rapidly update and inform clinicians of the patient’s evolving condi-
12
Figure 1.3: Example CBF maps from an SAH patient imaged with stable xenon-enhanced
CT. A medication was given to increase blood pressure, and baseline (XeCTBL) and post-
intervention (XeCTIN ) scans showed an overall CBF decrease. A color scale showing level
of absolute CBF is shown, with blue representing very low flow and red representing very
high flow, quantified in mL/100g/min.
tion. The next sections describe a few of these parameters and techniques for monitoring
them.
1.4.2 Intracranial Pressure
First used in the 1960s [136], ICP monitoring has since been the most universally accepted
neuromonitoring technique by clinicians [53]. The gold standard method for measuring
ICP is via intraventricular catheter. A small burr hole is drilled in the skull, and a catheter
is passed into one of the lateral ventricles. The catheter is connected to an external pressure
transducer. Ventriculostomy has the benefit of allowing for both monitoring and treatment.
CSF can be drained as a first effort to relieve elevated ICP, as mentioned in Section 1.3,
and also to acquire samples for metabolite analysis. It is also known as the most accurate,
low-cost, and reliable method for measuring ICP [19].
The main drawback of the intraventricular catheter is the risk of infection or signifi-
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cant hemorrhage. However, most clinicians believe that the benefits of ICP information
outweigh the risks. Hematomas associated with ventriculostomy had an average incidence
of 1.1% in a review of eight studies [19], while risk of infection in two other studies was
found to be about 11% [146, 8].
Other methods for monitoring ICP include subdural, subarachnoid, and epidural probes.
These may be less invasive than intraventricular probes, but they have proven themselves
to be not as accurate.
1.4.3 Cerebral Perfusion Pressure
Monitoring ICP means CPP can be calculated as well. However, unlike ICP, no target
thresholds for upper and lower limits of CPP have been agreed upon [7, 196]. Usually
clinicians aim to increase CPP levels in order to increase perfusion, but this is only the case
if cerebral autoregulation is damaged.
Cerebral autoregulation is a homeostatic phenomenon wherein blood vessels will dilate
or constrict in order to keep CBF relatively constant despite changes in CPP, within the
range of 50 to 150 mmHg [173]. Below or above this range, the relationship between CPP
and CBF is linear. This linear behavior occurs when autoregulation is impaired, which often
happens to brain-injured patients. Thus, an increase in CPP will only lead to an increase
in CBF when CPP is either outside the autoregulatory range or when autoregulation is
damaged.
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1.4.4 Cerebral Blood Flow
Severe head injury leaves patients at risk of cerebral ischemia due to secondary injury as
described in Section 1.3. Inadequate perfusion likely increases the probability of a poor
outcome, but no standard method of directly measuring CBF has been widely accepted for
use in neurocritical care. This could be due to the fact that thresholds for absolute CBF are
unclear [221].
CBF may be measured by the so-called Kety-Schmidt technique [119], wherein the
arterial and jugular venous concentrations of a contrast agent such as nitrous oxide are
measured, and global CBF is calculated from the tissue uptake rate. However, the Kety-
Schmidt technique can only give a measure of non-continuous global CBF.
Thermal diffusion and laser Doppler probes are both microsensor methods of contin-
uously monitoring CBF. The thermal diffusion flowmetry (TDF) method is based on the
temperature difference measured by a thermistor (heated to a few degrees above tissue
temperature) and a temperature probe [235]. The temperature difference can be translated
to a quantitative measurement of CBF. The probe is implanted through a burr hole either
directly into the white matter or on the cortex; thus, TDF an invasive measure of microvas-
cular blood flow [221].
Laser Doppler flowmetry (LDF) uses the Doppler shift of light – the frequency change
that light undergoes when it reflects off of moving red blood cells – to measure flow in
superficial volume under the probe [81]. It consists of a low power laser source and detector
placed a small distance apart that penetrates only to a depth of about a millimeter. Thus to
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measure cortical flow, it must be used in an invasive way.
Both TDF and LDF are invasive regional measures of CBF, and thus only a limited
number of such probes may be implanted in patients. This means that only a small region
of CBF may be measured in a single patient, and thus the diagnostic output may not be
reflective of other areas of the injured brain. Although both techniques measure microvas-
cular flow, they are also restricted to the white matter due to logistical issues with probe
placement. While TDF can give an absolute measure of CBF, LDF only provides a rela-
tive measure [18]. However, presently neither of these techniques have become standard in
the neurointensive care unit, most likely due to the substantial operator expertise required
[247].
One technique that measures not flow, but cerebral blood flow velocity (the rate at
which blood moves through a particular vessel), has increasingly become commonplace for
neurocritical care clinicians: transcranial Doppler (TCD) ultrasound. An ultrasound probe
emits a high-pitched sound wave that scatters, and the speed of the blood in relation to the
probe causes a phase shift, which is then translated into blood velocity [219]. TCD has
become a standard way to diagnose vasospasm after SAH, defined as a mean flow velocity
of over 200 cm/s. Being non-invasive, it is often performed daily at the bedside to get a
snapshot of the patient’s flow velocities, but TCD is logistically challenging to implement
continuously for days or even hours. It also does not involve any ionizing radiation or
contrast agents.
However, efficient diagnosis with TCD requires much experience and skill, and it holds
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the risk of being highly operator dependent [256]. The operator utilizes the thin portion of
the skull as an acoustic window to permit penetration of ultrasound waves to the intracranial
blood vessels. However, if the acoustic window is inadequate or not sufficiently transparent,
that can limit TCD use in certain patients [182]. It also only measures macrovascular flow
velocity, or blood flow velocity in the large vessels of the brain, which does not necessarily
reflect microvascular perfusion in patients with cerebrovascular disease [184]. For this
reason, any focal microvascular CBF impairments may still return a normal TCD diagnosis.
1.4.5 Cerebral Oxygenation
Similarly, just as invasive intracranial pressure monitoring to derive CBF is a routine part
of patient care in the neurointensive care unit, many clinicians rely on invasive monitors
for measurement of brain oxygen levels. The most commonly used method is jugular bulb
oximetry. It involves sampling the blood of the jugular bulb, which is the cranial tip of the
internal jugular vein that contains pure cerebrovenous blood [87]. The result is an invasive,
global measurement of jugular venous oxygen saturation. This technique, however, has
been critiqued as somewhat fraught with technical problems and non-reflective of regional
cerebral metabolic changes [87, 42, 47, 249].
Some neurointensivists utilize invasive electrodes to measure the partial pressure of
brain tissue oxygen (PbtO2) [139, 239, 133]. This technique involves the intraparenchymal
insertion of a Clark type electrode, which generates a current dependent on the amount of
oxygen near the catheter tip. These monitors provide continuous monitoring of cerebrovas-
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cular oxygenation, but they are also invasive, and their measurements are limited to a small
(∼mm3) volume of white matter tissue.
1.5 Potential Role of Hybrid Diffuse Optics
In the work presented within this dissertation, we validate and explore hybrid diffuse opti-
cal monitoring – as in, the combination of DOS + DCS in a single instrument/probe setup
– as a means to non-invasively and continuously measure microvascular CBF and blood
oxygenation in a neurocritical care population. DOS measures tissue oxygen levels based
on the different absorption properties of oxy- and deoxyhemoglobin [244, 96], while DCS
measures CBF by using the intensity fluctuations of light scattered many times from mov-
ing red blood cells [13, 15, 177, 142]. Having both blood flow and oxygenation informa-
tion can better elucidate the patient’s condition, as they can give correlated or uncorrelated
trends.
DOS, more commonly called near-infrared spectroscopy (NIRS) by clinicians, has been
studied previously in brain-injured patients. Specifically, DOS has been compared to in-
vasive electrode monitors [123, 3, 98, 197, 22, 4], as a means of detecting intracranial
hemorrhage and contusion [95, 220], as a surrogate approach to measure of CBF using
tracers [118], and, more recently, as a measure of autoregulation in stroke patients [59, 88].
Thus far, DCS has been used to study autoregulatory function in stroke patients [59] and to
study CBF in ill neonates [24, 23, 25, 191].
Hybrid diffuse optics holds potential to be a useful neuromonitoring tool for this pa-
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tient population because of its continuous output, its non-invasive nature, its ability to put
multiple probes on different locations on the head, and its lack of ionizing radiation. This
dissertation further explores the feasbility and applications of DCS/DOS. Chapters 2 and
3 describe underlying theory in detail, as well as recent instrumentation advances. Both
chapters are geared towards the application of DCS/DOS for monitoring adult brain. The
basic hybrid diffuse optical device used in the experiments featured in this dissertation is
also outlined in depth, particularly the DCS module.
Chapter 4 presents a validation study of DCS-measured CBF against a gold-standard
technique that measures absolute CBF: stable xenon-enhanced CT. Importantly, this suc-
cessful validation is performed on neurocritical care patients, since this injured population
is of central interest to us here.
The next chapter (Chapter 5) appears to be a departure from the application of DCS/DOS
in those with brain injury, in that we looked at healthy subjects across the age continuum
during a posture change. However, it originally began as a way to quantify the normative
response during head-of-bed manipulation – a common intervention in the neurocritical
care unit. We found that age did not have an effect on CBF responses to posture change,
but that the healthy response was clearly differentiated against the brain-injured population.
Chapter 6 investigated cerebral hemodynamics during head-of-bed manipulation in pa-
tients after severe brain injury. We chose head-of-bed manipulation because of its ease of
implementation, as well as the fact that it is a commonly performed intervention in the
neurocritical care unit. Not only did we find that the patient response differed significantly
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from the normative response, but we also found that the heterogeneity of the patients re-
vealed itself through a widely varying CBF response to head lowering. This result supports
arguments for individualized patient management, and indicates how hybrid diffuse optics
could add useful information to further guide clinicians and to customize treatment.
The final chapter (Chapter 7) studies humans at high altitude. While many people work
at and are stationed at high altitudes, our understanding of cerebral hemodynamics in such
an environment is quite limited. Cerebrovascular stress in the form of acute mountain
sickness or the potentially fatal high altitude cerebral edema can put people who live above
2400 m at risk. Our investigation successfully implemented DCS at high altitude for the
first time, and it measured changes in CBF during a hyperventilation task at high altitude.
The results in this dissertation have led to three publications [120, 61, 121], with an-
other currently in preparation (based on results from Chapter 7). Notably, my validation
publication [120] was the first paper featuring DCS in human brain studies to break through
the clinical journal barrier (i.e., Neurocritical Care for neurosurgeons). At this stage, it is
important for us to aim for clinical journals, because wider audience among doctors will
help push DCS/DOS technology into the clinic. I am also a co-author on several other pub-
lications with members of this lab and our collaborators [24, 59, 58, 154, 212, 156, 141].
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Chapter 2
Theory of Diffuse Optics
Diffuse optical methods can non-invasively measure tissue optical properties and tissue
dynamics millimeters to centimeters below the surface of the skin. This chapter outlines the
basic theory behind the two optical monitoring techniques we use to probe hemodynamics
in the adult brain: diffuse optical spectroscopy (DOS) and diffuse correlation spectroscopy
(DCS). Diffuse optical spectroscopy, also called near-infrared spectroscopy (NIRS), is used
to probe slow variations in absorption and scattering of biological tissues due to changes
in the concentrations of tissue chromophores. Diffuse correlation spectroscopy utilizes the
fast intensity fluctuations of scattered light to characterize the movement of red blood cells,
i.e., to provide a measure of relative blood flow.
Both techniques take advantage of the so-called ”therapeutic window” of common bi-
ological tissue chromophores wherein the absorption of light is low [112]. This window
(from about 650 nm to 900 nm) lies between the visible absorption bands of hemoglobin
and the near-infrared absorption band of water. Figure 2.1 shows the full absorption spectra
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of the main chromophores in tissue – oxyhemoglobin, deoxyhemoglobin, water, and lipid;
it also shows a close-up of the therapeutic window optical range. µa(λ), the absorption
coefficient, has units of cm−1 and is the reciprocal of the absorption length, or the typical
distance traveled by a photon before it becomes absorbed. µa(λ) is a very important ”opti-
cal property” that characterizes the tissue medium, since it depends on the concentrations
of oxyhemoglobin, deoxyhemoglobin, water, and lipid.
The low absorption of hemoglobin, water, and lipid in this near-infrared window allow
light to penetrate to deeper regions of tissue. When this discovery was made, it was then
speculated that near-infrared light could non-invasively probe the workings of the brain
through skull and scalp. While light can penetrate through the skull and into the brain, tis-
sue is a highly scattering medium, and a model had to be derived to understand the process
of photon propagation through such a turbid substance. It was found that light transport
through such turbid media over longer distances can be well-approximated by a diffusive
model. This model applies when light scattering dominates rather than absorption, i.e., the
photon scattering length are much smaller than the absorption length. In this regime, one
is able to separate out of the two effects.
The scattering equivalent to the absorption length, the wavelength-dependent scattering
length is defined as the typical distance traveled by a photon before being scattered. The
reciprocal of this distance is µs(λ), called the scattering coefficient. However, we typically
use a different and arguably more important parameter to characterize scattering called the
reduced scattering coefficient and denoted by µ′s(λ). This reduced scattering coefficient is
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Figure 2.1: (top) Absorption spectra of common biological tissue chromophores in the
range 250 to 1000 nm – oxygenated hemoglobin (HbO2), deoxygenated hemoglobin (Hb),
water, and lipid. Absoprtion is quantified by µa, the absorption coefficient. (bottom)
Zoomed-in spectra, the so-called ”therapeutic window” from 650 to 950 nm where the
absorption of tissue chromophores is relatively low. This lack of absorption allows light
within this window to penetrate up to centimeters deep into biological tissues to probe
chromophore concentrations.
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the reciprocal of one photon random walk step, or the distance a photon travels before its
direction becomes randomized. It depends on both µs and the degree of forward scattering
anisotropy of a typical scattering event. If the photon propagation is well-modeled, one
can readily calculate the concentration changes of tissue chromophores in the brain such
as oxy- and deoxyhemoglobin. This is the DOS technique that is oriented towards these
concentration measurements.
The work in this dissertation focused not only on blood oxygenation, but also on blood
flow. DCS is a technique that also uses the diffusive behavior of light in tissue, but tracks
the fast fluctuations of light due to scattering off of moving red blood cells in order to
derive a measure of flow. It shares the same advantages of DOS with respect to looking at
deeper tissues, and so it is natural to use the two together to obtain information about blood
hemodynamics in order to paint a fuller picture of brain physiology.
In this chapter, we will first outline the basic theory behind DOS, starting from the
radiation transport equation and deriving the photon diffusion equation. Two different ge-
ometries will be discussed: the infinite medium and the semi-infinite medium. Much of
the oxygenation work in this dissertation uses another analysis technique (i.e., an approx-
imation of the diffusion apprach) called the differential pathlength method; this approach
will be explained. Lastly, we will outline DCS theory, i.e., going from single scattering to
multiple scattering regimes, and finally deriving the correlation diffusion equation.
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2.1 Diffuse Optical Spectroscopy (DOS)
2.1.1 The Diffusion Approximation
The derivation of the photon diffusion equation commonly begins with the photon transport
equation [55]. It is derived from linear transport theory, which is itself an approximation of
the complex light transport problem posed by the highly scattering media, that allows us to
avoid fumbling with Maxwell’s equations [28]. In most cases, diffraction and interference
effects may be neglected, and geometrical analysis based on ray tracing or energy transport
helps us understand and visualize the problem. In this approach, one can visualize the
photons to propagate in straight lines between scattering events.
Light radiance, L(~r, Ωˆ, t), is defined as the power of light per unit area per solid angle
traveling in the Ωˆ direction at position ~r and time t in the sample; its units are W/(cm2·sr).
Photon fluence rate, denoted as Φ(~r, t), and photon flux or current density ~J(~r, t), both
have units of W/cm2. They are defined as integrals of the radiance, i.e.,
Φ(~r, t) =
∫
L(~r, Ωˆ, t)dΩˆ, (2.1)
and
~J(~r, t) =
∫
L(~r, Ωˆ, t)ΩˆdΩˆ. (2.2)
The photon fluence rate can be thought of as the total number of photons emerging from a
small volume element per unit area per time, i.e., it is the total sum of the radiance emerging
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from ~r. The photon flux is a similar quantity, but it is directional, i.e., it is a vector sum of
the radiance emerging at ~r.
An initial radiance can have various processes affect it within an infinitesimal volume
such as scattering, absorption, additional light scattered in, or light source emission. With
a lot of work [46], one can derive a transport equation for the radiance:
1
ν
∂L(~r, Ωˆ, t)
∂t
+∇·L(~r, Ωˆ, t)Ωˆ = −µtL(~r, Ωˆ, t)+µs
∫
L(~r, Ωˆ, t)f(Ωˆ, Ωˆ′)dΩˆ′+S(~r, Ωˆ, t).
(2.3)
Here ν = c/n is the speed of light in the medium, with n being the index of refraction
of the medium. We define a transport coefficient µt = µs + µa that describes the rate
(in cm−1) that photons are lost through absorption or scattering. The second term on the
right hand side accounts for photons scattered into the volume from other places via use
of a normalized phase function, f(Ωˆ, Ωˆ′). This phase function gives the probability of
a photon scattering from direction Ωˆ to Ωˆ′. The last term is for photons generated by the
light source. S(~r, Ωˆ, t) is the power per volume emitted; its units are W/(cm3· sr). Equation
(2.3) basically describes radiance conservation in each infinitesimal volume element within
the sample [16].
To simplify the photon transport equation, we approximate Equation (2.3) by expand-
ing the radiance and source terms using spherical harmonics (Yl,m(Ωˆ)) with coefficients
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φl,m(~r, t), and then we truncate the series at l = N , i.e.,
L(~r, Ωˆ, t) =
N∑
l=0
l∑
m=−l
φl,m(~r, t)Yl,m(Ωˆ), (2.4)
and
S(~r, Ωˆ, t) =
N∑
l=0
l∑
m=−l
ql,m(~r, t)Yl,m(Ωˆ). (2.5)
This analysis scheme is called the PN approximation, and, for this dissertation, we will
only retain terms with l = 1 or lower. This approximation is called the P1 approximation.
The P1 approximation is only valid for radiance that is nearly isotropic, i.e., in situations
wherein Φ(~r, t)  3| ~J(~r, t)|. For this situation to occur, the medium must have µs  µa
and the positions of interest ~r must be far from the light source. In the P1 approximation,
the radiance can be approximated as
L(~r, Ωˆ, t) ≈
1
4pi
Φ(~r, t) +
3
4pi
~J(~r, t) · Ωˆ, (2.6)
and the source term is approximated as
S(~r, Ωˆ, t) ≈
1
4pi
S0(~r, t) +
3
4pi
~S1(~r, t) · Ωˆ. (2.7)
We also assume that the normalized phase function depends only on the cosine of the
angle between the incident and outgoing wave vectors and not on the values of the angles
themselves. This assumption implies that f(Ωˆ, Ωˆ′) = f(Ωˆ · Ωˆ′), and it is an acceptable
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assumption when the scattering medium is isotropic.
If we insert these expression for the radiance and source into the photon transport equa-
tion (Equation (2.3)), we obtain [189]:
1
ν
∂Φ(~r, t)
∂t
+
3
ν
∂ ~J(~r, t)
∂t
· Ωˆ +∇ · Φ(~r, t)Ωˆ + 3∇ ·
[
~J(~r, t) · Ωˆ
]
Ωˆ
= −µtΦ(~r, t)− 3µt
[
~J(~r, t) · Ωˆ
]
+ µs
∫ [
Φ(~r, t) + 3 ~J(~r, t) · Ωˆ
]
f(Ωˆ, Ωˆ′)dΩˆ′
+ S0(~r, t) + 3 ~S1(~r, Ωˆ, t) · Ωˆ. (2.8)
The anisotropy factor g conveys how much forward scattering is in each scattering event.
It is defined as the average cosine of the scattering angle for a typical scattering event, i.e.,
g =
∫
f(Ωˆ · Ωˆ′)Ωˆ · Ωˆ′dΩ′ = 〈cos θ〉. (2.9)
For our applications – human brain grey matter – we typically have values of g = 0.88
or larger; if g = 1, then photons are scattered completely in the forward direction [30].
We also define the reduced scattering coefficient µ′s = µs(1 − g), whose reciprocal is the
so-called photon random walk step length.
Then multiplying Equation (2.8) by Ωˆ and integrating over Ωˆ gives
1
ν
∂ ~J(~r, t)
∂t
+
1
3
∇Φ(~r, t) + [µa + µ
′
s]
~J(~r, t) = ~S1(~r, t). (2.10)
We next neglect the term containing ∂ ~J(~r,t)
∂t
by assuming that variations in the diffuse total
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flux are much slower than the mean time between scattering events [189, 55]. We also
assume isotropic sources (i.e., S(~r, Ωˆ, t) = S(~r, t)), so that all l 6= 0 terms of the source
become zero. Usually this assumption can be justified by noting that collimated sources
are simply isotropic sources displaced one transport mean free path away from the actual
source location [16].
So then Equation (2.10) becomes
∇Φ(~r, t) = −3 [µa + µ
′
s]
~J(~r, t), (2.11)
which is known as Fick’s law of diffusion, and defines the photon diffusion coefficient.
If we insert all of these approximations for the radiance and source (Equations (2.6)
and (2.7)) into the photon transport equation (Equation (2.3)) and then integrate over Ωˆ, we
have
1
ν
∂Φ(~r, t)
∂t
+∇ · ~J(~r, t) + µaΦ(~r, t) = S0(~r, t). (2.12)
Upon inserting Equation (2.11) into Equation (2.12), we retrieve the typical form for the
photon diffusion equation in a homogeneous medium:
∂Φ(~r, t)
∂t
−D∇2Φ(~r, t) + νµaΦ(~r, t) = νS0(~r, t), (2.13)
where the diffusion coefficient D is defined as
D =
ν
3(µa + µ′s)
≈
ν
3µ′s
. (2.14)
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2.1.2 Diffuse Photon Density Waves (DPDWs)
For the data presented in this thesis, we often used what is called the intensity-modulated or
frequency-domain (FD) technique of DOS.1 This technique involves modulating the light
source at a specific frequency such as 70 MHz and then detecting the amplitude and phase
changes of the ”differential waves” as they pass through tissue. With that information, we
can readily extract the optical properties (µa and µ′s) of the medium. Specifically, when a
light source is frequency-modulated, the photon fluence will oscillate at the same frequency,
creating a macroscopic scalar disturbance, part of which is a wave called the diffuse photon
density wave (DPDW) [71]. The DPDW is the AC component of the photon fluence rate,
i.e., of
Φ(~r, t) = ΦDC(~r) + ΦAC(~r, t)
= ΦDC(~r) + ΦAC(~r)e
−iωt, (2.15)
where ω = 2pif , and f is the modulation frequency.
If we insert the AC component of Equation (2.15) into Equation (2.13), we can rewrite
it in Helmholtz equation form:
(∇2 + k2AC)ΦAC(~r) = −
ν
D
S0(~r), (2.16)
1As opposed to continuous-wave (CW), where the laser intensity remains constant over time), or time-
resolved (TRS), where the laser is pulsed and one measures the broadened pulse shape as it propagates
through tissue). We find FD to be a ”happy medium” of sorts, in terms of greater information content than
CW but not as complicated or expensive electronics as TRS.
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where
k2AC =
iω − νµa
D
(2.17)
is the complex wavenumber (kAC = kr + iki). The solution to Equation (2.16) for an
infinite homogeneous medium is [71]:
ΦAC(~r, t) =
νSAC
4piDr
eikr−iωt, (2.18)
with SAC as the source modulation amplitude, and r = |~r|. The DPDW is a spherical wave
that must decay to zero at large distances from the light source (ki ≥ 0), and this restricts
the real and imaginary parts of the wavenumber solution to be [131]:
kr =
√
νµa
2D


√
1 +
(
ω
νµa
)2
− 1


1/2
(2.19)
ki =
√
νµa
2D


√
1 +
(
ω
νµa
)2
+ 1


1/2
. (2.20)
The amplitude of the DPDW is A(r) = νS0e−kir/(4piDr), and the phase is θ = krr.
DPDWs demonstrate many familiar wave-like properties such as refraction [169], diffrac-
tion [14], interference [201], and dispersion [233].
2.1.3 The Semi-Infinite Medium Solution
The simplest geometry that approximates source and detector optical fibers on a tissue
surface is the homogeneous, semi-infinite medium (see Figure 2.2). In this geometry, there
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Figure 2.2: A semi-infinite medium geometry, with planar boundary between a homoge-
neous turbid medium (index of refraction nin) and non-scattering medium (index of refrac-
tion nout). w, h, and d go to infinity, and the medium is azimuthally symmetric about the
z-axis. The unit vector nˆ points from inside the tissue perpendicularly outwards. The dia-
gram also shows the radiance L(Ωˆ) incident upon the boundary and reflecting back inside
the turbid medium with Fresnel coefficient RFresnel(Ωˆ).
exists a planar boundary at z = 0 with a homogeneous turbid medium at z < 0 and a
non-scattering medium at z > 0. Given the case where the indices of refraction match and
the boundary is then perfectly transmitting, any light passing from the scattering medium
through to the non-scattering medium will not return back to the scattering medium [92].
Thus, a discontinuity in the radiance L(~r, Ωˆ, t) arises when Ωˆ points into tissue from air.
This is a violation of the diffusion approximation expressed in Equation (2.6), which stated
that the radiance is primarily isotropic.
However, in the case of mismatched indices of refraction, much of the radiance incident
upon the boundary from the turbid medium will be reflected back inside. This allows us to
avoid the discontinuity in radiance found with a perfectly transmitting boundary.
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We start by setting the irradiance, or total inward radiance, at the boundary equal to the
integral of the reflected radiance:
Ein =
∫
Ωˆ·nˆ<0
L(Ωˆ)Ωˆ · (−nˆ)dΩ
=
∫
Ωˆ·nˆ<0
RFresnel(Ωˆ)L(Ωˆ)Ωˆ · nˆdΩ (2.21)
where nˆ = −zˆ is the outward normal unit vector (see Figure 2.2) and RFresnel(Ωˆ) is the
Fresnel reflection coefficient for light incident upon the boundary at angle Ωˆ from within
the turbid medium.
From here, we can substitute in Equation (2.6) for L and the equation for the Fresnel
reflection coefficient for unpolarized light to get to the partial-flux boundary condition valid
at z = 0 [92]:
Φ = zbnˆ · ∇Φ (2.22)
where zb = 2D 1+Reff(1−Reff ) , and Reff is the effective reflection coefficient to take into account
the index of refraction mismatch. For instance, tissue has nin = 1.4 and air has nout = 1.0.
Unfortunately, the partial-flux boundary condition, while exact, is difficult to use in
practice. A simpler boundary condition is typically used, called the extrapolated-zero
boundary condition, which is a good approximation to the partial-flux boundary condi-
tion even though there is no strict physical implication behind it [131]. It is a convenient
mathematical device to simplify the analysis. The extrapolated-zero boundary condition
involves having the fluence rate fall to zero at a point on the air side of the boundary, which
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we will say is at a distance zb outwards from the boundary:
Φ(z = −zb) = 0. (2.23)
The fluence rate is extrapolated into the non-scattering medium with a straight line with the
same slope found at the boundary. Thus, the fluence rate on the air side of the boundary
can be given by
Φ(z) =
∂Φ(~r)
∂z
|z=0z + Φ(z = 0). (2.24)
Setting Equation (2.24) equal to zero, we find that zb = 2/3µ′s.
We can use the method of images to obtain the solution of a DPDW for a homogeneous
semi-infinite turbid medium, made up of a superposition of a DPDW in an infinite medium
and a DPDW of a negative image source outside of the turbid medium on the air side. They
are symmetric to one another with respect to the extrapolated boundary.
Figure 2.3 shows a diagram of this extrapolated boundary situation. A collimated
source at the air-tissue boundary can be well-approximated as an isotropic light source
a distance of one transport mean free path (`tr = 1/µ′s) into the medium. The negative
image source is placed at −(`tr + 2zb). Then for a detector at (r, z), the solution of the
diffusion equation is
Φ(r, z) =
νS0
4piD
[
eikr1
r1
−
eikr2
r2
]
, (2.25)
with r1 =
√
r2 + (z − `tr)2 and r2 =
√
r2 + (z + `tr + 2zb)2. And in the limit r 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Figure 2.3: A diagram of the extrapolated boundary condition for a semi-infinite geometry.
There exists a planar boundary between a homogeneous turbid medium (index of refraction
nin) and non-scattering medium (index of refraction nout). Source and detector fibers are
shown, with separation ρ between then. There is an isotropic source one transport mean
free path (z = `tr) into the turbid medium, and a negative image source located at z =
−(`tr + 2zb).
(`tr + 2zb), Equation (2.25) simplifies for r on the surface to
Φsemiinf(r, z = 0) ≈
νS0
4piD
e−kr
r2
[
2k(`trzb + z
2
b )
]
= A0
e−krr
r2
ei(−kir+θ0)
= A(r)eiθ(r), (2.26)
Conveniently, these can be written as
ln[r2A(r)] = −krr + lnA0 (2.27)
θ(r) = −kir + θ0, (2.28)
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making it easy to use multiple (at least two, but preferable more) source-detector distances
to linearly fit for slopes ki and kr. For instance, a titration test to characterize a DOS module
typically uses an automated translation stage to measure amplitude and phase at many
different distances over a range of ∼1 cm to 10 cm (see Section 3.1.3). Both amplitude and
phase will vary linearly (within a certain range) with respect to source-detector separation.
The slopes of the amplitude and phase plots are equal to kr and ki, respectively.
Lastly, the optical properties of interest, µa and µ′s, may be solved for using the follow-
ing equations:
µa =
ω
2ν
[
ki
kr
−
kr
ki
]
µ′s =
2ν
3ω
kikr. (2.29)
2.1.4 The Differential Pathlength Method
Out of convenience, much of the optical property data in this dissertation was measured by
a simpler method called the differential pathlength approach. In this case, only one source-
detector distance is required to find temporal changes in tissue optical properties, which
permits for much more compact probes and instrumentation. In this case, we use only the
intensity of detected light at different wavelengths to calculate changes in absorption.
Derivation of the differential pathlength method begins with the Beer-Lambert law,
which relates absorption of light to the properties (concentration and thickness) of an opti-
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cally thin sample material through which different wavelengths (λ) of light travel:
OD(λ) = −ln
(
I(λ)
I0(λ)
)
= −µa(λ)L. (2.30)
Here OD(λ) is called the optical density of the sample, I0(λ) is the intensity of the light
incident on the sample, I(λ) is the transmitted intensity, µa(λ) is the absorption coefficient,
and L is the sample thickness or light pathlength.
By extracting values of µa(λ) from Equation (2.30), we can then calculate the concen-
tration of chromophores in the sample. In order to back-calculate N chromophore con-
centration changes, one requires at least N wavelengths of light. Using elementary optical
absorption theory, we use the following relation between the absorption coefficient and
chromophore concentration
µa(λ) =
∑
i
i(λ)Ci. (2.31)
Here Ci is the concentration of the ith chromophore in the sample, and their corresponding
wavelength-dependent extinction coefficients are i. If we are only interested in looking at
the changes in absorption, then we have
∆µa(λ) =
∑
i
i(λ)∆Ci. (2.32)
One of the conditions for the Beer-Lambert law (Equation (2.30)) to hold, however, is
that the material must not scatter the light. Biological tissue is highly scattering. In turbid
media, both scattering and absorption attenuate the intensity, and furthermore, there is a
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distribution of photon pathlengths from source to detector rather than a single pathlength.
Hence, for our applications we use the so-called modified Beer-Lambert law (MBLL),
which effectively accounts for changes due to light scattering and absorption [48]. The
method is primarily useful for deriving ”changes” in chromophore concentrations from
”changes” in light transmission. It is thus a differential method.
Given a turbid medium with baseline optical properties µa0(λ) and µ′s0(λ), the baseline
optical density is OD(µa0(λ), µ′s0(λ)). Changes in those optical properties are signified
by ∆µa(λ) and ∆µ′s(λ). The MBLL is derived from a first-order Taylor expansion of the
optical density [39, 17, 23]:
OD [µa0(λ) + ∆µa(λ), µ
′
s0(λ) + ∆µ
′
s(λ)] ≈ OD [µa0(λ), µ
′
s0(λ)]
+
∂OD [µa0(λ), µ
′
s0(λ)]
∂µa(λ)
∆µa(λ) +
∂OD [µa0(λ), µ
′
s0(λ)]
∂µ′s(λ)
∆µ′s(λ)
= OD [µa0(λ), µ
′
s0(λ)] + dA∆µa(λ) + dS∆µ
′
s(λ), (2.33)
with dA =
∂OD[µa0(λ),µ′s0(λ)]
∂µa(λ)
and dS =
∂OD[µa0(λ),µ′s0(λ)]
∂µ′s(λ)
. We call these the absorption and
scattering differential pathlengths, respectively.
In studies of brain hemodynamics, we typically assume scattering changes are small,
i.e., ∆µ′s ≈ 0, and that dA = L`DPF (λ). `DPF (λ) is the so-called differential pathlength
factor (DPF). This wavelength-dependent factor, which is unitless, takes into account the
increased distance that the light must travel from source to detector because of scattering
and absorption effects. With no scattering, `DPF (λ) = 1.
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Inserting these two approximations into Equation (2.1.4) and looking only at changes
in OD, we reach the typical form of the MBLL
∆OD(λ) = ∆µa(λ)L`DPF (λ), (2.34)
where ∆OD(λ) is the change in optical density at a given wavelength, ∆µa(λ, t) is the
change in absorption coefficent, L is the source-detector separation, and `DPF (λ) is the
differential pathlength factor.
In the case of brain tissue, the main chromophores that absorb light are oxy- and de-
oxyhemoglobin (∆HbO2, ∆Hb). In this case, the MBLL can be written as follows:
∆OD(λ) = [HbO2(λ)∆HbO2 + Hb(λ)∆Hb]L`DPF (λ). (2.35)
HbO2(λ) and Hb(λ) are the wavelength-dependent extinction coefficients for oxy- and
deoxyhemoglobin.
For instance, to calculate changes in oxy- and deoxyhemoglobin concentrations using
two wavelengths (λ1, λ2), we may use the following equations:
∆HbO2 =
Hb(λ1)∆µa(λ2)− Hb(λ2)∆µa(λ1)
Hb(λ1)HbO2(λ2)− HbO2(λ1)Hb(λ2)
∆Hb =
HbO2(λ2)∆µa(λ1)− HbO2(λ1)∆µa(λ2)
Hb(λ1)HbO2(λ2)− HbO2(λ1)Hb(λ2)
. (2.36)
39
These can be combined for a measure of total hemoglobin concentration change (∆THC):
∆THC = ∆HbO2 +∆Hb. (2.37)
Values of differential pathlength factor depend on source-detector separation, tissue
geometry, baseline optical properties, and wavelength of light. When we used the MBLL
in this dissertation, values were taken from the literature for adult brain. These values were
adjusted for age and also interpolated for wavelengths that were not reported [52]. As a
warning, the MBLL is not accurate for when changes in µa and µ′s are large compared to
baseline values, or when changes are localized [17, 223].
2.2 Diffuse Correlation Spectroscopy
Light scattering can provide information about the motions of small objects such as red
blood cells via tracking speckle fluctuations. Similarly, diffuse correlation spectroscopy
derives changes in blood flow using the speckle fluctuations of light that is multiply scat-
tered in biological tissue [13, 15]. This is done by measuring the time dependence of
detected light intensity and computing the temporal intensity autocorrelation function. The
decay rate of this autocorrelation function is related to the motions of scatterers, and in
tissue the most prominent moving scatterers are red blood cells. What is unique about DCS
(as opposed to laser Doppler flowmetry, for instance) is its ability to probe the dynamics of
deeper tissues (>1 cm below the surface). DCS exploits the fact that the behavior of the
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intensity and electric field correlation functions in a highly scattering medium can also be
approximated with a diffusion equation.
This section will discuss single scattering and multiple scattering; then it outlines a
derivation of the photon correlation diffusion equation, and describes various DCS blood
flow validation studies.
2.2.1 Dynamic Light Scattering
In the classic single scattering version of the ”dynamic light scattering” (DLS) experiment,
a laser beam is pointed at a solution of dilute particles and a point-like photon detector
collects light (Figure 2.4, top). The sample solution is sufficiently dilute so that light is
scattered either once off a particle or not at all. As seen in Figure 2.4, bottom, the incident
light electric field (with wavevector ~kin) induces oscillating dipole moments in the parti-
cles, which in turn radiate light fields in all directions (with wavevector ~kout). Momentum
transfer is denoted by ~q = ~kout − ~kin, where q = |~q| = 2k0 sin θ2 . The magnitude of
the wavevector is k0 = |~kin| = |~kout| = 2pinλ , and θ is the scattering angle. The motion
of the particles and the resulting scattered light phases cause constructive and destructive
interference at the detector that manifest as a flickering of light intensity over time.
These fluctuations are recorded, and the unnormalized light intensity autocorrelation
function (G2) is calculated by a hardware correlator:
G2(τ) = 〈I(t)I(t+ τ)〉 (2.38)
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Figure 2.4: Single-scattering dynamic light scattering (DLS) setup. Light is incident (with
wavevector~kin) upon a very dilute solution of particles, and a detector is placed at scattering
angle θ. The light scatters once off of the particle and the resulting field has wavevector
~kout. The electric field at the detector is a superposition of scattered fields from all particles
in the sample.
42
with τ being the autocorrelation delay time and intensity I(t) = | ~E(t)|2. The brackets
denote an ensemble average (for calculations), and for an ergodic system, this is equal
to a time average2. Figure 2.4, right, shows the trail of photon pulses over time for every
instance that the photon-counting detector is triggered by a photon. These pulses are binned
to get a time series of intensity counts, and this time series is autocorrelated and normalized
to calculate the normalized intensity autocorrelation function g2(τ):
g2(τ) =
〈I(t)I(t+ τ)〉
〈I(t)〉2
. (2.39)
g2(τ) is related to the normalized temporal electric field autocorrelation function (g1(τ))
g1(τ) =
〈 ~E(t) · ~E∗(t+ τ)〉
〈 ~E(t) · ~E∗(t)〉
(2.40)
(where ~E(t) is the scattered electric field) by way of the Siegert relation [186]:
g2(τ) = 1 + β|g1(τ)|
2. (2.41)
The Siegert relation is valid for Gaussian sources, and while direct laser output is not Gaus-
sian, the superposition of all the randomly scattered fields is. β depends on detection optics
and is inversely proportional to the number of detected speckles or modes. It is also af-
fected by the coherence length and stability of the laser, and ambient light, with an ideal
experimental setup having β = 1.
2In experiments, time averages are measured.
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In DLS, after calculating the field autocorrelation function g1, dynamics of the sample
can be determined by the following relation [16, 263]:
gs1(τ) = e
i2pifτe−
1
6
q2〈∆r2(τ)〉, (2.42)
where f is the frequency of incident light, and 〈∆r2(τ)〉 is the mean squared displacement
of the scatterers in the sample in time τ . For Brownian motion, 〈∆r2(τ)〉 = 6DBτ where
DB is the particle diffusion coefficient.
2.2.2 The Correlation Diffusion Equation
Since biological tissue is a turbid medium where photons multiply scatter, using DLS is
not an option. We must take into account each of many scattering events that contribute to
the phase shift of the emerging light fields. Physically, we can envision the detected field
as comprised of light rays traveling along many photon pathways, and the total temporal
electric field autocorrelation function as the weighted sum of these individual photon paths’
electric field autocorrelation functions.
Another approach is to develop an analogous linear transport equation for electric field
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correlation3 [1, 16], i.e.,
∇ ·GT1 (~r, Ωˆ, τ)Ωˆ + µtG
T
1 (~r, Ωˆ, τ) = S(~r, Ωˆ) + µs
∫
GT1 (~r, Ωˆ
′, τ)gs1(Ωˆ, Ωˆ
′, τ)f(Ωˆ, Ωˆ′)dΩ′,
(2.43)
where
GT1 (~r, Ωˆ, τ) = 〈
~E∗(~r, Ωˆ, t) · ~E(~r, Ωˆ, t+ τ)〉 (2.44)
is the unnormalized field autocorrelation function for the electric field ~E(~r, Ωˆ, t) at position
~r and time t propagating in the Ωˆ direction. gs1(Ωˆ, Ωˆ′, τ) is a correlation scattering function
for each single scattering event, i.e., derived from Equation (2.42) for single scattering.
f(Ωˆ, Ωˆ′) is the normalized differential single scattering cross-section, and S(~r, Ωˆ) is again
the source distribution. Note that at τ = 0, there is no field decorrelation, and Equation
(2.43) reduces to the familiar photon transport equation, i.e., Equation (2.3). The correla-
tion transport equation is applicable from single scattering to multiple scattering systems,
but like the photon transport equation, it is difficult to implement in practice.
To simplify things, one can again make a P1 approximation and ultimately derive the
field correlation analogue to the photon diffusion equation (Equation (2.13)) [16, 55], i.e.,
(
D∇2 − νµa −
1
3
ανµ′sk
2
0〈∆r
2(τ)〉
)
G1(~r, τ) = −νS(~r). (2.45)
Here G1(~r, τ) is the unnormalized field correlation function at ~r and integrated over all an-
3Time dependence has been left out of the correlation transport equation because we only consider mea-
surements with CW sources in steady state systems. In biological tissue, the dynamics are in a quasi-steady
state, since the scatterer dynamics are not changing over the time scale of the measurement.
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gles; S(~r) is the isotropic light source term; D ≈ ν/3µ′s is the photon diffusion coefficient,
and k0 = 2pi/λ is the wavenumber of the incident CW light. α represents the fraction of
total photon scattering events from moving scatterers. As in Equation (2.13), ν is the speed
of light in the medium, µa is the absorption coefficient, and µ′s is the reduced scattering
coefficient. A step-by-step derivation of Equation (2.45) can be found in Appendix A.2 of
David Boas’s dissertation [16, 13, 15].
The assumptions required for Equation (2.45) are as follows: the medium is highly scat-
tering, the scattering phase function and single scattering temporal autocorrelation function
depend only on the scattering angle (i.e. randomly oriented scatterers and isotropic dynam-
ics), and the photon random walk step length is much smaller than the dimensions of the
sample and the photon absorption length. Strictly speaking, we also assume that the cor-
relation time τ is much smaller than the time it takes for a scatterer to move a wavelength
of light (i.e., κ20〈∆r2(τ)〉  1). In biological tissue, the capillary network is serpentine
enough that red blood cell motions can be approximated as isotropic. Also, as is the case
with DOS, the DCS signal will be weighted towards the capillary network, since larger
vessels that have more directional flow will be highly absorbing.
For a homogeneous semi-infinite medium, the standard extrapolated-zero boundary
condition is used (see Section 2.1.3):
G1(z = −zb, τ) = 0. (2.46)
The field correlation function on the inside of the medium is well-modeled with the bound-
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ary condition that the function drops to zero at a distance zb = 23µ′s outside of the turbid
medium. Then the method of images is readily implemented to obtain a solution for G1(τ).
Predictably, the solution to Equation (2.45) is of a similar form as the semi-infinite
medium solution to the photon diffusion equation (Equation (2.25)):
G1(r, z, τ) =
ν
4piD
[
e−K(τ)r1
r1
−
e−K(τ)r2
r2
]
(2.47)
for a detector at (r, z), but the ”wavevector” depends on τ , i.e.,
K(τ) =
√
ν
D
[
µa +
1
3
αµ′sk
2
0〈r
2(τ)〉
]
. (2.48)
Again, r1 =
√
r2 + (z − `tr)2, r2 =
√
r2 + (z + `tr + 2zb)2, and `tr = 1/µ′s is the trans-
port mean free path. Importantly, the term 1
3
αµ′sκ
2
0〈r
2(τ)〉 is a loss term, akin to µa, that
represents the ”absorption” of correlation due to dynamic processes [16].
2.2.3 Diffuse Correlation Spectroscopy
When implementing diffuse correlation spectroscopy in practice, we have found over a
wide range of biological tissues that the Brownian diffusion model (i.e., 〈∆r2(τ)〉 =
6DBτ ) mentioned in Section 2.2.1 fits our correlation curves better than other models such
as random ballistic flow (〈∆r2(τ)〉 = 〈V 2〉τ 2, where 〈V 2〉 is the second moment of the
particle speed distribution) [34, 54, 263]. This general effect is demonstrated in Figure 2.5,
where an intensity autocorrelation function from human arm muscle is fit to both Brownian
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Figure 2.5: Measured normalized intensity autocorrelation function g2(τ) plotted against
delay time τ measured from human arm muscle with source-detector separation of 2.5
cm, fit to both Brownian diffusion and random flow models. We typically fit g2(τ) to
a Brownian model, which as seen from the figure, fits much better than a random flow
model.
diffusion and random flow models. The exact reason why the Brownian model fits so well
is still not fully understood. In general, red blood cells in the microvasculature experience
rolling, tumbling, and translating rather than straightforward ballistic flow, but apparently
these effects can be lumped into a diffusion coefficient.
Thus, in our analysis using Equation (2.47), we set 〈∆r2(τ)〉 = 6DBτ , and we can
fit our g2(τ) data for the quantity that we define as the blood flow index (BFI = αDB).
BFI has units of cm2/s, while true blood flow should have units of cm3/s. Thus, BFI
is not an absolute measure of blood flow. Interestingly, a few studies have found good
correlation between BFI and absolute blood flow [24, 261, 191], and BFI has been found
to accurately track relative changes in blood flow in most systems studied, including in this
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Figure 2.6: Normalized intensity autocorrelation functions (g2(τ)) plotted against delay
time τ from an arm cuff occlusion experiment. One curve shows g2(τ) during baseline,
when the arm cuff is ”off” or uninflated. When the arm cuff is ”on” or inflated, the decay
of g2(τ) becomes much slower due to less blood flow in the arm muscle due to artery
occlusion. The source-detector separation was 2.5 cm.
thesis (see Chapter 4). Thus, we often report the percent change from baseline of blood
flow, or what we call relative blood flow (rBF ):
rBF =
BFI − BFI0
BFI0
× 100%, (2.49)
where BFI0 is the baseline value of the blood flow index. Ultimately, calibration of BFI
may also be possible using DCS in conjunction with an absolute blood flow technique; this
problem is an area of active research in the field.
Figure 2.6 shows raw data from an arm cuff occlusion, an experiment frequently used
to test whether a new DCS module is properly able to measure changes in blood flow.
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The stark difference in g2 decay with and without the occlusion reflects the difference in
muscle blood flow while the arm cuff is uninflated versus when it is inflated. The arm cuff
being tightened around the arm provides sufficient artery occlusion to significantly lower
the blood flow, and thus we see a much slower decay in the autocorrelation function. This
is quantified by an order of magnitude change in BFI (BFICuffOff = 3.51× 10−9 cm2/s
versus BFICuffOn = 1.59× 10
−10 cm2/s).
Also notice in Figure 2.6 that the normalized autocorrelation curves have an intercept
of approximately 1.5 as the delay time approaches zero. From Equation (2.41), we see that
this means β = 0.5, which is a typical value for our experimental setup for human brain
measurements too. As mentioned in Section 2.2.1, β is dependent on source coherence,
detection optics, ambient light, and other factors, with an ideal setup having β = 1. We also
noted that β is inversely proportional to the number of detected speckles or modes. Since
the experiments on human brain performed in this dissertation use single mode detection
fibers that allow transmission of two orthogonal polarization modes, a β of 0.5 is reasonable
[263, 23].
The ”detection volume” of cortical tissue from which diffuse optical measurements are
recorded depends on the source-detector separation [74, 37] and the optical properties of
the tissue (i.e. the number and density of photon scatterers and absorbers). In the investi-
gations of adult brain described in this dissertation, the detection volume was standardized
by utilizing a DCS/DOS source-detector separation of 2.5 cm for all subjects. A 2.5 cm
source-detector separation corresponds to a penetration depth of about 1.25 to 1.5 cm. Al-
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though larger source-detector distances have been used for some DOS studies [149, 226],
a separation distance of 2.5 cm has been utilized effectively in several DOS studies of the
brain [57, 59, 130, 120] and provides a better signal for transcranial DCS than larger dis-
tances. Since the light path of DCS is approximately the same as that of DOS, due to
the similar wavelengths that are utilized, both methods sample essentially the same tissue
volume.
With regard to the DCS detection volume, thus far five published studies have quantita-
tively examined the penetration of DCS signals into the brain at the 2.5 cm source-detector
separation. In a study by Durduran [54], a human skull was used to verify experimentally
that DCS penetrates the skull and interrogates the properties of an underlying medium. In
this same paper, hypercapnia-induced changes in intracranial blood flow were also detected
and were shown to be distinct from concurrent laser Doppler flowmetry measurements of
scalp blood flow. Li et al [130] produced experimentally similar findings to Durduran [54]
using a three-layer model of the skull. Lastly, Gagnon et al [73] utilized analytic two-layer
solutions, Monte Carlo simulations derived from segmented MRI images and experiments
on layered phantoms to verify that DCS is able to penetrate through the scalp and skull
using a source-detector separation of approximately 2.5 cm.
A fourth study (Chapter 4 in this dissertation) validated DCS measurements of rCBF
using a 2.5 cm source-detector separation with concurrent Xenon-CT measurements of
rCBF in patients (mean age 48, range 18-82) with traumatic brain injury, aneurysmal sub-
arachnoid hemorrhage, and acute ischemic stroke [120]. This clinical study provided direct
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validation of DCS against an established diagnostic modality for measuring cerebral blood
flow. Finally, a 2.5 cm source-detector separation has also been used in a clinical study
that utilized DCS to characterize autoregulatory impairment in acute, ischemic stroke pa-
tients and to investigate cerebral autoregulation in subjects with vascular risk factors such
as hypertension and diabetes [59]. While the research described above clearly indicates that
light from the DCS probe penetrates through the skull and into the cortex, we have already
begun current studies using probes with both small and large source-detector separations
in order to more definitively account for scalp and skull signals.
DCS has been successfully validated by numerous studies on animals [150, 54, 260,
225, 264, 27, 156, 50] and some studies on humans [261, 24, 191, 58, 120, 265, 25, 155, 56].
These investigations have explored a wide range of tissue types, perturbations, and com-
parison modalities. With each study, we gather more evidence that DCS indeed measures
a quantity that trends with blood flow, and our lab also continues to develop DCS theory,
instrumentation, and probes further with every application.
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Chapter 3
Hybrid Optical Instrumentation
This chapter will review details involved in the hybrid implementation of DCS/DOS. In
Section 3.1, I will first describe the standard homodyne frequency-domain device (”Joel’s
Instrument”, so-called because it was typically stored in the lab of our frequent collaborator
Dr. Joel Greenberg) used in most of the dissertation experiments. In Section 3.1.2, I will
describe the changes in the next iteration of ”Joel’s Instrument,” called ”Small Optical
Joel’s Instrument (SOJI).” SOJI is an upgraded version of Joel’s Instrument, with significant
improvements implemented. Then I move on to describing the DCS modules. First, I start
with describing the basic 8-channel DCS device, both how to build and test it. Then I
move onto the next iteration of DCS devices, of using multiple wavelengths to extract
oxygenation information simultaneously. Lastly, I describe an ultra-portable DCS-only
instrument that was modified specifically for a study at high altitudes (see Chapter 7).
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Figure 3.1: A schematic of the intensity-modulated or frequency-domain technique for
DOS. Input light is sinusoidally modulated, and the subsequent amplitude attenuation and
phase shift of the detected light is used to extract information about the medium’s optical
properties.
3.1 The DOS Module
What follows is a brief description of both a basic DOS module as well as an upgraded
version. The basic DOS module has been described previously [263], and is the same
one that we have used for numerous experiments on human brain in the last few years
[61, 56, 120, 59]. I will start with the homodyne frequency-domain DOS module, pro-
viding information about its parts and characterization of the device. Then I will describe
important details about the 8-channel DCS module, i.e., its parts and characterization.
3.1.1 Basic DOS Module
Out of the three DOS schemes described in Section 2.1.2, Joel’s Instrument employs the
frequency-domain (FD) technique, where the light source intensity is modulated with a
radio-frequency (RF) sinusoidal signal. We extract information about the turbid medium
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Figure 3.2: Diagram of a basic homodyne detection DOS system. The oscillator provides
a reference signal to the laser and IQ demodulator. The light from the laser goes to, say,
an optical phantom, and is detected and amplified before being transformed by the IQ
demodulator to I and Q signals. Those then go through low pass filters (LPF) before being
transmitted to a computer through a data acquisition (DAQ) board.
from both the amplitude attenuation and phase shift of the input light versus the detected
light (see Figure 3.1). Our DOS module uses what is called a homodyne detection tech-
nique. Light is detected, translated into an electronic signal by the detector, then amplified
and sent to an in-phase/in-quadrature (IQ) demodulator. The outputs of the IQ demodulator,
i.e., the in-phase and in-quadrature parts, are respectively the sine and cosine components
of the signal.
A diagram of a basic homodyne detection technique is shown in Figure 3.2. The RF
oscillator provides a sinusoidal reference signal for both the laser diode and IQ demodulator
on the detection side. On the source side, this intensity-modulated light is transmitted to
a turbid medium through a multimode optical fiber. Light that has traveled through the
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medium and reaches the detector, typically a photomultiplier tube (PMT) or avalanche
photodiode (APD), is then amplified and put through the IQ demodulator.
In the IQ demodulator, both the reference signal from the oscillator (Aref sinωt) and
the signal from the detector (Adet sin(ωt+ θ), where θ is the phase shift with respect to the
reference) are split in two. One of the reference signal arms is shifted by 90◦, the other is
not. Neither of the detected signal arms is phase-shifted. The non-shifted reference and
detector signals are multiplied for the in-phase component:
I(t) =
1
2
Aref sinωt ·Adet sin(ωt+ θ) + Ioff
=
1
8
ArefAdet [cos θ − cos(2ωt+ θ)] + Ioff , (3.1)
where Ioff is the in-phase DC offset term. Similarly, when the 90◦-shifted reference and
detector signals are multiplied, they create the in-quadrature component:
Q(t) =
1
2
Aref cosωt · Adet sin(ωt+ θ) +Qoff
=
1
8
ArefAdet [sin θ + sin(2ωt+ θ)] +Qoff , (3.2)
where Qoff is the in-quadrature DC offset term.
The purpose of the low pass filters (LPF) after the IQ demodulator (see Figure 3.2) is
to remove the high frequency components of the signal (the 2ωt terms in Equations (3.1)
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and (3.2)), resulting in two DC signals
IDC = A cos θ + Ioff
QDC = A sin θ +Qoff (3.3)
where A = 1
8
ArefAdet. IDC and QDC then travel by RF-shielded cables to a digital-to-
analog data acquisition (DAQ) board to be then recorded by a computer.
We then can calculate the amplitude (A) and phase (θ) of the detected signal from IDC
and QDC and their DC offsets for each frame of data using our analysis software:
A =
√
[IDC − Ioff ]2 + [QDC −Qoff ]2
θ = arctan
[
QDC −Qoff
IDC − Ioff
]
. (3.4)
Ioff and Qoff are measured by obtaining values of IDC and QDC while blocking input
light. Typically it is best to have values of offset for every frame of data, since the levels
may change over the course of an experiment. A and θ can subsequently be used to obtain
optical properties of the medium via the methods described in Chapter 2.
In Joel’s Instrument, we use a modulation frequency of 70 MHz from an oscillator
whose output goes into an RF splitter. From there, the RF signal goes into each source and
detector circuit of the homodyne system. The instrument uses three different wavelengths
of near-infrared light for sources: 685 nm (ML1413R; Mitsubishi Electric, Japan), 785
nm (DL-4140-001S; Sanyo Electric, Japan), and 830 nm (DL-8032-001; Sanyo Electric,
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Japan). Each laser diode is driven sinusoidally at 70 MHz by a driving circuit; the RF signal
is combined with the DC component responsible for CW operation using a bias-tee (ZFBT-
4R2G+; Mini-Circuits, NY). And as stated earlier, the 70 MHz output from the oscillator
also provides a reference signal for the IQ demodulator (MIQY-70D; Mini-Circuits, NY)
in the detection circuit.
We mount components individually in modular nuclear instrument bins (NIM-BIN;
Mech-Tronics, IL) for sufficient RF shielding. This approach also makes connecting power
supplies to each component much simpler, since wiring is built into the larger frame that
houses the modules. NIM-BINs come in different widths, and we typically use 1”- or 2”-
wide modules. Also high-quality RF-shielded coaxial cables (RF Connection, Inc., CA)
are used between NIM-BINs that house the oscillator and those containing the laser and
detection circuits.
Joel’s Instrument has four DOS detectors each in their own NIM-BIN, two PMTs
(R928; Hamamatsu, Japan) and two APDs (C5331-01; Hamamatsu, Japan). APDs are
typically used when we detect ”a lot” of light, i.e. such as experiments with small source-
detector separations; APDs in this case employ gains of ∼100. PMTs have higher gains,
about 107, with almost no additional noise; they are used for applications which require low
light level detection. For instance, we use the PMTs to detect signal from human cortex
through scalp and skull for our DOS brain applications.
The detection circuit involves a series of components. Briefly, the detected light is
converted to an electronic signal by the PMT, then bandpass filtered at 70±7 MHz (SBP-
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70; Mini-Circuits, NY). The output is amplified by 24 dB (ZFL-500LN; Mini-Circuits,
NY) and then by 19 dB (ZFL-500HLN; Mini-Circuits, NY). This signal is sent to the IQ
demodulator, along with the reference signal from the RF oscillator. Lastly, I and Q are
low-pass filtered (SLP-30; Mini-Circuits, NY) to remove the high-frequency components,
and the final output signals go through 100 kHz low-pass filters [23] and then into the
analog inputs of a DAQ board (PCI-6032E; National Instruments, TX).
In order to deliver light to multiple locations or probes, we use a 4×8 optical switch
(Piezosystem Jena, Germany) capable of cycling through all three wavelengths plus a DCS
source, if needed, to 8 different source fiber positions. The switching time is roughly 2 ms,
and input light will experience a loss of around 1.4 dB. Digital signals from a DAQ board
hooked up to a computer are used to control the switching.
3.1.2 Upgraded DOS Device (”SOJI”)
Since Joel’s Instrument was built some years ago, we upgraded the device in virtually all
aspects. The result is an instrument we call SOJI, or Small Optical Joel’s Instrument. As
we will show in this section, and in Section 3.1.3, that the DOS module of SOJI improves
on almost every aspect of modules we had previously been using in our lab (which were
described in the previous section).
SOJI’s frequency-domain DOS device also employs a homodyne detection technique.
Figure 3.3 shows photos of the unwieldy old instrument compared to SOJI; SOJI has a
far smaller footprint and overall size (less than half the volume), even while containing
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Figure 3.3: Photos of the old instrument and the upgraded Small Optical Joel’s Instrument
(SOJI). Note that SOJI packs more lasers and detectors into less than half the space of the
older instrument.
more lasers and detectors. SOJI contains a total of 6 detectors (4 PMTs, 2 APDs) and 5
lasers (685, 705, 808, 830, and 850 nm). We have assembled smaller circuitry for the laser
drivers, so that we can pack 5 lasers in two 1” NIM-BINs. Joel’s Instrument used three 2”
NIM-BINs for only 3 lasers. The smaller laser drivers have also improved output stability
dramatically (see Section 3.1.3).
An issue with past instruments has been laser warm-up time. Even though they are
already quite stable, the lasers in SOJI are in the process of being fitted with thermoelectric
cooling (TEC), so that we will no longer have to wait up to 1 hour for the laser output to
stabilize. Each laser will sit on a thermoelectric cooler (CP1.0-31-06L; Melcor Corp., NJ)
driven by a high efficiency TEC controller chip (TEC5V6A-D; Analog Technologies, CA).
This feature is useful especially for human stroke studies, where clinical experiments tend
to pop up spontaneously and with little prior notice.
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Figure 3.4: Example results from testing temperature controlled lasers using the SOJI DOS
module. Data shows long-time stability of I and Q from two identical 808 nm lasers: one
with TEC and one without. Note that the laser without TEC takes ≈1 hour to warm up and
stabilize in the beginning.
We tested the temperature control using two identical 808 nm lasers (DL-8141-035;
Sanyo Electric, Japan): one with TEC and the other without. They both went to a solid
phantom, and for detection we used one of SOJI’s PMTs. SOJI started out ”cold.” Figure
3.4 shows results of this test. We recorded I and Q values overnight from both lasers
simultaneously; notice that the laser without TEC takes ≈1 hour to warm up and stabilize
at the beginning of the experiment. Over a long period of time, the two lasers behaved more
or less the same, but the first hour clearly reveals that TEC helps with initial amplitude drift
(see Table 3.1). Also, apparently phase is not strongly affected by temperature-related
instability.
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Table 3.1: Results of experiment comparing two identical 808 nm lasers, one with TEC
and the other without, in SOJI’s DOS module.
Quantity No TEC TEC
Amplitude Error, Whole Period, % 0.83 0.93
Amplitude Error, 1st Hour, % 1.7 0.71
Phase Error, Whole Period, degrees 0.12 0.13
Phase Error, 1st Hour, degrees 0.09 0.10
We have also upgraded the optical switch to a 5×8 microelectromechanical systems
(MEMS) switch (DiCon Fiberoptics Inc., CA). It has improved transmission and stability,
and does not require an additional driver circuit. Also, we have found smaller and more
stable AC-DC power supplies (Acopian Technical Company, PA) for the detection and
source circuits. Improvements in stability and linearity are quantified in the following
section.
3.1.3 DOS Module Quality Testing
Before being used for human and animal experiments, DOS modules were thoroughly
tested for stability and accuracy. Its range of viability must be characterized so that we
know its limits of operation. This section describes the tests we need to do for any DOS
module.
Quality checking of DOS lasers involves investigating their modulation depth and long-
term stability. Modulation depth is defined as the modulation amplitude, or half the peak-
to-peak value, divided by the mean value. With a PIN diode, the modulation depth of
a given laser can be easily checked with an oscilloscope. Manipulating the DC operating
current of the driver and strength of RF modulation permits adjustment of modulation depth
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Figure 3.5: Example results of a long-term stability test using the SOJI DOS module.
Data shows little variation in AC amplitude (in mV) and phase (in degrees) from all five
wavelengths over a period of over 16 hours on a solid optical tissue phantom. Mean and
standard deviation values from each laser are noted.
to a desired ∼100%. Typical values for our lasers range from 80-90%.
Long-term stability is important, because we do not want changes in amplitude or phase
due to laser instability to be mistaken for physiological occurrences during a clinical exper-
iment. Typically an overnight stability test is performed for about 15 hours on an optical
tissue phantom. All lasers can be measured at once by going through the optical switch,
and offset stability can be checked by capping one source position in the switch.
An example stability plot from SOJI is shown in Figure 3.5. Amplitude must not have
jumps and its percentage standard deviation should remain below 2%. The standard devia-
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Table 3.2: Long-term stability (>16 hours) of amplitude and phase for all five wavelengths
of SOJI.
Laser Mean Amplitude Amplitude Error Phase Error
mV % degrees
850 nm 4.3 1.2 0.60
705 nm 56.3 0.35 0.15
830 nm 30.5 0.45 0.16
685 nm 44.0 0.28 0.15
808 nm 37.0 0.29 0.15
tion of phase must remain below 2◦. Stability details for each of the five lasers1 are shown
in Table 3.2.
It should be noted that these minimum requirements have been barely maintained, if at
all, by past instruments built in our lab [23, 263]. SOJI, on the other hand, shows greater
stability in this respect than any other instrument currently in use by our lab, including the
commercial ISS ImagentTMheterodyne device. A comparison of SOJI to past devices can
be found in Table 3.3. The stability of the basic DOS module found in the old instrument
(see Section 3.1.1) is closest to that of the Homodyne device values.
The dynamic range of the DOS module, including all electronic and optical compo-
nents, is investigated with a linearity test [36]. This is important because when calculating
changes in optical properties from the output of the module, we assume that the changes we
are seeing are proportional to the light detected, i.e., that intensity variations will translate
to a proportional change in light detected by our system. If we are outside of the linear
range, such as below the noise floor or in saturation mode of the detector, this assumption
will prove false.
Figure 3.6 (top) shows a diagram of how we investigate the dynamic range. Experimen-
1Data is from PMT 2, but the other five detectors showed similar results.
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Table 3.3: Comparison of instrument offset and signal stability for all detectors in four
different DOS instruments: Homodyne, Heterodyne, ISS ImagentTM, and SOJI. Data from
the former three devices are taken from Erin M. Buckley’s dissertation [23].
Instrument Detector Amplitude Error Phase Error
Homodyne PMT 1 1.0% 0.5◦
PMT 2 2.4% 1.5◦
APD 1 1.8% 0.7◦
APD 2 2.3% 1.3◦
Heterodyne PMT 1 1.0% 0.4◦
PMT 2 1.5% 0.7◦
ISS ImagentTM PMT 1 1.0% 0.8◦
PMT 2 1.0% 1.5◦
SOJI PMT 1 0.7% 0.1◦
PMT 2 0.3% 0.2◦
PMT 3 0.4% 0.2◦
PMT 4 0.1% 0.1◦
APD 1 0.5% 0.7◦
APD 2 0.3% 0.1◦
tally, we connect a mechanical attenuator that can be tuned to block off a certain amount
of light directly to one of the lasers in our system. Then, that light is split into two beams
with a 90-10 fiber splitter, i.e., 90% of the light goes to a solid phantom and 10% goes to
an optical power meter. A detector fiber is placed a fixed distance away from the source
fiber on the phantom, with the other end going to the detector of interest. Then the power
of the laser is attenuated in 1 dB steps from below the noise floor to above the saturation
point to fully characterize the instrument’s linear range. This procedure is repeated for all
detectors.
We plot input power (in dBmW) versus output voltage (in dBmV) to discover the volt-
age range to stay within during measurements (see Figure 3.6), bottom). In this range,
power and voltage have a linear relationship, slope is close to 2, and phase is fairly con-
stant. Table 3.4 shows the dynamic ranges of all detectors in SOJI in comparison to other
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Figure 3.6: (top) Diagram of a linearity test to find the dynamic range of DOS instrument
detectors. The laser output goes into a variable optical attenuator, which is used to change
the power fed into the 90-10 splitter. The 10% portion goes into a power meter, while the
90% goes to an optical phantom. (bottom) Example results of a linearity test using the SOJI
DOS module. This test used the 808 nm laser to find the dynamic range of PMT 2. Note
that the slope of the amplitude versus intensity plot is close to 2, as it should be, and the
phase is constant within a wide range of intensities.
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Table 3.4: Comparison of dynamic range for all detectors in four different DOS instru-
ments: Homodyne, Heterodyne, ISS ImagentTM, and SOJI. Data from the former three
devices are taken from Erin M. Buckley’s dissertation [23].
Instrument Detector Dynamic Range (dB)
Homodyne PMT 1 51.3
PMT 2 31.6
APD 1 53.3
APD 2 41.7
Heterodyne PMT 1 55.3
PMT 2 48.1
ISS ImagentTM PMT 1 45.1
PMT 2 46.0
SOJI PMT 1 79.6
PMT 2 62.0
PMT 3 67.3
PMT 4 63.6
APD 1 82.4
APD 2 71.1
instruments currently used in our lab. All PMT bias voltages were fixed at 700 V, and we
used the linear range of phase (within 1◦) to fit for the amplitude linear range. Again, SOJI
has a much larger dynamic range than the others, making it more suitable for a wide range
of light levels and source-detector separations.
Next, we test the instrument’s ability to extract accurate optical properties. This is
done using a liquid tissue phantom, and we gradually vary the absorption and scattering
in a range that we might typically see in a clinical experiment. To vary scattering, we use
Intralipid, a fat emulsion often used to make solutions that closely mimic the response of
biological tissue. To vary absorption, we add small concentrations of either India ink or
nigrosin. Detailed recipes and instructions for tissue phantoms can be found in Regine
Choe’s dissertation [36].
Figure 3.7 shows an example Intralipid titration plot to test SOJI’s ability to extract
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Figure 3.7: Example results of an Intralipid titration test using the SOJI DOS module. The
plot on the left shows expected µ′s for all five wavelengths versus the experimentally derived
µ′s. This titration used Intralipid concentrations of 0.5, 1.0, and 1.5%. The plot on the right
shows expected versus experimentally derived µa values for the five different wavelengths.
In both plots, the red line is unity.
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Figure 3.8: Example results of an arm cuff test using the SOJI DOS module. The timeline
above the plot shows the arm cuff occlusion protocol used. The subject first rested for
several minutes with the probe on his arm. Then the cuff was then occluded, then released
for end recovery period. The shaded maroon area marks when the cuff was occluded. Three
PMTs were used at the same source-detector separation of 2.5 cm.
scattering properties. Experimentally, we used a large (≈18 L) fish tank in order to model
the infinite geometry, and we employed an automated translation stage to enable the source
fiber to move smoothly and in fixed steps to accurately measure at a wide range of source-
detector separations (usually <1 cm to >9 cm). PMT bias voltage were kept at 700 V, and
the Intralipid concentration levels varied around 0.5, 1.0, and 1.5%. No absorption agent
was added, so the solution’s µa levels were similar to those of water.
Lastly, the DOS device was tested on a human subject. For this purpose, we typically
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carry out an arm cuff occlusion experiment, placing the optical probe on the inner forearm
muscle. An inflatable blood pressure cuff is used to occlude blood flow to the lower part of
the arm. This prevents new oxygenated blood from coming in, while the muscle uses up the
oxygen contained in the blood already in the lower arm. The experimental result we expect
is a slow decrease in oxyhemoglobin and a mirrored slow increase in deoxyhemoglobin.
Then when the cuff is released, we expect and see an overshoot of oxyhemoglobin as the
oxygenated blood floods back into the lower arm.
An example arm cuff experiment result from SOJI is shown in Figure 3.8. Three PMTs
were used at the same source-detector separation of 2.5 cm, and all gave the correct trend
and magnitude of change for Hb and HbO2 concentrations. Analysis was completed with
the modified Beer-Lambert law using all five wavelengths of SOJI.
We also performed an experiment for testing human brain applications using a breath-
holding task. A probe is adhered to one side of the forehead, with a source-detector separa-
tion of 2.5 cm. The subject sits in a chair quietly for 2 minutes to use as baseline data, then
he or she holds breath for 20 seconds, and then there is a recovery period of 3 minutes. The
breath hold task is repeated 3 times, with results averaged over the 3 events.
Figure 3.9 shows an example result from SOJI’s breath hold experiment. The trends of
Hb and HbO2 are as expected – both increase over the period of breath holding, and then
drop once the subject has started to breath normally again. This is due to the increase in
CBF as the body tries to deliver more oxygen to the brain.
These simple and straightforward human experiments are also used to test DCS mod-
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Figure 3.9: Example results of a breath hold test using the SOJI DOS module. The timeline
above shows the breath hold protocol used – a baseline rest period of several minutes, then
the subject held his breath until the last possible moment, then started breathing again
during the recovery period. The maroon shaded area shows when the actual breath hold
period took place. Three PMTs were used at the same source-detector separation of 2.5
cm.
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ules (see Section 3.2.6). Usually once the instrument has both DOS and DCS modules
completed and individually tested, they will be placed on a cart together with a computer
and human experiments will be performed before taking the hybrid device to the clinic.
3.2 The DCS Module
This section focuses on the basic DCS module that can be found on many of our lab’s
hybrid DOS/DCS devices. This basic module was used to take the majority of the DCS
data in this dissertation. I will describe each of its components, including how to properly
wire them together, and I will describe the tests we employ to be done to characterize the
device once it is built.
3.2.1 Lasers
The requirements for a DCS laser include: a long coherence length to preserve the co-
herence between fields from both the shortest and longest pathlengths through the tissue;
sufficient power for a fairly clean correlation curve; a near-infrared wavelength to probe
through deep tissue; and compactness so it can be inserted easily into a portable device.
Our current best model is a CW, single longitudinal mode (SLM), 785 nm laser from Crys-
taLaser Inc. (DL785-100-SO, CrystaLaser Inc., NV). This laser has a coherence length of
> 50 m (and a corresponding very narrow linewidth, < 0.00001 nm). The laser is available
in different power outputs (maximum available in SLM: 120 mW), and we have found that
the 100 mW output works well for most of our experiments. The downside of having too
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much power is the danger of burning the skin of a patient. Of course, it is easy to attenu-
ate power, and thus far 100 mW has not posed an issue for any of the adult brain studies
featured in this thesis. Also, the 785 nm wavelength has traditionally been used in our lab
out of convenience and availability, but other wavelengths can be used as well (see Section
3.3).
Application of this laser to DCS requires three custom options that the company pro-
vides on request. The first is the placement of an optical isolator in front of the beam.
This is a device that transmits light traveling in one direction while blocking light traveling
in the opposite direction. An optical isolator is necessary for DCS because any light that
reflects backwards from, say, an optical fiber tip will disrupt the laser and can degrade its
coherence. Unfortunately, an optical isolator effectively takes output power away from the
laser. Just to give you an idea, for a 100 mW laser, after the optical isolator, the power will
have dropped to ∼85 mW. The second option is fiber coupling out of the laser with a 65
µm multi-mode fiber terminated with an Fiber Connector [ferrule] (FC) end. This option
also reduces transmission, for example, the 100 mW laser after the optical isolator and fiber
coupling will have a power of∼72 mW. Lastly, the third option enables TTL modulation to
turn the laser on and off. This is useful for the hybrid instrumentation, so that during DOS
acquisition you can turn the DCS laser off directly rather than having it go through another
optical switch and lose more light.
One bit of soldering required early on is to make a TTL output cable for each laser in
your module. There is a plug that looks like a phone jack plug on the back of the laser
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power supply with two pieces of exposed wire, one black and one red, and then a looped
wire. Solder the black wire to another long piece of black wire (about a foot and a half
long), and same with the red wire to a long red wire. Then solder those pieces to a female
BNC end, with the black wire going to ground and the red wire going to signal.
These lasers have good output stability, listed by the manufacturer as < 1% over 24
hours. However, one should always test laser stability with a power meter before starting to
wire up the DCS components. It is best to do so when you first receive the lasers because
if there is a stability issue, it can often take months for the company to make repairs.
Use the following quick checklist for testing the DCS laser upon arrival from the com-
pany:
• Test power straight out of the laser output, and make sure it is close to specifications.
If the power is much lower, then send back to CrystaLaser.
• Test power through the company-provided 65 µm FC-FC fiber; make sure power is
close to specifications.
• Connect laser to DAQ digital output and make sure a TTL pulse can turn the laser on
and off (HIGH turns laser on, LOW turns laser off).
• Test power straight out of the laser output when TTL is low, to ensure that the power
is only few µW or less. This leakage has been an issue, and if the power is not low
enough, then send back to CrystaLaser for adjustment.
• Configure to record analog output from power meter and leave on at least overnight
74
Figure 3.10: An example of a DCS laser with good output power stability.
(∼ 15 hours). Stability over this period should be <1%.
Figure 3.10 shows an example of a good result from an overnight stability test. The
output power is roughly what it should be, the percent standard deviation is <1%, and
there are no large jumps in power.
3.2.2 Detectors
For detection, the DCS module uses arrays of single-photon counting avalanche photodi-
odes (APD). DCS requirements on the detection side include: good photon detection effi-
ciency in the near-infrared range; single-photon detection capability; and compactness. We
have found that PerkinElmer meets these requirements with their 4-channel APD arrays
(SPCM-AQ4C, PerkinElmer Inc., Quebec, CA) and interface boards (SPCM-AQ4C-IO,
PerkinElmer Inc., Quebec, CA). One interface board goes with every single APD array,
and it is used to facilitate power and signal connections to the APD array. The photon
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Table 3.5: SPCM-AQ4C Power Supply Requirements.
Voltage Min. Voltage Max. Voltage Typical Current Max. Current Power (for 2 Arrays)
+2 V 1.95 V 2.05 V 1.0 A 4.0 A 2×6 W = 12 W
+5 V 4.75 V 5.25 V 0.20 A 1.0 A 2×5 W = 10 W
+30 V 29 V 31 V 0.01 A 0.04 A 2×1.2 W = 2.4 W
Table 3.6: SPCM-AQ4C Power Supplies Used.
Model Voltage Max. Current Ripple Noise Voltage Range
Astec LPT81 +3.3 V 8 A 50 mV p-p 1.8 - 3.5 V
Murata DMS-PS1-CM +5 V 1 A 40 mV p-p 5 V
Lambda HSB-28-1.0 +28 V 1 A < 3 mV p-p 26.6 - 29.4 V
detection efficiency at 785 nm is ∼ 50%.
The array requires three different voltages to run: +2 V, +5 V, and +30 V. Table 3.5 sum-
marizes the SPCM-AQ4C power requirements. PerkinElmer recommends that the power
supplies be well-regulated and low ripple noise (< 50 mV p-p).
The +2 V power supply is for cooling the APDs. As count rates increase, the card will
heat up, which will cause the cooler circuit to compensate by transferring heat from the
detector to a heatsink. The number of counts we typically see (< 500 kHz) will not be high
enough to disturb operation significantly (occurs at counts > 2 MHz). However, because
these are the most expensive components of the DCS module, precautions should be taken
regardless. For instance, PerkinElmer suggests usage of 18 wire gauge size or larger for
the +2 V connections, because when the coolers can draw over 4 A.
The +5 V power supply is for the TTL pulses. PerkinElmer recommends that the +5
V and +30 V grounds should be connected all at a single point, while the +2 V grounds
should be connected to each other, but not to the +5 V and +30 V grounds. Details of the
power supplies we found to suit our eight-channel DCS module are listed in Table 3.6.
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The interface card has two rows of 4 BNC connectors each. The top row (further from
the board) is a gate input, for controlling APD function via digital input. With no gate signal
or floating gate inputs, the APDs will be ready to count photons. An applied TTL HIGH
signal will gate the channels off. Jumpers on the board can be configured to either control
each detector individually, or one digital signal to turn them all on or off simultaneously.
We have not applied this gate input feature of the SPCM-AQ4C yet, and we only control the
APD power by toggle switch within the circuit. However, using software controls instead
would be useful for future work.
The bottom row (closer to the board) of BNC connectors are TTL signal output of pho-
ton counts from the APDs. These outputs get directly connected to the hardware correlator.
3.2.3 Correlator
We use a hardware multi-tau correlator (Correlator.com, Bridgewater, NJ) that takes TTL
signal output for each photon from the APDs and then calculates various parameters that it
then outputs via USB connection to a computer. The hardware approaches were developed
more than 40 years ago and are still the method of choice. The schemes are ingenious.
To experimentally perform the photon correlation measurement, the correlator hard-
ware must perform four basic tasks:
1. Count the arrival of input pulses over sampling intervals spaced on a grid defined by
the sampling time ∆to.
2. Delay the count sequence for some lag time τ , say k∆to (k being number of chan-
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nels), and store this sequence.
3. Multiply the two count sequences.
4. Accumulate the products, or calculate their sum.
Efficiency is important – steps 2-4 is done in parallel for k channels that correspond to
different lag times. In our case, we use what is called a ”multiple-tau” scheme, in which
data is processed at many different sample times simultaneously. Experimentally we aim
to carry all of these steps out in real time.
”Multiple-tau” or ”multi-tau” correlation refers to the multiple samples times (taus) that
are processed simultaneously by the correlator. This approach greatly reduces the compu-
tation load, and permits experimenters to access both small τ and large τ . For example, a
8-channel correlator with multi-tau capability would have the layout shown in Figure 3.11:
• First tier: Registers 1-16 have bin width to = 200 ns
• Second tier: Next 8 registers have to = 400 ns (bin width doubles every 16 registers)
• Third tier: Next 8 registers have to = 800 ns
• ... and so on.
At the start of a measurement, the digital counter reports photon counts within each
bin time of the first register. Those values in the first register shift to the next register as a
new value comes in from left. This goes on until all registers are filled. Before each shift,
temporal autocorrelation functions (G2) are calculated, e.g., G2(τi) = 〈ni · no〉, where ni
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Figure 3.11: Diagram of multi-tau correlation scheme from [263].
is the photon count in ith register, no is the photon count in the register for zero delay time
(τ = 0), and τi is the delay time between ni and no. The autocorrelation functions are then
normalized in a separate register to create the normalized temporal autocorrelation function
g2. An average of these g2 traces are calculated over the entire duration t (which is preset
by the user, usually about 2.5 s) to produce a final, averaged g2 curve. This then is a single
data point in time, of which we use a continuous stream of, to then calculate relative flow.
3.2.4 Visual Basic Code
We use a Visual Basic code to manipulate the correlator (start, stop, update), to change
duration time, to plot the normalized autocorrelation functions, and to log the data into
files for analysis. What follows is a detailed interpretation of the code.
Initializing: The first part of the code is for defining the variables that will be used
throughout the code, for loading the graphical user interface (GUI) form and its compo-
nents, and for initializing the correlator. First we define the data type, and in some cases
the dimension or value of the global variables. Because the 4 vs. 8 channel modes dif-
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Table 3.7: VB Code Global Variables.
Variable Name Data Type 4CH Value 8CH Value
TIMEFLEX Double 47.18592 ms 104.8576 ms
FIRSTDELAY Double 40 ns 200 ns
CHANTOT Double 512 256
NumFirstRegister Integer 32 16
NumNextRegister Integer 16 8
NumRegisterGroups Integer 30 30
Variable Name Data Type 4CH Size 8CH Size
CORRELATORcorr Single 0 to 2048 0 to 2048
CORRELATORtraceA Single 0 to 2048 0 to 2048
CORRELATORDelayTime Single 0 to 512 0 to 256
CORRELATORCounts Single 0 to 3 0 to 7
fer in correlator bin size and other factors, some of these global variables have different
values depending on the mode in which we choose to run the flow box. For instance, the
smallest bin size (called FIRSTDELAY in the code) is 40 ns for 4 channel mode, but 200
ns in 8 channel mode. Table 3.7 shows the variable name, data type, and 4 vs. 8 channel
values/dimensions. Following the table are definitions of the variables.
• TIMEFLEX: Time interval in which correlator returns data, in seconds.
• FIRSTDELAY: Bin width of first register, in seconds.
• CHANTOT: Total number of bins across all registers in a single channel.
• NumFirstRegister: Number of bins in first register, with lag time
FIRSTDELAY.
• NumNextRegister: Lag time keeps doubling after this register interval.
• NumRegisterGroups: Total number of registers (not including the first).
• CORRELATORcorr: Contains normalized, averaged g2 data for all channels.
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Table 3.8: More VB Code Global Variables
Variable Name Data Type
State Integer
newlabel Single
Tau Single
SequenceCounter Integer
CORRELATOROk Boolean
CORRELATORElapsedTime Single
CORRELATORTraceCount Integer
CORRELATORDuration Double
CORRELATORTimeleft Double
CORRELATORDataToPlot Variant
• CORRELATORtraceA: Contains photon counts for all channels. With each
TIMEFLEX, the counts are accumulated until the end of duration time.
• CORRELATORDelayTime: Array of lag times τ , calculated in the code.
• CORRELATORCounts: Intensity values (in photon counts per second) for all chan-
nels.
Other variables are defined in the global area (Table 3.8), many having to do with the
duration time that G2 is averaged over or the correlation initialization. One important vari-
able is State, which plays a large part in the Timer function in Visual Basic; Timerwill
check the value of State at a pre-defined time interval and cause actions to be performed
according to its value.
• State: For the sub Timer. Value of State is checked in every pre-defined time
interval, and actions are performed (defined in sub Timer) according to its value.
• newlabel: Only used in 8CH mode. Needed because correlator in 4CH mode takes
first four outputs as 1-4, but in 8CH mode alternates as 1-3-5-7 as first four outputs.
81
newlabel used to detangle them to right order.
• Tau: A shorthand way to calculate relative changes of flow, calculated by taking the
time for g2 to decay 1/e. When baseline button is clicked, use that particular frame’s
Tau as baseline and values thereafter as relative changes.
• SequenceCounter: Number keeps track of each completed logged file/frame, as
in g2 logged of full duration time.
• CORRELATOROk: Will be ”True” if correlator initializes correctly, otherwise will be
”False”.
• CORRELATORElapsedTime: Returned by correlator, how much time correlator
has been averaging for between when USB told to start and stop.
• CORRELATORTraceCount: How many G2 traces have been generated so far.
• CORRELATORDuration: Duration time, G2 traces accumulated during this time
will be averaged for final G2.
• CORRELATORTimeleft: Difference in time of CORRELATORDuration and
CORRELATORElapsedTime. How much time left to average over.
• CORRELATORDataToPlot: CORRELATORcorr reshaped into g2 for each chan-
nel; gets plotted against DelaysToPlot.
Also in the global section of the code is the definition of two subs (subroutines) and
two functions that involve communication with the correlator via USB 2.0 port. These four
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Table 3.9: USB Controls.
Sub Name Type Argument Variables Return Variables
USBInitialize Function none USBInitialize as Byte
USBStart Sub none none
USBStop Sub none none
USBUpdate Function ElapsedTime as Single USBUpdate as Byte
TraceCount as Any
corr1 as Single
TraceA as Single
controls access the appropriate .dll file2. Details about each control are seen in Table 3.9.
There is an additional sub USBFree that is defined, but never used in the code.
• USBInitialize: Will return a value of zero if correlator not initializing correctly;
otherwise will be non-zero. Often non-zero if correlator not connected, or driver not
installed properly.
• USBStart: Begin acquiring data from correlator, start
CORRELATORElapsedTime at zero.
• USBStop: Stop acquiring data from correlator, stop updating
CORRELATORElapsedTime.
• USBUpdate: Returns new data values. ElapsedTime is amount of time passed while
averaging the correlation curve, total time being the duration t. TraceCount is the
number of correlation curve traces averaged for the final curve. corr1 is the normal-
ized and averaged correlation curve data. TraceA is the current individual trace.
Here ends the global heading of the code. The bulk of the code is made up of many
2There are .dll files specific to 4 (flex05-4chPascal.dll) or 8 channel
(flex05oem8chautoPASCAL.dll) mode.
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public subs. A flow chart (Figure 3.12) shows the preliminary section of the code, begin-
ning from defining the variables that we have just discussed to various initial procedures
done before taking a measurement.
During the FormLoad sub, the number of sources and detectors being used are defined
(NUMSOURCES, NUMDETS) and the dimensions of CORRELATORCounts and Tau are
altered accordingly. The number of channels (detectors) is fixed at 8 by default, but it can
be changed to 4 with a click of a button once the form fully loads.
Next is the initialization process, which involves filling CORRELATORDelayTime
with the lag times (τ ) corresponding to 8 channel mode. It is important to know that in the
code we must calculate the values of τ based on the configuration of the correlator, and the
numbers are not automatically fed into the computer by the correlator:
For i = 0 To NumFirstRegister
CORRELATOR_DelayTime(i) = i * FIRSTDELAY
Next i
For j = 1 To NumRegisterGroups
For i = 0 To NumNextRegister
CORRELATOR_DelayTime(i + (j - 1) * NumNextRegister
+ NumFirstRegister) = CORRELATOR_DelayTime((j - 1)
* NumNextRegister + NumFirstRegister + i - 1)
+ FIRSTDELAY * 2 ˆ j
Next i
Next j
After creating the lag times, the correlator is checked by checking the value returned by
USBInitialize. Remember that if the correlator is not initializing properly because it
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Figure 3.12: Part 1 of the VB code: Preliminary actions such as defining variables, check-
ing on correlator, creating lag times.
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is not plugged in or there is a driver issue, then it will return as zero. If there is a problem,
as seen in Figure 3.12, it will display an error message but still show the default update
time (TIMEFLEX) and duration (CORRELATORDuration) before it rests. If there is no
problem, it will show the times without an error message. Next the code defines the timer
interval as the default update time. At this point, if we want to switch to 4 channel mode,
we can click the ”4CH” button where it will redefine certain 4 channel specific variables,
refill the lag time array, and display the new update time and duration. Changing update
time or duration requires only typing the time in and clicking the appropriate button.
Taking Data: Now the program is ready for its job–reading g2 data from the correlator
and logging it into files for further analysis. There are two options for scan type:
• Single scan: Take a single frame of data, or a single g2 curve for each channel at one
time point.
• Sequence scan: Keep taking continous frames of data every duration time interval
for each channel until the ”Stop” button is clicked.
We can choose which scan type we want by clicking the corresponding button. Essentially
the same chain of events occurs, except for single scan it only loops one time, and for
sequence scan it continues looping until the user presses ”Stop” (Figure 3.13).
The use of buttons gets turned off, and the time left on the correlator
(CORRELATORTimeleft) is reset to the duration time. Then the state of the timer is
specified, and this is where single scan and sequence scan differ. Then the USB function is
started, the elapsed time on the correlator starts counting, and the events governed by the
86
Figure 3.13: Part 2 of the VB code: Taking data, choose either single scan or sequence
scan.
timer begin to take place. The timer is not always exact, and so sometimes the duration
countdown will go negative. When it stops, the use of buttons returns.
The details of each state of the timer is given in Figure 3.14. There are four timer states
that are used throughout the program (States 0, 2, 4 and 100), and two that are defined but
never used (States 1 and 3). Essentially the timer works as follows: at every pre-defined
interval time, the timer will check the state (i.e., value of State variable) and according
to the value, perform the appropriate actions under the specific state that are dictated in the
timer sub.
During the intialization process that occurs when the form is loading, the timer interval
is set as the correlator update time (TIMEFLEX):
Timer1.Interval = TIME_FLEX * 1000.
This is because we assume that there is no need to check the state any faster than the
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Figure 3.14: Timer: In VB, this will check the state value at a pre-defined interval and do
the following actions accordingly.
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correlator itself can update and produce a new trace. The four cases perform actions as
follows:
• Case 0: Do nothing.
• Case 2: For single acquisition. First checks if the elapsed time on the correlation
matches the duration, as in if it is done averaging g2. If not, then it keeps reading the
data (in sub ReadData); if so, then it plots a rough estimate of rCBF, stops the USB
data acquisition, and logs the data into a file.
• Case 4: For sequence acquisition. The only difference here is that this case will
reset the time left on the correlator before plotting and logging the data. This causes
the scan to keep looping.
• Case 100: If there is a problem with the correlator, it displays a message (”Prob-
lem with correlator!”) and then does nothing (Case 0).
The last part of the code needed is the essential sub ReadData, which actually gets
the data from the correlator, plots the normalized data, and puts it into variables that will
later be logged into files. The flow chart is documented in Figure 3.15. First it checks
if data is already being read, if not it then checks if the correlator is returning nonzero
values through USBUpdate. If they are nonzero, the time is updated on the correlator and
an array of total counts is created. The total counts is converted into average counts per
second and the correlation curve plot is updated with a new g2. This is looped until the
elapsed time is equal to the preset duration time.
89
Figure 3.15: ReadData: This sub takes the data from the correlator, updates/averages G2,
and calculates average count rate for each detector.
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Logging the Data: The last part of the code deals with logging data such as our final
averaged, normalized g2 and counts per second into files to be analyzed by MATLAB. The
code does this by first printing a header containing the duration time used for taking the data
and counts per second for each channel used. Then another sub is used to print columns
of data that include the delay times and the corresponding g2 value for each time for all
channels. Lastly, the final row of the file is designated for marks–whether the user pressed
the ”Mark” button to indicate an event occuring. It logs ”1” for a particular file with mark
pressed, or ”0” for no mark.
3.2.5 DCS Module Assembly
A basic 2-laser, 8-channel DCS module contains:
• Two 100mW, CW, long coherence length (> 50 m), 785 nm lasers (CrystaLaser Inc.),
$7000.00 each
• Two APD 4-channel SPCM arrays + Two SPCM AQ4C cards (PerkinElmer Inc.),
$9000.00 each array + $265.00 each card
• One 8-channel multi-tau digital correlator (Correlator.com), $7000.00 each
• One Murata +5 V power supply, $54.00 each
• One Lambda +28 V power supply, $41.16 each
• One ASTEC +2 V power supply, $194.00 each
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Figure 3.16: Front and back panels of a standard 8-channel DCS module.
• One box enclosure, $330.54 each (Bud Industries)
• One power module with switch/fuse, $15.95 each (Tyco)
• One square AC fan, $22.00 each
• One square nickel-plated fan guard, $1.00 each
• Two red LED indicator lights, $2.249 each (Lumex)
• Two 4PDT ON-NONE-ON toggle switches, $22.90 each (Electroswitch)
• Two BNC female-to-female adapters, $7.56 each (Pomona Electronics)
• Two 309 Ohm .125W resistors, $0.137 each
• Five 50 Ohm 3W resistors, $1.218 each
It is, of course, possible to vary certain components. For instance, one could reduce
the number of channels to four or choose to use low power lasers instead, but the basics
remain the same. The basic 8-channel DCS module is shown in Figures 3.16 and 3.17. The
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Figure 3.17: Inside views of a standard 8-channel DCS module.
front panel (Figure 3.16, left) shows the inputs for the lasers in the upper left, their power
supplies in the bottom left, and the two 4-channel APD arrays on the right. In between
them are toggle switches for channels 1-4, and 5-8 with their respective indicator lights.
Notice that with this arrangement, one must turn on channels 1-4 and 5-8 together – each
channel cannot be turned on individually.
The back panel (Figure 3.16, right) has BNC inputs used for turning the lasers on and off
with a TTL pulse, a USB cable that powers and allows communication with the correlator
(silver cord), and the power switch. Not shown is the fan attached to the top of the box.
Figure 3.18 shows the electrical connections one must make from the APD cables to the
power supplies. The grounds of the power supplies connect directly to the APDs, but the
voltages must go through the toggle switch. The toggle switch also controls the indicator
light (powered by 5 V power supply).
In addition to the wiring of the APDs, you also must connect the fan directly to the
N and L pins of the power entry module so that it powers up as the switch is turned on.
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Figure 3.18: Circuitry of power supplies to APDs.
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BNC cables connect the correlator to the APDs, and then a USB cable (male B to male A)
connects the correlator to the computer.
3.2.6 DCS Module Quality Testing
Before going into the clinic, the DCS module must be tested thoroughly for quality, in
a fashion similar to the DOS module (see Section 3.1.3). After assembly and soldering,
the wired connections must be checked. Then the device has to be tested for stability and
accuracy.
Before turning the device on, it must be verified that the parts and power supplies are
correctly connected. Then, each component must be powered up, i.e., after confirming that
they are receiving the right voltages. The following list details this procedure step-by-step:
1. Make sure AC power is unplugged, and the power switch is OFF. Unplug the power
to both sets of APDs. Also unplug power to both lasers, making sure that the lasers
are switched OFF.
2. Get a multimeter and turn dial to the beeping thing. (Have circuit diagram alongside
you as you check that all appropriate connections are made.)
3. Make sure no connections exist where there shouldn’t be any by using the voltmeter.
4. Now plug in AC power. Remember that power to APDs should still be disconnected.
Turn power switch ON.
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5. First thing you should notice: fan starts spinning. If it is spinning, then you have
wired the fan correctly.
6. Pick up your multimeter again, but this time turn the dial to measure AC voltage.
Use this setting to test the voltage going to the lasers, as well as the fan (if it is not
spinning). BE CAREFUL! You could easily shock yourself, or cause a short circuit.
Watch where you put those test pins.
7. Check that the AC voltages coming into the power supplies is correct (check N, G
and L pins).
8. Test that the AC voltages coming into both lasers is correct. If they are, turn off the
power switch and plug the laser power cords in.
9. Turn ON the power switches of both lasers. Turn the key of Laser 1 and place a piece
of white paper in front of the output. You should see a red spot. Repeat for Laser 2.
10. Switch your multimeter to measure DC voltage. Start with the power supplies,
putting one test pin on +V and the other on -V. You should get a value very close
to 2 V, 5 V and 30 V for the respective power supplies.
11. Now turn your attention to the wires you disconnected from the APDs. Use jumper
wires to test that the +V and +V return pins are receiving the appropriate voltages (2
V, 5 V or 30 V). Repeat for both sets of wires.
12. Congratulations! Now you can turn on the device with everything connected. Even
close the lid if you want.
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As with the DOS module, the laser stability of the DCS module must be confirmed.
As stated in Section 3.2.1, stability for all lasers should be checked with a power meter
overnight as soon as they arrive from the company. Then, once the DCS module is com-
pletely wired up, and the connections are tested, then the stability of the device as a whole
must be verified. Typically a probe is made to hold optical fibers at multiple source-detector
separations. Then the probe is held so it is just touching the surface of a liquid Intralipid
phantom, so as to mimic a semi-infinite medium geometry. Data is recorded overnight.
First we must check intensity (i.e. photon counts per second) over time, which is out-
putted in kHz by the correlator. Figure 3.19, top, shows an example intensity plot from a
successful stability test. Notice that percent standard deviation is small (<2%), and there
are no large jumps in the data. Even though intensity values are not used explicitly in cal-
culating BFI , they can be an indication of good laser performance. A laser that has large
jumps in intensity could be unstable in coherence as well, which would affect the stability
of BFI .
Next we observe the stability of β over time. Again, this is a feature of the correlation
curve that may not affect values of BFI directly, but can give insight into whether there are
issues with laser coherence or other mishaps with experimental setup. Figure 3.19, bottom,
shows an example plot of β from an overnight stability test. The values should be close to
0.5 with no abrupt changes in value.
Figure 3.20 shows a plot of relative BFI versus time for a DCS module during an
overnight stability test. For analysis, we used the first 50 or so frames as baseline BFI ,
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Figure 3.19: Example result of intensity and β from an overnight stability test on a basic
DCS module. Intensity values are returned by the correlator in photon counts per second,
or kHz. Note that percent standard deviation over ∼13 hours is <2%. β should be close to
0.5 and with no large jumps, as seen in the second plot.
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Figure 3.20: Example result of relative BFI from an overnight stability test. BFI was
derived from fitting a correlation diffusion model to g2 curves obtained from a liquid phan-
toms. The first 50 frames (integration time 3 s) were used as baseline.
then the remainder of the timeseries is normalized to this baseline to find relative BFI
in terms of percent change. This is to see how large the variations of relative BFI are
(acceptable would be <2%), and to ensure that there are no abrupt jumps. Also, individual
frames of g2 data and their fitted curves should be plotted. In some cases, such as when the
source-detector separation is small and we are on the edge of the diffusion approximation,
or when a brain-injured patient has an injury that affects blood flow strangely, the model
will produce badly fit curves. In these instances, corresponding data should most likely be
left out of analysis.
A method to test whether the DCS module is able to distinguish changes in flow is to
use a liquid phantom with a magnetic stirrer (see Figure 3.21). The speeds depend on what
is available on the stirrer, but we went from having the stirrer completely off to the stirrer on
at low speed. This scheme was used to make sure the same correlation curves were being
produced for both 8-channel and 4-channel modes (see Figure 3.22). This test is carried
out to confirm that the two modes are working correctly, retrieving the same BFI values,
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Figure 3.21: Diagram of stirring test. A liquid phantom is placed on top of a magnetic
stirrer that is capable of different stirring speeds. Optical fibers go to the laser source and
detectors (an array of APDs), which take data to the correlator and laptop. This test is to
enable that the DCS box is capable of distinguishing changes in flow.
and that 4-channel mode has increased sensitivity and higher resolution.
As with the DOS module, we must advance our DCS device from testing on tissue
phantoms to real human subjects. The arm cuff experiment described in Section 3.1.3 is
typically performed after the DOS/DCS hybrid device has been fully compiled on the cart.
Figure 3.23 is an example result from a basic DCS module during an arm cuff occlusion
and release. After an initial stable baseline period, blood flow should sharply drop to about
80% of baseline during occlusion (typically at a pressure of 180 mmHg). Then there will be
a rapid overshoot as the blood rushes back into the forearm. Lastly, the blood flow should
slowly stabilize back to its baseline value.
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Figure 3.22: Examples of g2(τ) during stirring test, directly comparing curves during 8-
channel versus 4-channel modes. Notice how g2(τ) in 4-channel mode is noisier, because
it is has a higher resolution and smaller bins to enable less smoothing of the correlation
curve. Also the 4-channel g2(τ) is able to retrieve more of the initial part of the curve,
since the first delay time is smaller.
Figure 3.23: Relative blood flow (rBF) from blood pressure arm cuff testing. When arm
is cuffed, rBF drops sharply to about 80% of initial baseline value. Then when cuff is
released, an overshoot occurs initially, then rBF slowly returns to baseline level.
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3.3 Multi-Wavelength DCS
For the DCS module in SOJI, we decided to add multi-wavelength capability. This capabil-
ity was added so that we might potentially use as a standalone DCS device that will also be
able to take oxygenation data using the differential pathlength method described in Section
2.1.4. We wished to explore how easy it might be to extract absorption properties with
DCS CW lasers. Some preliminary experiments were performed to ensure that different
wavelengths of laser could be employed to take BFI data (i.e., in addition to our usual
785 nm laser) with the hope that reasonable changes in oxygenation could be measured
simultaneously.
We added two additional lasers: a 50 mW, 690 nm laser (DL690-050-SO; CrystaLaser
Inc., NV) and a 100 mW, 830 nm laser (DL830-100-SO; CrystaLaser Inc., NV). This adds
one more wavelength to a previously published study [208], wherein the authors refer to
multi-wavelength DCS as ”DCS flow oximetry.”
3.3.1 DCS Multi-Wavelength Phantom Results
To investigate whether or not there is any discrepancy in DCS using different wavelengths,
we decided on a simple single scattering experiment to start with (see Section 2.2.1). We
used a dynamic light scattering setup (see Figure 3.24) to determine the average size of
both spherical ”particles” Intralipid and in monodisperse polystyrene colloids. All three
lasers were fed into a 3× 1 optical switch, whose output was then put through a collimator,
a lens to focus the beam, and a polarizer. The cuvette containing the sample solution was
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Figure 3.24: Schematic of an initial dynamic light scattering experiment to test the ef-
fects of different wavelengths on DCS results. The sample contained a solution of either
Intralipid or monodisperse polystyrene spheres.
placed at the focal point of the lens. Then a single-mode detection fiber was placed at 90◦
from the beam path, split, and sent to the 4 photon-counting APDs.
We can obtain the translational diffusion coefficient, D, for the particles in the samples
from the measured correlation curve. Then, using the standard Stokes-Einstein theory,
we can calculate the particle radius. The particles were assumed to be spherical. The
electric field correlation function will have the form g1(τ) = e−Γτ , where Γ = DK2. For
non-interacting Brownian particles in a homogeneous solvent, D = kBT/f , where kB is
Boltzmann’s constant, T is the temperature, and f is the frictional coefficient of the particle.
For spherical particles, f = 6piηRH . η is the solvent viscosity and RH is the hydrodynamic
radius of the particle.
Figure 3.25 shows example data and linear fit of g1 versus τ from a dynamic light
scattering experiment with a solution containing polystyrene spheres. Table 3.10 summa-
rizes results from using Intralipid (0.03 to 0.4 µm) [240] and two different diameters of
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Figure 3.25: Example g1 data and linear fit from a dynamic light scattering experiment with
a solution containing polystyrene spheres.
polystyrene spheres (0.5 and 1.0 µm). Note that while the percentage error in predicting
particle size is sometimes larger than desired, the value of diameter given by the three
different wavelengths are always within error of one another. We conclude that using dif-
ferent wavelengths for DLS does not have a significant effect on measuring particle size
properties.
3.3.2 Initial Human Experiment
Of course, we also want to determine how well multi-wavelength DCS works in practice
with a real human subject. To this end, we performed the arm cuff experiment described at
the end of Sections 3.1.3 and 3.2.6.
Figure 3.26 shows an example result from an arm cuff occlusion experiment using our
multi-wavelength DCS setup. The top figure shows relative blood flow changes for all
three wavelengths during the test. All show the correct trends that we look for during arm
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Table 3.10: Summary of dynamic light scattering experiments using solutions of Intralipid
and two different diameters of polystyrene spheres. No error is listed for Intralipid because
there is a wide distribution of particle sizes, but our measurements were well within that
range.
Solution Quantity 830 nm 692 nm 785 nm
Intralipid, 0.03 - 0.4 µm Diameter, µm 0.33 0.31 0.33
SD Diameter, µm 0.01 0.01 0.01
Error, % N/A N/A N/A
Polystyrene, 0.5 µm Diameter, µm 0.53 0.63 0.57
SD Diameter, µm 0.04 0.09 0.05
Error, % 6% 26% 14%
Polystyrene, 1.0 µm Diameter, µm 0.82 0.90 0.88
SD Diameter, µm 0.05 0.06 0.04
Error, % 18% 10% 12%
cuff occlusion and release, and, more importantly, the timeseries from all wavelengths are
equivalent to one another. This information tells us that the values of relative blood flow
given by DCS does not depend on the wavelength of the source laser, as long as we take
the differing optical properties into account during analysis.
Figure 3.26, bottom, compares calculated changes in oxyhemoglobin (∆HbO2) and
deoxyhemoglobin (∆Hb) from multi-wavelength DCS and SOJI. The resulting timeseries
from DCS is noisier and with lower time resolution than SOJI’s, but the trends and magni-
tude of overshoot (in µM) match relatively well.
3.3.3 Ultra-Portable Multi-wavelength DCS Module
For the requirements of a study performed at high-altitude (Chapter 7), we had to mod-
ify a 2-channel DCS module [263]. Because the device had to travel across an ocean
and up a mountain, we had to make it ultra-portable as well as we had to add multi-
wavelength DOS capability to the DCS-only device. To do this, an 830 nm long-coherence
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Figure 3.26: Example result from an arm cuff experiment on a human subject using multi-
wavelength DCS, with the red lines marking occlusion and release. The top figure shows
a relative blood flow (rBF ) timeseries from each of the three different wavelengths, giv-
ing an equivalent and correct result. The bottom figure shows the calculated changes in
oxyhemoglobin (∆HbO2) and deoxyhemoglobin (∆Hb) both from the multi-wavelength
DCS and SOJI. While the DCS result is noisier with a lower time resolution, it matches the
trends seen by SOJI.
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Figure 3.27: Photo of the ultra-portable, 2-channel DCS module that was modified for
multi-wavelength operation.
length, continuous-wave laser was added so that we could extract hemoglobin concentra-
tion changes with the differential pathlength method (see Section 2.1.4).
The original DCS module, seen in Figure 3.27, contained a 785 nm laser, two indi-
vidual APDs, and a 2-channel multi-tau correlator. To modify it into an ultra-portable
multi-wavelength DCS module, we added an 830 nm laser, a compact DAQ board for
switching between lasers using TTL pulses, and a Labview code was created that displayed
oxygenation changes along with laser intensities, correlation curves, etc. The graphical in-
terface also was made more user-friendly, since large parts of the study would be operated
completely by doctors lacking DCS expertise.
The idea behind the multi-wavelength DCS was that the wavelengths would switch
off using the DAQ board, so intensity timeseries would be recorded and used to extract
oxygenation information, while each would still be taking g2 data at every frame. This
allows the device to be ultra-portable and still gather both blood flow and oxygenation data.
However, the oxygenation data will have distinct disadvantages from even a basic FD-DOS
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device as described in Section 3.1.1. For instance, the data may be affected by room light,
since the detected light is not filtered for a certain frequency. Also, only changes in Hb
and HbO2 can be observed, not absolute values. In a less extreme situation where such a
compact setup is not needed, a traditional hybrid DOS/DCS instrument should be utilized.
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Chapter 4
Validation of DCS in Brain-Injured
Adults
This chapter is based on work I have published in clinical journal Neurocritical Care [120].
The most important result is that changes in cerebral blood flow (CBF) measured by diffuse
correlation spectroscopy (DCS) are well-correlated with changes in CBF as measured by
xenon-enhanced computed tomography.
Measurement of CBF provides valuable information for clinical management of neuro-
critical care patients, but current modalities for monitoring CBF are often limited by prac-
tical and technological hurdles. Such hurdles include cost, exposure to ionizing radiation,
and the logistical challenges and increased risk to critically ill patients when transportation
out of the neurointensive care unit is required [248]. Furthermore, standard radiological
modalities such as CT, PET, and MRI cannot provide continuous measures of CBF that
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may be required in clinically unstable patients. Bedside techniques for monitoring CBF
include transcranial Doppler (TCD) ultrasonography [63], and thermal diffusion [235] and
laser Doppler flowmetries [124]. However, TCD ultrasonography is limited to observations
of large vessel flow velocities, which do not necessarily reflect microvascular perfusion in
patients with cerebrovascular disease [184], and both thermal diffusion and laser Doppler
flowmetries are invasive.
Diffuse correlation spectroscopy is a novel noninvasive optical technique with potential
as an alternative approach for bedside CBF monitoring. DCS uses near-infrared light within
the therapeutic spectral window (i.e., wavelengths from ∼650 to ∼950 nm) to provide a
continuous, transcranial measure of blood flow. Changes in blood flow are obtained from
DCS by measuring the decay rate of the detected light intensity autocorrelation function
(g2) [13, 142, 177]. At present, quantitative absolute measurements of CBF with DCS are
difficult to obtain, and thus we typically derive microvascular relative CBF (rCBFDCS),
i.e., blood flow changes relative to some baseline period. Diffuse optical spectroscopy
(DOS), otherwise known as near-infrared spectroscopy, is a more widely known optical
monitoring technique that derives concentration changes of oxy- and deoxyhemoglobin
(∆HbO2,∆Hb) [244, 96]. In this study, we have integrated DCS with DOS in a hybrid
optical instrument that simultaneously monitors CBF and oxy- and deoxyhemoglobin con-
centrations. The instrument thus facilitates monitoring both CBF and oxygen metabolism
in neurocritical care patients. The continuous and noninvasive nature of these optical tech-
niques may lead to new clinical tools in the neurointensive care unit.
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DOS and, more recently, DCS have been employed to measure tissue perfusion and
oxygenation in human populations. For example, DCS/DOS has detected changes in au-
toregulatory function associated with ischemic stroke [59] and healthy aging [61]. rCBFDCS
measurements also have been validated against fluorescent microspheres in brain-injured
piglets [264]. This study is the first to evaluate rCBFDCS in an adult neurocritical care
population.
In the study, we assessed the feasibility of DCS as a continuous monitor of CBF in neu-
rocritical care patients by comparing DCS measurements of CBF with a more established
technique, stable xenon-enhanced CT (XeCT) [176, 258]. XeCT is a diffusible tracer tech-
nique that provides quantitative CBF by administering xenon via inhalation and using the
time-dependent concentration of xenon in tissue as a measure of perfusion. XeCT CBF
calculations are based on the modified Kety-Schmidt equation, which describes the rela-
tionship of CBF to the tracer blood/brain partition coefficient and tracer concentration in
the brain and arterial blood [119]. We performed continuous bedside DCS/DOS with two
serial concurrent XeCT measurements in a cohort of patients in whom pharmacological
or physiological interventions aimed at altering CBF were administered. We hypothesized
that rCBFDCS would correlate with CBF measured by XeCT in co-registered spatial re-
gions of the injured brain, and that correlations would also exist between CBF measured
by both techniques and DOS parameters.
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4.1 Methods
Patients were considered eligible for study enrollment if they were ≥18 years old and were
receiving care in the Hospital of the University of Pennsylvania neurointensive care unit
for aneurysmal subarachnoid hemorrhage, traumatic brain injury, or ischemic stroke. Pa-
tients were recruited through the Department of Neurology and the Neurosurgery Clinical
Research Division under a research protocol for the study of portable xenon-enhanced CT.
Written consent for both the XeCT and optical monitoring portions of the study was pro-
vided by the subject (if able) or by a legally authorized representative. All studies were
conducted in the patient’s room, following protocols approved by the University of Penn-
sylvania Institutional Review Board.
As part of routine neurocritical care, a variety of physiologic parameters were mon-
itored throughout the duration of the study. Intracranial pressure (ICP) was monitored
either by an external ventricular device or a fiberoptic intraparenchymal catheter (Camino-
MPM1; Integra NeuroSciences, Plainsboro, NJ). Cerebral perfusion pressure (CPP) was
calculated from the difference between mean arterial pressure (MAP), measured by an ar-
terial line, and ICP. Peripheral oxygen saturation (SpO2) was measured by a pulse oxime-
ter, and when available, partial pressure of brain tissue oxygenation (PbtO2) was monitored
(Licox R©CMP; Integra LifeSciences, Plainsboro, NJ). The PbtO2 monitor consisted of a
polarographic Clark-type electrode inserted into cerebral white matter.
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4.1.1 DCS/DOS
The hybrid diffuse optical device used in this study contains both DCS and DOS modules.
The DCS module uses two long-coherence-length, continuous-wave 785 nm lasers (Crys-
taLaser Inc., Reno, NV) for sources, eight photon-counting fast avalanche photodiodes
(Perkin Elmer, Canada) for detection, and two 4-channel autocorrelator boards (Correla-
tor.com, Bridgewater, NJ) to compute g2. The DOS module employs three wavelengths
of amplitude-modulated near-infrared light (685, 785, and 830 nm) for sources, and two
photomultiplier tubes for detection. The probe held four optical fibers (one source and de-
tector each for DCS/DOS) at a fixed configuration (Figure 4.1) to permit the two optical
modalities to measure nearly concurrent changes in approximately the same volume of tis-
sue. The source-detector separation was 2.5 cm, and the depth of penetration of light into
tissue was approximately 1.25-1.5 cm. As shown in Figure 4.1, perturbations from voxels
within the darkest banana-shaped region (about 1.25 cm deep) have the greatest influence
on the detected optical signal, with lighter regions having progressively less influence. This
penetration depth permits the near-infrared light to interrogate microvasculature within the
surface region of adult cerebral cortex [57].
Optical probes were positioned on both sides of the forehead, over the left and right
frontal poles. rCBFDCS, ∆HbO2, ∆Hb, and ∆THC for each hemisphere were updated
every 7 s. Positioning and shielding of the probes were adjusted until adequate signal was
confirmed prior to data collection. In one instance, optical data could not be obtained;
this patient had traumatic epidural and subdural hematomas along the anterior bifrontal
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Figure 4.1: Right: Schematic of the source-detector separation of the optical probe. The
resulting area of highest probability signal origin is shown as dark gray, with the lighter
areas having lower probability of signal. Left: Schematic of optical probe, with DCS/DOS
source-detector pairs in crossed configuration at a fixed separation of 2.5 cm to measure
approximately same volume of tissue.
convexities. These particular hematomas prevented sufficient photon transmission through
the cortex due to excessive absorption by the concentrated blood.
DCS data analysis used a Brownian diffusion model to characterize relative blood flow
[142, 177], along with a semi-infinite, homogeneous medium model for the optical prop-
erties of the head to fit the measured autocorrelation functions [16]. Decay curves that
failed to fit the model produced low confidence results and were omitted from the analysis.
A modified Beer-Lambert law was used for DOS analysis [52]. Details of both DCS and
DOS analyses have been published previously [15, 34].
4.1.2 Stable Xenon-Enhanced CT
Xenon CT studies were performed with a portable CT scanner (Neurologica Ceretom R©,
seen in Figure 4.2, left) and a stable xenon delivery circuit using the following parame-
ters: inhalation of 28% xenon mixed with oxygen, 100 kV/5-6 mA CT parameters, low
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Figure 4.2: Right: Timeline of the DCS/XeCT validation study. Two XeCT scans were per-
formed, baseline and post-intervention scans. A clinical intervention – either blood pres-
sure alteration or hyperventilation – was administered in between the two scans. DCS/DOS
monitored the patient continuously throughout. Left: A photo of a patient during the
DCS/XeCT study. A black cloth covers the optical probes on the patient’s forehead, and
the portable XeCT scanner is shown.
dose resolution (2 s scan), 8 time points (2 during baseline and 6 during xenon adminis-
tration), 6 imaging locations (two 1 cm images per 2 s scan), and estimated dose CTDIw
= 120 mGy (CereTom portable CT scanner, Neurologica, Danvers, MA). Six adjacent 10-
mm-thick axial quantitative CBF maps (along with their respective confidence maps) were
generated using product software (Xenon-CT System 2, Diversified Diagnostic Products
Inc, Houston, TX) to derive blood flow (ml/100 g brain/min) for each voxel of the CT
image [258, 83, 165, 158].
The XeCT scans were used clinically to evaluate the effect of a physiological interven-
tion on CBF, e.g., manipulation of MAP or arterial partial pressure of carbon dioxide. The
specific intervention performed was at the discretion of the attending neurointensivist and
varied depending on the particular clinical scenario. For example, if regions of oligemia
were observed on the baseline XeCT, then MAP was increased by approximately 20% by
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administering increased doses of vasopressors. If regions of hyperemia were observed,
then vasopressor dose was lowered, antihypertensive medications were administered, or
ventilation rate was increased. A second XeCT scan was then performed after a minimum
of 10 min to re-evaluate CBF after the intervention. DCS/DOS monitoring was continuous
throughout the scans. A timeline schematic of the study is shown in Figure 4.2, right.
Regions-of-interest (ROIs) of approximately 6-8 ml from the CBFXeCT images, cor-
responding to the regions of cerebral cortex under the optical probes, were chosen by a
physician blinded to the optical results. Figure 4.3 shows a representative noncontrast CT
image slice where optical probes can be seen on the forehead, with outlined ROIs on the
corresponding CBF map. ROIs with greater than 30% of pixels having motion artifact or
beam-hardening artifact, e.g., due to surgical staples or monitoring equipment, were iden-
tified by visual inspection and excluded from the analysis [262].
4.1.3 Statistical Analysis
For each ROI, the change in relative CBFXeCT (rCBFXeCT ) was calculated as the per-
centage change from the baseline scan:
rCBFXeCT = (CBFXeCT,IN − CBFXeCT,BL)/CBFXeCT,BL. (4.1)
Here CBFXeCT,IN refers to absolute CBFXeCT measured after intervention from the sec-
ond scan, and CBFXeCT,BL is absolute CBFXeCT from the baseline scan. All continuous
time-series data (DCS/DOS/MAP) were computed using the average (〈〉) of the 2-min pe-
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Figure 4.3: Left: Representative axial slice from bone-windowed, non-contrast CT scan
(Pt. 7) showing optical probes on both sides of the forehead (red arrows). Right: CBF
map from XeCT baseline scan of the same axial slice with ROIs under DCS/DOS probes
outlined. Color scale shows absolute blood flow in mL/100g/min.
riod prior to xenon administration for both baseline (∆tBL) and intervention (∆tIN ) XeCT
scans:
rCBFDCS =
〈rCBFDCS(∆tIN)〉 − 〈rCBFDCS(∆tBL)〉
〈rCBFDCS(∆tBL)〉
. (4.2)
The changes in DOS parameters and vitals were defined as
∆Y = 〈Y (∆tIN)〉 − 〈Y (∆tBL)〉, (4.3)
with Y representing the parameter of interest. The period prior to xenon administration
was used to exclude the possible effects of hemodynamic change due to pharmacological
effects of xenon gas [44].
Spearman’s rank coefficients were used to assess various correlations between rCBFXeCT ,
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rCBFDCS , ∆HbO2, ∆Hb, and ∆THC. To analyze the effects of xenon wash-in on CBF,
a paired Student’s t-test was used to compare population-averaged CBF from the minute
before xenon inhalation had begun to population-averaged CBF at the time that xenon had
fully washed in (6 min after start of inhalation).
4.2 Results
Clinical and study data for the 10 episodes of measurement are provided in Table 4.1. The
eight patients (five males/ three females) had a mean age of 48 years (range, 18 to 82 years).
The Glasgow Coma Score (GCS) ranged from 3 to 15 on admission, and from 3 to 9 on
the day of measurement, while study timing ranged from ICU day 2 to 9. Interventions
included decrease in vasopressor medication dose (four patients), increase in vasopressor
medication dose (two patients), increase in ventilator respiratory rate (one patient), and
increase in antihypertensive medication dose (one patient). Pharmacological and physio-
logical interventions are summarized in Table 4.1.
Comparisons between XeCT and DCS/DOS parameters were performed using at least
one ROI from seven patients (due to poor XeCT confidence, thus exclusion, for both ROIs
in Pt. 5), while comparisons between DOS and DCS parameters were performed using data
from all eight patients. Changes in blood pressures, CBFXeCT , and DCS data for baseline
and intervention measurements with sufficient confidence are in Table 4.2.
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Table 4.1: Patient clinical and study data.
No. Gender Age Injury Initial Study Intervention
GCS GCS
1 F 62 SAH 15 8 Phenylephrine ↓
2 M 18 TBI 3 7 Ventilator respiratory rate ↑
3 M 23 AIS 7 3 Labetalol ↑
4 M 46 SAH 14-15 6 Norepinephrine ↑
5 M 38 SAH 15 9 Phenylephrine ↑
6 M 82 TBI 11 6 Norepinephrine ↓
7-1 F 50 SAH 3 3 Norepinephrine ↓, Phenylephrine ↓
7-2 3 Norepinephrine ↓
8-1 F 55 SAH 14 3 Norepinephrine ↓, Phenylephrine ↓
8-2 3 Vasopressin ↓
GCS, Glasgow Coma Score; SAH, subarachnoid hemorrhage; TBI, traumatic brain injury; AIS, acute
ischemic stroke.
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Table 4.2: ∆MAP, ∆CPP, CBFXeCT , rCBFXeCT , and rCBFDCS .
No. Blood Pressure, mmHg Left CBFXeCT , mL/100g/min Right CBFXeCT , mL/100g/min Left rCBF , % Right rCBF , %
∆MAP ∆CPP CBFBL CBFIN CBFBL CBFIN XeCT DCS XeCT DCS
1 -35 -33 53.5 32.2 63.2 45.1 -39.8 -41.6 -28.7 -14.7
2 -7 -9 57.6 54.2 47.0 46.5 -18.4 4.1 -14.2 -5.5
3 -22 -17 57.1 45.0 ** ** -21.1 -45.0 ** -36.9
4 25 23 38.5 25.9 18.3 27.7 -32.8 -15.4 51.1 **
5 19 20 ** ** ** ** ** -11.2 ** -38.0
6 -17 -18 25.5 21.4 37.9 28.6 -15.8 -21.1 -24.7 -22.2
7-1 -28 -30 60.1 64.0 ** ** 6.5 ** ** 18.5
7-2 -10 -14 ** ** 38.6 35.1 ** 39.9 -9.1 20.2
8-1 -17 -10 61.6 64.2 67.5 65.7 4.1 3.2 -2.7 13.9
8-2 -8 -2 86.5 76.7 ** ** -11.3 -5.9 ** 7.7
** XeCT or DCS data were not of acceptable confidence for use
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4.2.1 Comparison of rCBFXeCT and rCBFDCS Data
Changes in CBF measured by DCS and XeCT correlated well and were in good agree-
ment, as shown in Figure 4.4. Figure 4.4, top, shows the observed correlation between
rCBFXeCT and rCBFDCS (RS = 0.73, P = 0.010), indicating a positive and significant
association between the two quantities. The linear fit by simple regression has a slope equal
to 1.1, with an offset of 9.3%.
Figure 4.4, bottom, is the Bland-Altman plot that defines agreement between two tech-
niques measuring the same parameter [12]. The difference of the two quantities is plotted
versus the average, and all but one data point is within two standard deviations of the dif-
ference mean, meaning relatively good agreement.
∆HbO2 was moderately correlated with rCBFXeCT and bordered on significance (RS
= 0.57, P = 0.053). Correlation was not found for either ∆Hb (RS = -0.51, P = 0.087) or
∆THC (RS = 0.41, P = 0.193).
Detailed results follow for a subarachnoid hemorrhage patient (Pt. 1), a 62-year-old
female with a ruptured aneurysm at the middle cerebral artery bifurcation. We studied her
on the 9th day after aneurysm rupture, which was clipped on the 2nd day. After the base-
line XeCT scan, the phenylephrine drip rate was gradually lowered by 274 µg/min, and a
decrease in CBF was observed by both modalities for the post-intervention scan. A time-
line of scans and drip rate changes is shown in Figure 4.5, corresponding to the continuous
time-series of rCBFDCS monitored throughout the study. In this case, clinicians decided
to decrease the phenylephrine level after seeing the post-intervention scan because they felt
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Figure 4.4: Scatter plot (top) and Bland-Altman plot (bottom) illustrating the correlation
and agreement, respectively, between rCBFDCS and rCBFXeCT calculated from ROIs
located on the frontal poles of each patient, under the optical probes. The fit line has a
slope of 1.1 and an offset of 9.3%. All but one data point is within two standard deviations
of the difference between rCBFDCS versus rCBFXeCT .
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Figure 4.5: Time-series of continuous rCBFDCS from an example patient (Pt. 1) dur-
ing concurrent validation with XeCT with timeline showing phenylephrine levels. Letters
A-D indicate alterations of phenylephrine drip rate. Vertical lines for baseline (BL) and
post-intervention (IN) XeCT scans indicate beginning and end of scan. Phenylephrine at
baseline was 300 mcg/min, then lowered to (A) 150 mcg/min, (B) 66 mcg/min, (C) 26
mcg/min. Level at post-intervention scan was 26 mcg/min. Clinical decision made to raise
drip rate after scans to (D) 66 mcg/min.
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that CBF was too high. High CBF can be dangerous because of increased ICP as well as a
potential higher chance of aneurysm rebleed. Thus, phenylephrine, and subsequently CBF,
was lowered to a more moderate level.
Comparing the relative changes in CBF from both modalities, rCBFXeCT fell -39.8%
and -28.7% for left and right ROIs respectively, while rCBFDCS fell -41.6% and -14.7%.
MAP showed a decrease of 35 mmHg. Agreement was very good in this patient, in the sign
and magnitude of the CBF changes, as well as in hemispheric disparity.
4.2.2 Effects of Xenon Inhalation
Figure 4.6 illustrates one patient’s reaction to xenon inhalation. rCBFDCS and ∆THC
changed by 10.9% and 2.1 µM , respectively, in the left frontal cortex and 6.4% and 1.3
µM , respectively, in the right frontal cortex, while MAP increased by 16 mmHg. Such
responses observed among the cohort were heterogeneous, and, as a result, they were not
significant in the population as a whole (2.6%± 11.5%, P = 0.191) with a range of -21.3%
to +29.2% relative to baseline. ∆HbO2 (0.1 µM ± 1.9 µM , P = 0.853) and ∆THC (0.4
µM ± 1.4 µM , P = 0.089) varied similarly, while ∆Hb increased (0.4 µM ± 1.0 µM , P
= 0.035).
Figure 4.7 shows the spread in individual patient responses in both optical parameters
and vitals. Many times, even left and right probes in the same patient behaved in an opposite
manner. This is undoubtedly due to the heterogeneity of patients’ injuries and degree of
impaired autoregulation.
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Figure 4.6: Example of xenon-enhanced flow activation. Vertical lines indicate the follow-
ing marks: beginning of baseline CT scan (BL), xenon gas washing in, and lastly end of
xenon-CT scan. Measurements from the left and right frontal optical probes are indicated
by light gray and dark gray lines, respectively. Once xenon begins to wash in, rCBFDCS in
both hemispheres begins to increase (top panel) and elevated CBF is maintained throughout
the duration of the scan. ∆THC increases in both cerebral hemispheres during the scan
(middle panel), with a concurrent rise in MAP (bottom panel).
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Figure 4.7: All individual patient results of xenon-enhanced flow activation. The first
point indicates baseline (BL), and the following points are the number of minutes that
pass after xenon gas begins to wash in. At minute 5, the xenon has stopped. Each color
represents a different episode of measurement, where two scans occurred per episode. Note
the heterogeneity of patient responses.
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4.3 Discussion
In this preliminary study, the feasibility for non-invasive continuous bedside CBF and oxy-
genation monitoring in the neurocritical care unit using a hybrid optical device was demon-
strated. Importantly, DCS/DOS monitoring of frontal cortical microvascular hemodynam-
ics was performed non-invasively across a range of patients without requiring transport
outside the neurointensive care unit. Only frontal epidural or subdural hemorrhages with
large enough absorbance to prevent photon detection posed a barrier to the optical sig-
nal. DCS measurements of changes in relative CBF correlated well with changes in CBF
measured by a well-established, low-throughput technique: stable xenon-enhanced CT. In
addition, significant correlations between DCS measurements of rCBF and DOS mea-
surements of ∆HbO2 and ∆THC were demonstrated. The association between ∆HbO2
and rCBFXeCT only bordered significance (P = 0.053), while no correlation was found
for ∆THC or ∆Hb with rCBFXeCT .
DCS has not been previously validated in critically brain-injured patients. XeCT is one
method used to assess CBF in these patients, with the advantage of providing quantitative
CBF measurements and coverage through much of brain parenchyma. However, XeCT
requires exposure to ionizing radiation and cannot provide continuous or even frequent
CBF measurements. The good correlation between DCS- and XeCT-measured CBF in this
study suggests that DCS may therefore complement existing perfusion imaging techniques
by providing continuous, bedside monitoring of CBF in specific cortical ROIs.
As a secondary aim, we examined the correlations between changes in DOS parame-
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ters (∆HbO2, ∆Hb, and ∆THC) and changes in CBF, as determined by both DCS and
XeCT. DOS assessment of ∆HbO2 is sometimes used as a surrogate of CBF. In this study,
we found moderate correlation with rCBFDCS but not with rCBFXeCT . One explanation
for this finding is simply that more data were available to compare DCS to DOS than to
compare XeCT to DOS (due to low confidence images from XeCT). The small number
of patients was the main limitation of the study, and may have introduced a bias. How-
ever, perturbations in cortical metabolic rate, ICP, arterial inflow, or venous drainage may
also complicate the relationship between ∆HbO2 and CBF in neurocritical care patients.
Our findings suggest that direct measurements of CBF using DCS are superior to DOS
surrogates and will enhance the diagnostic specificity of transcranial optical monitoring.
Both DCS and DOS detected the effects of xenon inhalation on CBF and oxygenation.
This well-documented phenomenon (”xenon-enhanced flow activation”) occurs with the
inhalation of stable xenon. As an inert gas, xenon is an anesthetic in high concentrations
(70%) [44]. Horn et al. [101] observed xenon-enhanced flow activation in a brain-injured
population (using thermal diffusion flowmetry) and demonstrated variability in the magni-
tude of CBF response (-29% to +44% relative to baseline) that was similar to the variability
detected by DCS (-21.3% to +29.2% relative to baseline). Studies by Giller et al. and Hart-
mann et al. recorded a heterogeneous response in blood velocity and flow even in a healthy
cohort [90, 77]. To our knowledge, there are no prior studies employing optics to investi-
gate the effects of xenon inhalation on oxygenation. Examination of the full time-course of
CBF throughout XeCT scans could improve the accuracy of the CBF map, but calculations
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of a simulated 3545% CBF increase due to xenon-enhanced flow activation yield only a
minor 35% enhancement in calculated flow as most of the calculations are completed prior
to the onset of flow activation [166, 78]. Thus, despite inducing changes in CBF during
xenon gas inhalation, the resulting enhancement or reduction in calculated CBF is small
compared to errors due to CT noise, motion artifacts, etc.
Like DOS, DCS has several clinical limits. Light penetration depth is only a few cen-
timeters due to light attenuation by tissue. In the present application, flow measurements
were limited to near the surface of the cerebral cortex. In addition, optical data could not
be resolved in the presence of underlying extra-axial hemorrhage. Edema directly beneath
the optical probes may also prevent signal detection when light absorption is high. Further-
more, since DCS detects changes in CBF more reliably than absolute blood flow. Thus,
measurements during a baseline period must be obtained prior to longterm monitoring.
Development of an absolute measure of CBFDCS is an area of active research, although
arguably, trends in CBF may be more clinically relevant since absolute healthy/ischemic
thresholds remain unclear [217, 221, 79].
DCS is also limited by the fact that it is a local measure of CBF, and each sourcedetector
pair is only able to probe a region of several cubic centimeters in size. However, multiple
probe pairs could be strategically placed with the guidance of CT or MRI to provide contin-
uous monitoring of the most clinically relevant areas of the brain. Continuous noninvasive
CBF measurements in multiple regions could be generated using DCS with significantly
less morbidity than using multiple intracerebral monitors.
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The good correlation between DCS and XeCT observed in this pilot study provides sup-
port for further evaluation of the clinical utility of DCS. Given the dynamic, evolving, and
heterogeneous nature of intracranial pathology in brain-injured patients, continuous CBF
monitoring may provide the neurointensivist with an important tool for early detection of
secondary injury. Since CBF reductions often precede the onset of new clinical symp-
toms and infarction, DCS monitoring has the potential to detect changes in cerebrovascular
physiology while ischemic changes are still reversible. In addition, the configuration of hy-
brid instrumentation with DOS would provide comprehensive assessment of cortical blood
flow and oxygenation using a single device and the same probes. Additional studies are
warranted to assess the utility of DCS/DOS for neurocritical care, such as by correlating
long-term DCS/DOS measurements of cerebrovascular hemodynamics with patient out-
come.
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Chapter 5
Effects of Posture Change on Healthy
Adults
Posture change evokes hemodynamic responses in the cerebral and systemic vasculature
aimed at maintaining cerebral perfusion. Venous return of blood flow to the heart is altered,
leading to dynamic changes in vascular tone and the initiation of the systemic baroreceptor
reflex. These cerebral and systemic hemodynamic responses occur in close temporal rela-
tion to maintain cerebral blood flow (CBF) across a mean arterial pressure (MAP) range
of approximately 60-160 mmHg in normotensive people. Studies of healthy subjects have
demonstrated that the systemic response to postural change, the baroreceptor reflex, is im-
paired with aging [80]. In addition, aging is associated with lower baseline blood flow
velocities in the anterior cerebral artery (ACA), middle cerebral artery (MCA) and pos-
terior cerebral artery (PCA) [126], as well as lower baseline CBF [145] and an increased
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incidence of orthostatic hypotension [210]. The effect of healthy aging on cerebrovascular
autoregulation (CA), however, has yet to be fully elucidated.
The most commonly used modality for assessing the effect of aging on CA has been
transcranial Doppler (TCD) ultrasonography. TCD experiments have demonstrated that
healthy elderly subjectsmaintain adequate autoregulatory function under both dynamic [26,
132, 218] and static conditions [26, 132, 257]. These TCD findings may be explained by
a pronounced vasodilatory response to decreased cerebral perfusion pressures in elderly
subjects during acute orthostatic stress [218]. However, while TCD studies have generally
yielded consistent results about the absence of an aging effect in CA, these studies rely on
an assumption that macrovascular CBF velocity is indicative of microvascular CBF.
The application of diffuse correlation spectroscopy (DOS), otherwise known as near-
infrared spectroscopy (NIRS), to CA studies has provided an opportunity to evaluate this
key assumption. Studies of healthy subjects using TCD and DOS concurrently have gener-
ally validated the correlation between macrovascular CBF velocity and microvascular oxy-
genation during steady-state conditions [184], during alterations in end-tidal CO2 (EtCO2)
[213] and during orthostatic stress [125]. However, data from several DOS studies have
conflicted with TCD data regarding the effect of healthy aging on autoregulatory function.
For example, Mehagnoul-Schipper et al [149] found that elderly (mean age 74 years), but
not young (mean age 27 years) subjects experienced significant declines in frontal cortical
blood oxygenation and blood volume during supine-to-standing posture change. This find-
ing was reproduced in a follow-up experiment in which serial DOS measurements were
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performed in elderly subjects (mean age 75 years) during orthostatic stress [148]. Hunt et
al [103] studied ten healthy subjects of mean age 60 years and demonstrated a significant
postural decline in the ratio of oxygenated hemoglobin to total tissue hemoglobin concen-
tration. The lack of concordance between TCD and DOS data in autoregulation studies may
reflect differences in measured parameters and underscores the importance of developing
a modality that can directly measure microvascular CBF to more completely characterize
autoregulatory function.
We thought instead of using diffuse correlation spectroscopy (DCS) to provide direct
measurements of microvascular relative CBF (rCBF ) instead of the surrogate measures of
CBF provided by DOS – total hemoglobin concentration (THC), oxyhemoglobin concen-
tration (HbO2) and deoxyhemogobin concentration (Hb). These measurements are only
accurate markers of CBF if arterial oxygen content and cerebral metabolic rate remain
constant.
In this prospective observational study, we aimed to explore the effects of healthy aging
on cerebral hemodynamic responses to posture change by utilizing hybrid diffuse optics
for comprehensive cerebrovascular hemodynamic monitoring. We studied a large cohort
of subjects across the age continuum, rather than examining cerebral hemodynamics at the
extremes of age. We also examined the correlation between DCS and DOS measurements
in order to assess whether hybrid diffuse optics can provide additional information about
cerebral hemodynamics that cannot be obtained by DOS alone. Finally, by defining the nor-
mative response of cerebral hemodynamics to posture change across the age continuum, we
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aimed to establish a control data set for comparison with clinical brain-injured populations,
such as those with ischemic/hemorrhagic stroke or traumatic brain injury. Note that this
chapter is based on work I have published in Physiological Measurement [61].
5.1 Methods
This study was conducted at the Hospital of the University of Pennsylvania. The study
protocol was approved by the Institutional Review Board at the University of Pennsylvania.
Written informed consent was provided by all subjects, who were recruited by posting fliers
in the Hospital of the University of Pennsylvania and from a database maintained by the
Center for Cognitive Neuroimaging at the University of Pennsylvania.
Subjects were excluded from the study if they had a history of hypertension, diabetes
mellitus, hyperlipidemia, atrial fibrillation, congestive heart failure, coronary artery dis-
ease, previous myocardial infarction, previous stroke, previous transient ischemic attack,
carotid artery disease, current smoking, previous smoking within 5 years, pulmonary dis-
ease, renal disease, or recent administration of vasoactive medications. The target enroll-
ment was 60 subjects. Subjects were enrolled across the age continuum, with a minimum
age of 18 years old. The National Institutes of Health Stroke Scale (NIHSS), a tool used by
clinicians to objectively quantify impairment due to stroke, was performed prior to study
initiation for all subjects.
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5.1.1 Optical Instrumentation
A portable, custom-built instrument (see Section 3.1.1) was used to measure rCBF , THC,
HbO2 and Hb using DCS and DOS [54]. Two optical probes were secured on both sides
of the forehead with medical grade adhesive materials and a head strap. The probes were
covered with a loose-fitting black cloth to minimize ambient light interference with the
optical signal. The regions of frontal cortical tissue investigated by each probe were ap-
proximately 4 to 5 cm apart. Each probe consisted of one light source and two detectors
– one for DCS detection and the other for DOS detection. The distance between the light
source and detectors was 2.5 cm.
Four high-speed, high-sensitivity avalanche photodiodes were used as photon counting
detectors for DCS. Data output from these photodiodes were sent to a multi-tau hardware
correlator for calculation of autocorrelation functions in real time. We then extract a blood
flow index (BFI) by fitting the autocorrelation function to a semi-infinite homogeneous
model (see Section 2.2.2). The correlator produces an independent autocorrelation curve
every 0.04 seconds. However, we used an averaging time of 3 seconds for each of the two
probes, allowing for one frame of DCS data to be acquired every 6 seconds. This 6-second
DCS data acquisition interval was followed by a 1-second DOS data acquisition interval for
both probes. Thus, a new set of DCS and DOS cerebral hemodynamic data was acquired
every 7 seconds.
The DCS light source consisted of a long coherence length, continuous wave laser (785
nm). Concurrent DOS data were obtained using three lasers (690, 785, and 830 nm), whose
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intensities were modulated at 70 MHz. A modified Beer-Lambert law (see Section 2.1.4)
was used for DOS analysis, with a differential pathlength factor (DPF) of 5.86 and 6.51 for
wavelengths of 830 nm and 690 nm, respectively [52].
5.1.2 Monitoring of Systemic Vitals
Blood pressure and heart rate (HR) were measured by a BpTRUVital Signs Monitor (VSM
MedTech Devices Inc., model BPM-300; Brooklyn, NY) prior to study initiation with sub-
jects resting in the seated position. A FinaPres (FINger Arterial PRESsure, Finapres Medi-
cal Systems, Finometer Pro Model 1 with BeatScope PC-based software; Amsterdam, The
Netherlands) device was then secured non-invasively on the right third finger for continu-
ous beat-to-beat measurement of HR, mean arterial pressure (MAP), systolic blood pres-
sure (SBP) and diastolic blood pressure (DBP). Imholz et al [105] have comprehensively
reviewed the FinaPres technology and its validation with intra-arterial blood pressure mea-
surement.
An adjustable armrest was used to keep the subject’s right third finger at the level of the
right atrium (fourth intercostal space, mid-axillary line) throughout the study. Finger posi-
tion was confirmed using the FinaPres automated height monitor, after zeroing the finger to
the level of the right atrium at the beginning of the study. The FinaPres device factors finger
height into its hemodynamic measurements to correct for any hand movements that may
occur with respect to the heart level. A loose-fitting, black piece of cloth was placed over
the patient’s right hand in order to minimize ambient light interference with the FinaPres
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Figure 5.1: Posture change protocol. Subjects were monitored for 5 minutes each at four
positions: Head-of-bed 30◦, initial (baseline) supine, standing, and recovery supine.
signal.
A disposable rubber mouthpiece was placed in the subject’s mouth with an EtCO2 mon-
itor attached to the opening of the mouthpiece (Micro-Capnograph CI240, Columbus In-
struments; Columbus, OH). A nose clip was placed over the nares to prevent nose breath-
ing. The capnograph was used to record EtCO2 continuously. A pulse oximeter (Nellcor;
Boulder, CO) was placed on the index finger of the patient’s right hand to record peripheral
arterial oxygen saturation (SpO2).
5.1.3 Posture Change Protocol
Measurements were performed in a quiet room with dim light at room temperature. The op-
tical probes were placed securely on the forehead and a stable FinaPres signal was obtained.
Cerebral hemodynamics, systemic hemodynamics, SpO2 and EtCO2 were then monitored
for 5 minutes each at the following postures (see Figure 5.1) head-of-bed angle 30◦, supine
(initial supine), standing, and supine (recovery supine).
The supine and standing positions were chosen for the protocol so that healthy sub-
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jects would be evaluated in natural postures. The head-of-bed 30◦ position was included
to provide normative, control data for future studies of clinical populations since this is a
posture at which many stroke and neurointensive care patients are kept to minimize aspira-
tion risk or decrease intracranial pressure. The head of the hospital bed was lowered from
a 30◦ to a 0◦ angle during the transition to the initial supine position, and then the subject
was asked to stand up and lie back down for the subsequent transitions to the standing and
recovery supine positions. Confirmation of optical probe placement, FinaPres finger level
and EtCO2 monitor placement was performed at the time of all posture changes, which
occurred over the span of 5 to 10 seconds for the transition from head-of-bed 30◦ to initial
supine and 30 seconds to 1 minute for the transitions from initial supine to standing and
standing to recovery supine. Subjects fasted and avoided caffeine intake for 3 hours before
the study and were also asked to void urine prior to study initiation.
5.1.4 Statistical Analysis
Analyses were carried out using library(nlme) and library(gregmisc) in R version 2.8.1
[228]. Two-sided hypothesis tests were carried out with a type I error rate of 0.05. For each
subject, the outcome of interest for rCBF was quantified relative to BFI at the initial
(baseline) supine position (BL), as follows:
rCBFi = (BFIi −BFIBL)/BFIBL (5.1)
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where BFIi is BFI measured at the ith position (i = head-of-bed 30◦, standing, or re-
covery supine). The outcomes of interest for all other cerebral and systemic hemodynamic
parameters (THC, HbO2, Hb, MAP, SBP, DBP, HR, SpO2 and EtCO2) were normalized
as follows:
∆Yi = Yi − YBL, (5.2)
where Y is the parameter of interest measured at the ith position.
A running Gaussian filter was used to smooth the DCS/DOS time series data, with a
window size of 4. At each body position, the DCS/DOS, FinaPres, SpO2 and EtCO2 data
were then averaged over the 5 min period. The beginning and ending timepoints of the
transitions between each posture were marked on both the FinaPres and optical data. The
cerebral and systemic hemodynamic data acquired during these transitions between pos-
tures are not reported because the study aimed to examine postural cerebral hemodynamic
changes, not dynamic autoregulatory changes.
Our study yielded repeated measures data on individual subjects. To account for, and
take advantage of the correlation between repeated measures on the same individual, a
linear mixed effects model was used to estimate the effect of body posture and age on
changes in the outcomes of interest [178]. The linear mixed effects model allowed for
heterogeneity in the variance of the outcome at each position. As there was no significant
hemispheric difference in any of the cerebral hemodynamic parameters at any of the body
positions, hemisphere (left or right) was not included as a covariate in the model. Rather,
measurements from the different hemispheres were analyzed as repeated measurements at
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each body position. Model fit was assessed using residuals.
We assessed the overall effect of body position on each hemodynamic parameter. We
then built models that included postural effects as well as both age and gender effects that
were allowed to vary by position. There was no a priori hypothesis regarding an effect of
gender on postural changes in cerebrovascular hemodynamics, but gender was included in
the model as a possible confounder. We used a global likelihood ratio test to ask whether
postural changes associated with age or gender were significant, by comparing the full
model to a reduced model without the term of interest. If the global likelihood ratio test
showed either strict (P < 0.05) or marginal (P < 0.10) evidence of statistical significance, a
Wald test was used to determine which specific postures might be associated with changes
from the initial supine posture. Specifically, we tested for nonzero age or gender effects
at each posture. This approach of comparing specific body postures to the initial supine
posture only if there was evidence of a global effect meant that a small number of statistical
tests were conducted, hence reducing the possibility of spurious false positive findings.
In order to account for other potential confounders, the correlation of age with body
mass index (BMI), baseline hemodynamics and baseline EtCO2 in the study population
was assessed using a Pearson’s correlation coefficient. There was no evidence of a sig-
nificant association of age with the baseline hemodynamics or baseline EtCO2 (P > 0.05
for all variables), but there was a trend toward an association between increasing age and
increasing BMI (P < 0.10). We therefore included BMI as a covariate in our models to
explore the possibility that age effects were confounded by BMI. However, inclusion of
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BMI in the models had little impact on the significance of the age effect, so results from
the models that included BMI as a covariate are not reported.
Associations between postural changes in DCS measurements of rCBF and DOS mea-
surements of THC,HbO2, Hb andHbDiff were explored using Pearson’s correlation co-
efficient. HbDiff is calculated as HbO2−Hb and has been shown to be a better indicator
of regional CBF than THC when SpO2 is kept constant [234]. We also investigated asso-
ciations between the supine-to-standing changes in systemic and cerebral hemodynamics
using Pearson’s correlation coefficient. These correlation analyses excluded six subjects
whose DOS data were not analyzed because of poor optical fiber-to-detector connection
in the DOS instrument. Three subjects had poor quality EtCO2 data due to capnograph
malfunction, and two had poor quality systemic hemodynamic data due to low FinaPres
signal. These subjects were excluded from the analyses of body posture effects on EtCO2
and systemic hemodynamics, respectively.
5.2 Results
The demographic and baseline hemodynamic characteristics of the 60 healthy subjects are
presented in Table 5.1. Age ranged from 20 to 78 years old (see Figure 5.2), with a mean
of 42.3 years. The mean BMI was 24.7 kg/m2, with a baseline BP of 115.4/74.5 mmHg
and HR of 71.3 beats per minute. None of the subjects experienced syncope or reported
pre-syncopal symptoms during the study.
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Table 5.1: Demographic information and baseline characteristics of study population (N =
60). Data listed as mean ± standard error.
Variable Mean ± SE
Male:Female 28:32
Age, years 42.3 (range 20-78)
BMI, kg/m2 24.7 ± 0.5
SBP, mmHg 115.4 ± 1.9
DBP, mmHg 74.5 ± 1.4
HR, bpm 71.3 ± 1.4
EtCO2, mmHg 39.4 ± 0.5
NIHSS All subjects scored 0
Figure 5.2: Bar graphs demonstrating the number of subjects in each age range, by decade.
Note the few number of subjects at the upper (60+ years) range of ages – an inherent
weakness of the study.
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Table 5.2: Cerebral hemodynamic and systemic responses to posture change for all subjects
(N = 60).
Parameter Head-of-Bed 30o Supine to Initial supine to
to supine stand recovery supine
rCBF , % 18.2 ± 1.5 * -25.9 ± 1.5 * 9.7 ± 1.8 *
∆THC, µM 1.9 ± 0.3 * -2.6 ± 0.4 * 1.6 ± 0.4 *
∆HbO2, µM 2.0 ± 0.3 * -3.4 ± 0.3 * 1.4 ± 0.3 *
∆Hb, µM -0.07 ± 0.1 0.8 ± 0.1 * 0.2 ± 0.1
∆MAP, mmHg -0.9 ± 0.8 5.4 ± 1.0 * 6.3 ± 0.7 *
∆SBP, mmHg 0.2 ± 1.0 1.3 ± 1.3 7.9 ± 1.0 *
∆DBP, mmHg -1.3 ± 0.7 8.6 ± 0.8 * 4.2 ± 0.6 *
∆HR, bpm -0.2 ± 1.4 12.4 ± 0.9 * -2.2 ± 0.3 *
∆SpO2, % -0.1 ± 0.1 0.8 ± 0.2 * 0.0 ± 0.1
∆EtCO2, mmHg -0.1 ± 0.2 -2.0 ± 0.3 * 0.0 ± 0.2
Data are expressed as mean ± standard error.
* Significant change with new posture, P < 0.01.
5.2.1 Cerebral Hemodynamic Responses to Posture Change
Figure 5.3 (top) displays DCS timeseries data of rCBF from a sample subject. Figure 5.3
(bottom) displays DCS timeseries data of rCBF averaged over the entire study population
on a minute-by-minute basis. Table 5.2 shows the mean changes in rCBF , THC, HbO2
and Hb that occurred with each posture change across all subjects.
All cerebral hemodynamic parameters varied significantly with body posture (P <
0.0001). Supine-to-standing posture change led to significant decreases in rCBF , THC
and HbO2, as well as a significant increase in Hb, across the age continuum (P < 0.01).
Changes in rCBF , THC and HbO2 were also significant during the transition from head-
of-bed 30◦ position to supine position. All of the cerebral hemodynamic parameters except
Hb differed significantly between the initial supine position (after transition from head-of-
bed 30◦) and the recovery supine position (after transition from standing, P < 0.01 for each
parameter). Figure 5.4 provides bar graphs for average changes in rCBF , THC, HbO2
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Figure 5.3: (Top) Timeseries data of rCBF for an example subject. (Bottom) Timeseries
data of rCBF averaged at 1 minute intervals for the entire study population (N = 60).
Standard error bars are provided at each 1 minute interval. The red vertical lines between
each posture represent the transition periods between body postures. Data within these
lines was excluded from data analysis.
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and Hb with each posture change for the entire study population.
Figure 5.4: Bar graphs for mean changes in rCBF , THC, HbO2, and Hb with each
posture change for the entire population. Error bars show standard error from the mean.
Asterisk (*) indicates a significant change from the initial (baseline) supine value.
Among the four cerebral hemodynamic parameters considered, age did not significantly
alter the magnitude of postural changes in rCBF (P = 0.25), THC (P = 0.34) or Hb (P
= 0.60) in an initial global likelihood ratio test. This test, however, provided evidence of a
trend toward significance for age-relatedHbO2 postural responses (P = 0.058). Subsequent
investigations of specific postural changes indicated a significant association between age
and HbO2 change during supine-to-standing posture change (P = 0.01). Specifically, the
magnitude of decline in HbO2 during the supine-to-standing posture change decreased
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significantly with age.
146
Table 5.3: Cerebral hemodynamic and systemic responses to posture change, including gender effects (N = 60).
Head-of-Bed 30o Supine to Initial supine to Gender
Parameter to supine stand recovery supine effect
M F M F M F p-value
rCBF , % -21.3 ± 2.1 † -15.2 ± 2.0 † -28.8 ± 2.1 -23.8± 2.0 14.0 ± 2.6 † 5.8 ± 2.4 † <0.01
∆THC, µM -2.9 ± 0.4 † -1.3 ± 0.4 † -3.2 ± 0.6 -2.4 ± 0.5 2.6 ± 0.5 † 0.9 ± 0.5 † <0.01
∆HbO2, µM -2.7 ± 0.4 † -1.5 ± 0.3 † -4.0 ± 0.5 -3.2 ± 0.4 2.3 ± 0.4 * 0.7 ± 0.4 * <0.01
∆Hb, µM -0.1 ± 0.1 † 0.2 ± 0.1 † 0.8 ± 0.2 0.8 ± 0.2 0.3 ± 0.2 0.1 ± 0.1 0.09
∆MAP, mmHg 2.0 ± 1.2 0.2 ± 1.1 6.8 ± 1.4 4.5 ± 1.3 6.0 ± 1.1 6.4 ± 1.0 0.40
∆SBP, mmHg 0.9 ± 1.5 -0.9 ± 1.4 2.2 ± 2.0 0.5 ± 1.8 7.0 ± 1.4 8.2 ± 1.3 0.50
∆DBP, mmHg 2.2 ± 1.0 0.7 ± 0.9 10.5 ± 1.2 7.4 ± 1.1 4.5 ± 0.8 4.0 ± 0.8 0.23
∆HR, bpm 0.5 ± 0.6 0.2 ± 0.4 15.2 ± 1.1 * 12.4 ± 0.9 * -2.0 ± 0.5 -2.2 ± 0.3 0.03
∆SpO2, % -0.007± 0.2 0.2 ± 0.2 0.7 ± 0.2 0.7 ± 0.2 -1.7 ± 0.2 * 0.4 ± 0.2 * <0.01
∆EtCO2, mmHg -0.3 ± 0.3 0.4 ± 0.3 -2.7 ± 0.4 -1.7 ± 0.4 -0.1 ± 0.3 0.2 ± 0.2 0.18
Data are expressed as mean ± standard error.
Values are for the average 40-year-old male (M) versus the average 40-year-old female (F) based on the fit of the linear mixed effects model.
† Significant gender effect on postural change, P < 0.05. * Significant gender effect on postural change, P < 0.01.
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Gender was associated with significant differences in overall postural changes in rCBF ,
THC, and HbO2 (P < 0.01) and showed a trend toward an effect on postural changes in
Hb (P < 0.10) (see Table 5.3). Subsequent investigations of specific postural changes did
not demonstrate differences between males and females in the supine-to-standing postural
changes for any cerebral hemodynamic parameter. However, females experienced a smaller
magnitude of postural change in rCBF , THC and HbO2 during the transition from head-
of-bed 30o to supine (P < 0.05 for the gender effect on all parameters) and during the
transition from initial supine to recovery supine (P < 0.05 for the gender effect on rCBF
and THC, P < 0.01 for the gender effect on HbO2).
Figure 5.5 provides scatter plots of the data with fitted lines representing the mean
supine-to-standing postural changes in each cerebral hemodynamic parameter for both
genders, as predicted from the fitted models. The y-intercepts indicate the mean postural
hemodynamic changes for a subject of age 20, while the slopes represent age effects. As
discussed above, gender effects were not statistically significant for the supine-to-standing
postural changes in any cerebral hemodynamic parameter but were included here so that
the models would be consistent for all postural changes. For HbO2, supine-to-standing
postural declines were substantially larger for younger than for older subjects. For exam-
ple, at age 30, the linear model predicted a mean HbO2 change for males and females of
-4.59 µM and -3.75 µM, respectively, while at age 60 the model predicted values of -2.85
µM and -2.01 µM.
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Figure 5.5: Effect of age on the supine-to-standing postural change in rCBF , THC,
HbO2, and Hb. All data are presented for males (black) and females (gray). Left and
right hemisphere values for each subject are shown as separate points. Lines represent the
predicted value of a given cerebral hemodynamic parameter as a function of age for males
(black) and females (gray). 95% confidence intervals based on our model are shown as
dashed lines for males (black) and females (gray), along with P-values for the association
between age and supine-to-standing posture change. The age effect is only significant for
supine-to-standing on HbO2 (P = 0.01). No significant gender effect was observed for any
supine-to-standing postural hemodynamic changes (P > 0.05).
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5.2.2 Systemic Responses to Posture Change
Table 5.2 shows the changes in MAP, SBP, DBP, HR, SpO2 and EtCO2 that occurred with
each posture change. All systemic hemodynamic parameters varied significantly with body
posture (P < 0.0001). No significant changes occurred in the transition from head-of-bed
30o to supine position, but during the supine-to-standing posture change subjects across the
age continuum experienced a significant increase in MAP, DBP, HR and SpO2 (P < 0.01).
EtCO2 decreased significantly with transition from supine-to-standing posture across the
age continuum (P < 0.01). MAP, SBP, DBP and HR all differed significantly between the
initial supine position and the recovery supine position (P < 0.01).
Age significantly altered the postural changes in HR (P = 0.002) and EtCO2 (P =
0.01), but not the postural changes in MAP, SBP, DBP or SpO2. Older subjects experi-
enced smaller magnitudes of change in HR and EtCO2 during the supine-to-standing pos-
ture change. Gender was associated with significant alterations in the magnitude of postural
change in HR and SpO2, with females having a smaller increase in HR during the supine-
to-standing posture change (P < 0.01) and a small increase, rather than a decline, in SpO2
at the recovery supine position, as compared to the initial supine position (P < 0.01) (see
Table 5.3).
5.2.3 Correlations Between Parameters
DCS measurements of rCBF correlated weakly, but highly significantly, with DOS mea-
surements of THC (R = 0.25, P = 0.008), HbO2 (R = 0.30, P = 0.002) and HbDiff (R
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= 0.30, P = 0.002) during the supine-to-standing posture change. DCS measurements of
rCBF did not correlate with DOS measurements of Hb (R = 0.045, P = 0.64).
Mean supine-to-standing changes in rCBF were significantly associated with mean
changes in SBP (R = 0.30, P = 0.02). Postural changes in frontal cortical rCBF , THC,
HbO2, andHbwere not associated with any of the other systemic hemodynamic parameters
during the supine-to-standing position change.
5.3 Discussion
This study provides new insights into the effects of healthy aging on cerebral hemodynamic
responses to posture change. The main finding of the study is that healthy aging alters the
magnitude of change in frontal cortical HbO2, but not rCBF , THC, or Hb during supine-
to-standing posture change. This age effect was found to be continuous, not one that only
becomes significant at the extremes of age. We also demonstrated that posture change sig-
nificantly alters frontal cortical rCBF , THC, HbO2, and Hb across the age continuum.
This study also provides the largest cohort of normative optical data on postural hemo-
dynamic changes in a healthy population, which can serve as a reference for comparative
analysis in clinical, particularly brain-injured, populations.
The absence of an age-related effect on the magnitude of postural changes in rCBF
suggests that aging is not associated with a decline in global autoregulatory function, or
more specifically, a decline in the autoregulatory capacity of the anterior cerebrovascular
circulation. However, we did demonstrate that aging attenuates the magnitude of frontal
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cortical HbO2 decline during supine-to-standing position change, a finding that is consis-
tent with DOS measurements of postural HbO2 changes from a recent CA aging study by
Kim et al [122]. The incongruity between age-related postural changes in rCBF andHbO2
may be partly explained by considering prior studies that demonstrate an age-dependent
decrease in baseline CBF [145, 126]. Although our optical instrument does not measure
absolute changes in CBF, our observation that there is no age effect on postural changes
in relative CBF, when considered in the context of a higher baseline CBF in younger sub-
jects, suggests that there are age-dependent changes in absolute CBF with posture change.
Specifically, one would expect a larger absolute decline in CBF during supine-to-standing
posture change in younger as compared to older subjects. Assuming no change in frontal
cortical oxygen metabolism with posture change [170], a larger magnitude of decline in
absolute frontal CBF during supine-to-standing posture change may be expected to cause a
statistically significant, but clinically insignificant, increase in the magnitude of decline in
frontal HbO2 in young subjects.
Another possible explanation for the incongruity between age-related postural changes
in rCBF and HbO2 is that there are age-dependent effects on shunting of blood around the
circle of Willis during posture change. Indeed, a redistribution of cerebral perfusion to the
posterior circulation during supine-to-head-up tilt posture change has been demonstrated
across the age spectrum [246]. Furthermore, there is TCD evidence that posterior circula-
tion, but not anterior circulation, autoregulatory function is compromised in older subjects
[93, 218], suggesting that older subjects may be less able to redirect perfusion from the
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anterior to the posterior circulation during posture change.
Other potential explanations for the difference between age-related postural changes
in rCBF and HbO2, such as age-related postural changes in frontal cortical metabolic
rate or arterial oxygen saturation, are less likely. With regard to the former, there is no
evidence to suggest that frontal cortical metabolic rate is altered by posture change even
independent of age. Rather, positron emission tomography experiments have shown that
increased metabolism occurs primarily in the cerebellum, visual cortex and midbrain in
subjects standing still with eyes open, not in the frontal lobe cortex [170]. Indeed, we
might have expected to observe an age effect on postural changes inHb, independent of any
change in THC, if there were an age-related postural change in frontal cortical metabolic
rate. By contrast, we observed statistically significant declines in THC and increases in
Hb during the supine-to-standing posture change that were similar for all subjects across
the age continuum. With regard to the possibility of age-related changes in arterial oxygen
saturation, our pulse oximetry data did not demonstrate any age-related effect on postural
changes in SpO2 (P = 0.44).
An implication of the observed incongruity between age-related postural changes in
rCBF and HbO2 is that the hybrid diffuse optical technique provides an advantage over
using DOS alone for cerebral hemodynamic monitoring because DOS measurements of
HbO2 are not adequate surrogates for DCS measurements of rCBF . This point is under-
scored by our correlation analyses, which demonstrated that rCBF only weakly correlated
with changes in HbO2 (R = 0.30, P = 0.002), HbDiff (R = 0.30, P = 0.002) and THC
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(R = 0.25, P = 0.008) during the supine-to-standing posture change. Although these corre-
lations were statistically significant, the relatively low R-values indicate that microvascular
rCBF responses are only partially explained by HbO2 and THC responses. Similar find-
ings were observed in a recent study by Schytz et al [204] in which calculation of a blood
flow index using continuous wave DOS in conjunction with an intravenous tracer did not
correlate with 133Xe-SPECT measurements of CBF in a healthy population (R = 0.133, P
= 0.732).
The physiological basis for the weak correlations between DCS and DOS measure-
ments in healthy populations is not completely clear, but discrepancies are certainly ex-
pected in clinical populations for whom perturbations in cortical metabolic rate, intracranial
pressure, arterial inflow, or venous drainage complicate the relationship between CBF and
oxygenation. Indeed, absent or weak correlations between postural changes in frontal cor-
tical rCBF and THC have previously been demonstrated in acute ischemic stroke patients
(R = 0.11, P = 0.3) [59], as well as traumatic brain injury and aneurysmal subarachnoid
hemorrhage patients (R = 0.3, P = 0.01) [120]. These data suggest that DCS measure-
ments of microvascular rCBF cannot be predicted by DOS measurements of microvascu-
lar THC or HbO2 in either healthy or clinical populations. The DCS/DOS hybrid optical
technique thus may provide a more comprehensive assessment of cerebral microvascular
hemodynamics than can be obtained by using DOS alone.
An unexpected finding in this study was the relatively large magnitude of the mean de-
cline in rCBF during supine-to-standing posture change across the age continuum (25.9%
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± 1.5%). Notably, none of our subjects experienced pre-syncopal symptoms upon stand-
ing, and the 95% confidence interval of the postural rCBF decline (23.3 to 28.8%) does
not approach the 40% threshold that is associated with onset of pre-syncopal symptoms
in healthy young and healthy old subjects [69]. While there are no prior DCS studies of
healthy subjects to which our data can be compared, TCD studies have found declines in
MCA CBF velocity ranging from 15 to 20% in healthy subjects during orthostatic stress
[26, 132, 218].
In addition, Kim et al [122] observed an MCA blood flow velocity decline of 16 to
29% immediately following a supine-to-standing posture change, though this decline was
attenuated to 6 to 15% after 5 minutes of standing. Alperin et al [5] observed a 12% average
decline in global CBF using a vertical gap MRI during supine-to-sitting posture change in
ten healthy subjects (average age 39 years old). Though this magnitude of CBF change
is smaller than the supine-to-standing rCBF change observed in our study, one would
expect that standing causes a larger CBF decline than sitting since venous return of blood
to the heart is more compromised in the standing position. It should also be highlighted
that our data pertain only to frontal cortical CBF, and there may be regional variations in
CBF that contribute differently to the overall effects of posture on global perfusion. Finally,
the magnitudes of frontal cortical HbO2 change (-3.4 µM ± 0.3 µM) and Hb change (0.8
µM ± 0.1 µM) during supine-to-standing posture change found in our DOS measurements
are consistent with data from prior DOS studies [149, 148], suggesting that our optical
instrumentation protocol was not systematically flawed.
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Table 5.4: Comparisons between ”young” cohorts in the present study, Mehagnoul-
Schipper et al (2000) and Tachtsidis et al (2004).
Variable Study cohort Mehagnoul-Schipper Tachtsidis et al (2004)
et al (2000)
Baseline characteristics and systemic hemodynamics
N 10 10 10
Gender 4M, 6F 4M, 6F 8M, 2F
Age, years 27.1 ± 7.2 27.1 ± 6.9 24 ± 6
Age range, years 22 to 45 22 to 45 Not provided
BMI, kg/m2 23.4 ± 3.2 21.9 ± 3.2 Not provided
SBP, mmHg 110 ± 15 118 ± 7 Not provided
DBP, mmHg 70 ± 10 77 ± 6 Not provided
HR, bpm 71 ± 13 61 ± 7 Not provided
Supine-to-standing changes in DOS measurements
∆THC, µM -3.1 ± 1.3 0.2 ± 4.9 1.0 ± 2.93
∆HbO2, µM -3.9 ± 1.1 -1.2 ± 5.4 -0.57 ± 1.96
∆Hb, µM 0.7 ± 0.3 1.4 ± 2.4 Not provided
In order to further evaluate the validity of our optical instrumentation, we performed
a post hoc comparative analysis of our DOS measurements with those of two prior DOS
studies. We selected the ten ”young” subjects from our study population whose average age
(27.1 years) and age distribution (22 to 45 years) best match the ages of the young cohorts
in the Mehagnoul-Schipper et al [149] and Tachtsidis et al [226] studies. The cohorts
from the three studies had similar average BMI (21.9-23.4 kg/m2), SBP (110-118 mmHg),
DBP (70-77 mmHg) and HR (61-71 bpm). The supine-to-standing postural changes in the
DOS measurements of ∆THC, ∆HbO2, and ∆Hb in our study had distributions that were
broadly overlapping with all of the DOS measurements performed in the other two studies
except for the ∆HbO2 changes found by Tachtsidis et al [226] (see Table 5.4). While the
results from our study are generally consistent with these prior DOS data, two possible
explanations for the small differences may be that the duration of time at each posture
varied between the studies, and the source-detector separation for our study was 2.5 cm,
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whereas Mehagnoul-Schipper et al [149] and Tachtsidis et al [226] utilized source-detector
separations of 5.5 cm and 5 cm, respectively.
The observed 25.9% decline in rCBF is partly attributable to the significant decline in
EtCO2 that was found with postural change across the age spectrum, consistent with previ-
ous studies of EtCO2 changes during orthostatic stress [26]. Assuming that CBF changes
by approximately 2-4% for every mmHg change in EtCO2 [215], an rCBF change of 4-
8% would be expected from the 2.0 mmHg ± 0.3 mmHg mean decline in EtCO2 that was
found in our study population. Also contributing to the large postural decline in rCBF
is the presumed decline in cerebral perfusion pressure, despite the increase in MAP that
was measured at the level of the heart. As demonstrated by Harms et al [89], even when
MAP measured at the level of the heart remains constant or increases slightly in healthy
subjects during supine-to-standing posture change, the calculated MAP at the level of the
MCA declines by an average of 19 mmHg after 1 minute, and 14 mmHg after 5 minutes.
Meanwhile, the postural decline in intracranial pressure is likely smaller [5], suggesting
that the overall effect of supine-to-standing posture change in healthy subjects is a decrease
in cerebral perfusion pressure.
We also found significant differences between all cerebral and systemic hemodynamic
parameters, except Hb, SpO2 and EtCO2, at the initial supine position as compared to the
recovery supine position. In a post hoc analysis we examined the Pearson’s correlation
between cerebral hemodynamic parameters at the two supine positions. This analysis in-
dicated strong correlations (R = 0.67-0.76, P < 0.05) for all of the cerebral hemodynamic
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parameters at the two supine positions, suggesting good reproducibility of the DCS/DOS
measurements. These strong correlations are expected given that the light paths of DCS
and DOS are similar. Durduran et al [59] recently found a similarly high degree of repro-
ducibility in repeated measurements at the supine position in a population of acute ischemic
stroke patients using the same DCS/DOS apparatus. The significant differences in cerebral
hemodynamics at the two supine positions are therefore likely physiological in nature, not
due to instrument error. A plausible physiological mechanism that explains these findings
is an ”overshoot phenomenon,” whereby cerebral perfusion, blood volume and oxygenation
all increase transiently when the subject transitions to the supine position from standing.
It is likely that if we had observed our subjects for longer than 5 minutes at the recovery
supine position, rCBF , THC and HbO2 would have ultimately trended down to the levels
observed at the initial supine position.
The systemic hemodynamic responses to posture change observed in this study are in
general agreement with previous studies showing that aging significantly alters changes
in HR, but not MAP, DBP or SBP, during posture change [111, 149]. Our finding that
only SBP correlated strongly with changes in rCBF during the supine-to-standing posture
change differed from the correlations between postural changes in HbO2 and Hb, and
DBP and HR, found by Mehagnoul-Schipper et al [149]. A possible explanation for this
difference is that the standard error of the mean was quite low for the baseline SBP of our
study population, suggesting that our older subjects may have been healthier than the older
subjects in the Mehagnoul-Schipper et al [149] cohort. Additionally, whereas Mehagnoul-
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Schipper compared 18 subjects over 70 years old to 10 subjects under 45 years old, our
study included only one subject over 70 years of age.
The observed gender effect on several of the cerebral and systemic hemodynamic pa-
rameters was a finding for which we did not generate an a priori hypothesis. We included
gender effects in our statistical model in order to ensure that any effects we observed for
age were independent of gender effects. We are not aware of prior studies of the effect of
gender on cerebral hemodynamic postural changes in a healthy population. It is possible
that differences in behavior between the men and women in our study population, such as
frequency of exercise, may have affected our cerebral and systemic hemodynamic measure-
ments. We consider our observation of gender effects on postural hemodynamic responses
to be a finding that may form the basis for hypothesis generation in future investigations of
cerebral hemodynamics.
An important technical consideration relating to our optical instrumentation protocol is
that we used the same DPF value in DOS measurements for all subjects. Prior DOS aging
studies have similarly utilized an age-independent DPF [149, 148, 226], yet Duncan et al
[52] have shown that the DPF may change as a function of age. We therefore performed
a post hoc analysis to determine whether the utilization of age-specific DPFs from the
Duncan et al [52] study would alter our results. For our youngest subject (20 years old),
DPFs of 6.06 and 5.39 were used for the 690 nm and 830 nm wavelength calculations. For
our oldest subject (78 years old), DPFs of 7.62 and 6.87 were used. The postural changes
in HbO2 and Hb that were calculated for our oldest and youngest subject using these age-
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specific DPFs all had error bars that included the postural changes that were calculated with
our standard DPFs of 6.51 (at 690 nm) and 5.86 (at 830 nm). It therefore appears that the
utilization of age-specific DPF values would have had little substantive effect on our results
and would have made it difficult to compare our findings with prior DOS studies that used
age-independent DPF values.
Another technical consideration in optical studies of cerebral hemodynamics is vari-
ability in skull thickness and cerebrospinal fluid (CSF) layer thickness between subjects.
Okada and Delpy [168] demonstrated with a Monte Carlo simulation model that variations
in skull thickness and CSF layer thickness may alter the DOS detection volume. In an-
alyzing our results to derive physiological property variations, we have assumed that the
interrogated brain tissue volumes are determined solely by tissue optical properties and are
not age or gender dependent. We do not believe that skull thickness is a factor for our
measurements or conclusions. Skull thickness has been shown to vary randomly between
subjects in an age-independent and gender-independent manner [137] and would not there-
fore be expected to confound an analysis of age-related postural changes in the optical
signal. On the other hand, cerebral cortex thickness has been shown to decrease [199, 185]
and CSF layer thickness to increase [161, 84] as a function of age-related cerebral atrophy.
Similarly, gender may also affect the scalp-to-brain distance, with women being found to
have smaller age-related changes in intracranial CSF volume and left hemispheric atrophy
than men [84]. Finally, intracranial CSF volume may change during posture changes [5].
From an experimental standpoint, serial radiological imaging of all subjects at different
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postures to determine inter-subject or postural variations in skull and CSF layer thickness is
impractical. Thus, it is extremely difficult to discern whether a substantive systematic error
in our study could have been introduced by these age-, gender- or posture-related detec-
tion volume physiological changes. Nevertheless, we expect the effects of these potential
methodological errors to be ameliorated by the fact that each subject effectively acted as
his or her own control. The importance of absolute detection volume is reduced because we
are probing the relative changes in cerebral hemodynamics in the same volumes at different
postures. As a result, many of the random physiological effects that modify the absolute
optical signals are self-normalized. We therefore believe that the present study, as with
other optical studies, is accurate to within the methodological limitations of diffuse optics
[96].
Another consideration in optical measurements of cerebral hemodynamics is the pos-
sibility of extracranial blood flow influencing the optical signal. Our analysis implicitly
assumes that measured differential signals are due only to cortical tissue responses. With
our present probe-pad configuration, we believe that there is substantial evidence to suggest
that the potential effects of scalp blood flow are minimal. Previous studies performed by
our laboratory with the same probe apparatus and source-detector separation have validated
DCS measurements of rCBF in critically ill adults using an established tool for measuring
CBF, Xenon-CT [120], and have demonstrated in acute stroke patients that postural changes
in rCBF differ significantly between the infarcted and non-infarcted cerebral hemispheres
[59]. Postural changes in scalp blood flow, which would be expected to be similar on
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the left and right sides of the head, cannot account for this observed association between
the presence of infarction and unilateral alterations in postural rCBF changes. Together,
these studies performed in clinical populations indicate that DCS investigates cortical CBF
despite potential confounding by scalp blood flow changes.
It should also be noted that our optical instrumentation protocol was designed to pro-
vide an assessment of postural changes in cerebral hemodynamics, not an assessment of
static or dynamic CA. Static CA is measured by comparing CBF at two steady states after
an isolated change in MAP. Dynamic CA has been quantified using a variety of different
methodologies, such as by measuring the degree to which acute manipulations in MAP
impact CBF, the speed with which CBF returns to baseline after a change in MAP, or the
transfer function between spontaneous oscillations in MAP and oscillations in CBF [236].
In contrast to static CA or dynamic CA protocols, our posture change protocol produced
additional physiological changes in HR, SpO2, and EtCO2, not just changes in MAP. We
chose this protocol because posture change is an intervention that is commonly performed
to alter cerebral perfusion in the clinical setting, and we specifically aimed to provide a
normative data set for comparative studies between healthy populations and clinical popu-
lations.
5.4 Conclusion
In summary, this study suggests that healthy subjects across the age spectrum experience
significant postural declines in frontal cortical rCBF but that aging does not alter the
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magnitude of this postural rCBF decline. We demonstrated that hybrid diffuse optics can
be readily used for studying healthy populations in natural postures, and that DCS provides
cerebral hemodynamic data that cannot be obtained from DOS measurements alone. Our
optical data also provide normative values of frontal cortical microvascular hemodynamics
across the age spectrum, to which pathological values can be compared in future studies of
brain-injured populations.
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Chapter 6
Use of DOS/DCS in the Neurocritical
Care Unit
Severe brain injury can profoundly disturb cerebrovascular autoregulation and neuronal
metabolism [242, 45, 214, 49, 97]. Over 17% of the estimated 1.5 million people who
sustain a traumatic brain injury (TBI) each year in the United States are hospitalized, and
the direct and indirect costs for TBI patients totaled approximately 60 billion dollars in
2000 [128, 68]. In addition, more than 27,000 people in the United States suffer aneurysmal
subarachnoid hemorrhage (SAH) each year, and about 40% of hospitalized patients die
within 1 month of admission [107, 175, 198].
Importantly, the extent of secondary injury, more so than that of the primary injury, can
play a crucial role in ultimately determining outcome [32, 31, 114, 40, 82]. After the initial
ictus, patients are susceptible to secondary injuries whose pathophysiology often involves
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disturbed autoregulation. Thus, cerebral oxygenation and intracranial pressure monitoring
is commonly performed in neurointensive care units to facilitate diagnosis and treatment of
secondary injuries in severely brain-injured patients.
In TBI patients, post-traumatic edema and contusion expansion often leads to intracra-
nial hypertension and a subsequent drop in cerebral blood flow (CBF); SAH patients are
at risk of rebleeding and vasospasm, both of which can lead to cerebral ischemia, edema,
and intracranial hypertension [203, 179, 108, 227, 11]. Current modalities for continuous
monitoring of intracranial pressure (ICP) and cerebral perfusion pressure (CPP) require in-
vasive introduction of pressure transducers into the brain parenchyma or lateral ventricles.
Though these invasive ICP monitors provide a surrogate measurement of CBF, non-invasive
continuous bedside monitors of CBF are lacking. Existing techniques for measuring CBF
in patients include [15O]-PET, single photon emission computed tomography (SPECT),
gadolinium-enhanced perfusion magnetic resonance imaging (MRI), and arterial spin la-
beled bolus tracking perfusion MRI (ASL-MRI). All of these techniques require the patient
to be transported within the hospital, an activity which can be difficult or even dangerous
to the patient [221, 134, 256].
Xenon-enhanced computed tomography (Xenon-CT) has recently become more trans-
portable to patient rooms, but is not a continuous CBF measure [256, 35, 51]. Two more
portable techniques are currently used to monitor CBF continuously at the bedside. Tran-
scranial Doppler (TCD) ultrasonography is a valuable tool, but its capabilities are limited
to observing large vessel behavior, which is not always an accurate surrogate for microvas-
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cular perfusion [221, 159]. Thermal diffusion flowmetry (TDF) has also been gaining
popularity in neuro-intensive care units [235, 195, 211]. The drawback of TDF is that, like
intracranial pressure monitors, it is an invasive tool that needs to be placed into the brain
parenchyma. Thus, a continuous, non-invasive monitor of microvascular cerebral blood
flow is still lacking in the neuro-intensive care unit.
In this study, we evaluated the clinical utility of DOS and DCS in patients with severe
brain injury by validating DCS measurements of CBF with Xenon-CT, and DOS mea-
surements of cerebral oxygenation with invasive Licox monitors. We hypothesized that
changes in CBF and oxy-/deoxyhemoglobin concentration during head-of-bed manipula-
tions, induced hyperoxia, and pressor administration would be non-invasively detected by
our hybrid DCS/DOS optical instrument, and that DCS/DOS measurements would corre-
late with simultaneous measurements of CBF, PbtO2 or ICP by other techniques.
Brain-injured patients are a particularly challenging clinical population because of their
heterogeneous condition and susceptibility to secondary injury. To support the use of our
hybrid diffuse optical monitor for such a population, we have included in this paper a study
of validation against xenon-CT during a blood pressure challenge. After comparison with
xenon-CT, we began assessment of the applicability of the optical instrument to measure
changes in CBF and oxygenation in patients during change of head elevation and during
induced hyperoxia. These two interventions are commonly used in the critical care unit,
often invoking a large response in patient hemodynamics as seen by current invasive mon-
itors. Throughout the study, we hypothesize that the novel diffuse optical devices will
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provide continuous, non-invasive CBF and oxygenation information for this population at
the bedside.
6.1 Head-of-Bed Manipulation
It is common clinical practice in the neurocritical care unit to manipulate patient head-
of-bed angle as a strategy for altering intracranial pressure (ICP) and cerebral perfusion
[60, 64]. The efficacy of head-of-bed manipulation for improving cerebral blood flow
(CBF), however, is not well-understood. Reduction of ICP does not always lead to an
increase in cerebral perfusion pressure (CPP) [60, 255, 193, 160, 67], and even when CPP
increases with head elevation, the link between CPP and CBF can depend on head-of-bed-
position [160] and cerebrovascular resistance [43]. This complex relationship between ICP,
CPP and CBF may explain why no single optimal CPP has been defined for the severely
brain-injured patient [243], and why ICP- and CPP-targeted interventions sometimes fail to
improve outcome [115, 33, 41]. Since recovery of neurological function may depend more
directly on tissue perfusion [171] than on ICP or CPP, it is desirable to develop new tools
that directly measure CBF in the neurocritical care unit.
The current lack of understanding about the relationship between head-of-bed posi-
tion and CBF is largely attributable to the absence of an effective and convenient method
for measuring CBF at the bedside. Conventional imaging techniques capable of measur-
ing perfusion such as computed tomography (CT), positron emission tomography (PET),
and magnetic resonance imaging (MRI), are mainly suited for imaging in prone or supine
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positions, do not offer the possibility for continuous measurement of CBF, and are of-
ten unfeasible for single time-point perfusion measurements in clinically unstable patients.
Similarly, current ”bedside” techniques for monitoring CBF, which include transcranial
Doppler (TCD) ultrasonography [63], thermal diffusion [235], and laser Doppler flowme-
try [124], have significant limitations. TCD ultrasonography measures large vessel flow
velocities that do not necessarily reflect microvascular perfusion [184], and although ther-
mal diffusion and laser Doppler flowmetry monitor microvascular perfusion, routine use of
these techniques is limited by their invasive nature.
Diffuse correlation spectroscopy (DCS) is a novel optical technique for probing con-
tinuous changes in regional microvascular blood flow. DCS utilizes non-invasive near-
infrared light sources and detectors to track rapid temporal fluctuations of light intensity
in brain tissue that arise when light is scattered by moving red blood cells. The method
derives a blood flow index (BFI) from these intensity fluctuations whose trends have been
shown to correlate well with blood flow in both animals [150, 54, 260, 225, 264, 27, 156]
and humans [120, 24, 191, 58, 261, 265]. This BFI is readily used to calculate relative
CBF (rCBF ), i.e. blood flow variation relative to a baseline measurement. Validation of
DCS-measured rCBF in adult patients with severe brain injury has been carried out with
concurrent xenon-enhanced CT during induced manipulations of blood pressure and arte-
rial CO2 [120]. In addition, CBF responses during head-of-bed manipulation have been
studied with DCS in both healthy [61] and ischemic stroke populations [59, 155]. In these
early studies, DCS was combined with a more established optical technique called near-
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infrared spectroscopy (NIRS), also known as diffuse optical spectroscopy (DOS). DOS
uses wavelength-dependent light attenuation to measure concentration changes in oxyhe-
moglobin (∆HbO2), deoxyhemoglobin (∆Hb), and total hemoglobin (∆THC) concentra-
tions. Our hybrid optical instrument employs both techniques concurrently.
The primary aim of the present study is to use DCS/DOS to measure cerebral hemo-
dynamic changes in severely brain-injured patients during a simple clinical intervention:
head-of-bed lowering. Importantly, this patient group is different from those in the previ-
ous clinical studies of head-of-bed positioning described above. We compare postural CBF
responses in brain-injured patients to those of healthy subjects, and we assess posture-
induced correlations of DCS-measured rCBF and DOS-measured ∆HbO2, ∆Hb, and
∆THC versus other measured parameters such as ICP and CPP. Among other expecta-
tions, we hypothesized that continuous optical monitoring during head-of-bed lowering
would reveal differences in postural rCBF in the brain-injured patients versus the con-
trols. Note that this section is based on a paper that has been accepted for publication in
clinicial journal Neurocritical Care [121].
6.1.1 Methods
All subjects in the brain-injured cohort were adults (≥18 years) receiving care in the neu-
rointensive care unit at the Hospital of the University of Pennsylvania for subarachnoid
hemorrhage or traumatic brain injury. Each study was performed at the patient bedside us-
ing protocols approved by the Institutional Review Board at the University of Pennsylvania.
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Written consent was provided by the subject (if able) or by a surrogate.
Comparison data in healthy controls was obtained from a previous study that included
optical monitoring of head of bed positioning on 60 healthy volunteers [61]. Adult subjects
were included in the healthy cohort if they had no history of hypertension, diabetes mellitus,
hyperlipidemia, atrial fibrillation, congestive heart failure, coronary artery disease, previ-
ous myocardial infarction, prior stroke or transient ischemic attack, carotid artery disease,
smoking within the past 5 years, pulmonary disease, renal disease, or recent administration
of vasoactive medications. Subjects were chosen to be gender-matched, since we previ-
ously found gender (but not age) to have an effect on frontal cortical hemodynamics during
posture change [61]. Written informed consent was provided by all control subjects, and
the controls were studied at the Hospital of the University of Pennsylvania with protocols
approved by the Institutional Review Board.
Optical Instrumentation. The optical instrument was a custom-built, hybrid device
containing both DCS and DOS modules (see Section 3.1.1). The DCS module uses two
long-coherence-length, continuous-wave 785 nm lasers (CrystaLaser Inc., Reno, NV), two
4-channel avalanche photodiode arrays (Perkin Elmer, Canada) for single-photon detec-
tion, and an 8-channel multi-tau autocorrelator board (Correlator.com, Bridgewater, NJ)
to compute the temporal intensity autocorrelation functions. The homodyne, frequency-
domain DOS module employs three laser sources with wavelengths 685, 785, 830 nm, as
well as two photomultiplier tubes for light detection. A single frame of DCS data was
acquired every 6 s, followed by a 1 s DOS data collection interval. The data acquisition
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rate was therefore one frame of DCS + DOS every 7 s. Both modalities employ optical
fibers that affix to a black foam probe pad with source-detector separations of 2.5 cm. This
separation distance ensures that light can penetrate to depths below the tissue surface of
approximately 1.0 to 1.5 cm, a depth sufficient for light to reach the surface region of the
adult human cortex [120, 57]. Further theoretical and technical details about diffuse optics
can be found in recent reviews [55, 154, 157].
DCS data analysis employs a physical model to extract an index of local, microvascular
relative blood flow and has been previously described [142, 177, 16]. All optical data were
reviewed for motion artifacts prior to analysis, and epochs of data were excluded from
further analysis, if excessive noise produced low-confidence values of the BFI . For DOS
analysis, changes in ∆HbO2, ∆Hb, and ∆THC were calculated using a modified Beer-
Lambert law that utilized changes in signal amplitude attenuation at each wavelength, as
well as the subject’s age-dependent differential path length factor [52]. Complete details
about DCS and DOS analyses have been previously published [15, 34].
Optical Protocol during Head-of-Bed Manipulation. Most often, two optical probes
were affixed to both sides of the forehead equidistant from the midline, in order to mea-
sure hemodynamic changes in the frontal poles of the left and right hemispheres. Note,
two of the early patients provided unilateral data only as a result of restrictions in optical
probe size; later versions were more compact, and thus bilateral probes were used. For
the unilateral measurements, a probe was placed on either the left or the right side of the
forehead.
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Figure 6.1: Protocol for head-of-bed manipulation. The subject starts at a baseline head-
of-bed elevation of 30o for 5 minutes. Then the head-of-bed is lowered flat over a period of
30 seconds, and the subject rests supine for another 5 minutes.
During the measurements, a black opaque cloth was placed over the probes to shield
them from ambient light. Once adequate optical signal was confirmed, continuous measure-
ments of rCBF , ∆HbO2, ∆Hb, and ∆THC were made. The head-of-bed intervention
protocol is depicted in Figure 6.1. The subject was initially positioned at a baseline head-
of-bed elevation of 30o, wherein he/she rested quietly and still for 5 minutes. The head-
of-bed was then lowered to the supine position (0o) over a period of 30 seconds, and the
subject rested there for another 5 minutes. For the brain-injured patients, this intervention
was repeated consecutively up to three times, and in order to examine longitudinal changes
in frontal lobe hemodynamic response, for up to three measurement episodes usually on
consecutive days. Data from these multiple days were averaged. The healthy subjects were
monitored on a single day, all bilaterally, with the 30o-to-0o protocol performed once.
Monitoring of ICP, CPP and PbtO2 in Brain-Injured Patients. Cerebral and systemic
physiological parameters were monitored as part of routine care for patients in the neu-
rocritical care unit. ICP was monitored either by an external ventricular device or using
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a fiberoptic intraparenchymal catheter (Camino-MPM1; Integra LifeSciences, Plainsboro,
NJ). ICP transducers were zeroed at the level of the tragus. CPP was then calculated as
the difference between mean arterial pressure (MAP) and ICP. Prior to study enrollment,
select patients underwent placement of a continuous brain tissue oxygen partial pressure
(PbtO2) monitor (Licox R©CMP; Integra LifeSciences, Plainsboro, NJ) at the discretion of
the treating clinician. The PbtO2 monitor consisted of a polarographic Clark-type electrode
inserted into cerebral white matter.
Monitoring of MAP and Heart Rate (HR) in Brain-Injured and Control Subjects. In
brain-injured subjects, MAP and HR were measured continuously via a radial arterial-line
that was zeroed at the phlebostatic axis throughout the study. In healthy controls, continu-
ous measurements of MAP and HR were monitored using a non-invasive plethysmographic
device (Finapres Medical Systems, Finometer Pro Model 1; Amsterdam, The Netherlands)
whose probe was secured to each subject’s right third finger. An adjustable armrest was
used to keep the subject’s right third finger at the level of the heart at each head-of-bed
position.
Statistical Analysis. Mean changes in each cerebral and systemic physiological param-
eter due to head lowering were computed from continuous time-series data by taking the
average (〈 〉) during the 5-minute time period (t30o) at head-of-bed 30o as baseline for com-
parison against the 5-minute supine time period (t0o). Periods were defined as those data
measured after the optical signal had stabilized, with all data during the head-of-bed tran-
sition and all motion artifacts excluded from the analysis. Differential values for DOS data
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(∆HbO2, ∆Hb, ∆THC) as well as for systemic vitals (HR, MAP, ICP, etc.) were defined
as
∆Y = 〈Y (t0o)〉 − 〈Y (t30o)〉, (6.1)
with Y representing the parameter of interest. For DCS data, a percentage change from
baseline was employed to compute rCBF :
rCBF =
〈rCBF (t0o)〉 − 〈rCBF (t30o)〉
〈rCBF (t30o)〉
. (6.2)
A two-tailed Student’s t-test was used to determine whether the observed changes were
different from zero, and a one-way ANOVA was used to test whether the cerebral hemo-
dynamic responses of brain-injured patients differed from those of healthy subjects. When
both left and right frontal pole data were available, a Pearson’s coefficient was used to as-
sess correlations between bilateral measurements of rCBF , ∆HbO2, ∆Hb, ∆THC. A
Pearson’s coefficient was also used to assess correlations between rCBF , CPP, and ICP.
P-values less than 0.05 were considered to indicate statistical significance.
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Table 6.1: Patient clinical characteristics.
No. Gender Age Injury SAH Study Admission Study Imaging
Severity Day(s) GCS GCS Findings
1 M 28 ICH + SAH N/A 2,3 7 7,8 Arteriovenous malformation-associated left temporal
ICH with SAH
2 M 58 TBI N/A 11,13 15 3,5 Acute traumatic SAH, left subdural hemorrhage,
and hemorrhagic contusion
3 F 52 SAH HH2/F3+4 12,13 14 10,11 Left PCA aneurysm, diffuse vasospasm
4 M 40 SAH HH3/F4 8,9,10 7 7,7,3 ACOMM aneurysm, intraventricular hemorrhage,
left MCA/ACA vasospasm
5 M 60 TBI N/A 2,3 3 3,4 Bilateral frontal and temporal contusions, multiple
frontoparietal parenchymal hemorrhages
6 M 51 TBI N/A 4,6 14 6,7 Contusions in bilateral frontal and left temporal lobes,
traumatic SAH, parenchymal hemorrhage in frontal lobes
7 F 62 SAH HH1/F3 9 15 8 Right MCA aneurysm, bilateral ACA and right MCA vasospasm
8 M 18 TBI N/A 2 3 7 SAH along right cerebral convexity, subdural hemorrhages along
bilateral frontal convexities
9 M 46 SAH HH1/F3+4 9 14 6 ACA and left anterior choroidal artery aneurysms, diffuse
vasospasm (right > left hemisphere)
10 F 44 SAH HH4/F3+4 8 4 10 Posterior inferior cerebellar artery aneurysm, vasospasm of
distal vertebral arteries bilaterally
ICH, intracerebral hemorrhage; TBI, traumatic brain injury; SAH, subarachnoid hemorrhage; GCS, Glasgow Coma Score; HH, Hunt-Hess Score; F, Fisher
Grade; N/A, not applicable; MCA, middle cerebral artery; ACA, anterior cerebral artery; PCA, posterior cerebral artery; ACOMM, anterior
communicating artery
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6.1.2 Results
Patient and Control Characteristics. Table 6.1 summarizes all clinical and study data for
the brain-injured cohort. A total of ten patients (seven males/ three females) were included
in the study, with a mean age of 46 years (range, 18-62 years). Five patients were admitted
for subarachnoid hemorrhage (SAH) due to ruptured aneurysm, four for traumatic brain
injury (TBI), and one for an arteriovenous malformation (AVM)-associated intracerebral
hemorrhage (ICH) and SAH. For the TBI patients, the median admission Glasgow Coma
Scale (GCS) [229] score was 9 (range, 3-15), while the median study day GCS score was
5 (range, 3-7). For the aneurysmal SAH patients, the Hunt Hess classification grade [104]
was 1 (n=2), 2 (n=1), 3 (n=1), or 4 (n=1). The timing of optical data acquisition for the
patient cohort ranged from post-injury day 2 to 12 and the GCS score for patients on the day
of data acquisition ranged from 3 to 11. One patient was studied on 3 separate occasions,
five patients on 2 occasions, and four patients were studied once. Data from all episodes
of measurements were included in analysis. ICP was monitored for all patients (seven via
external ventricular drain, three via intraparenchymal catheter), and eight patients had a
brain tissue oxygen monitor in place during the study. The mean age for the ten healthy
controls was 39 years (range, 24-55 years; seven males/ three females).
Physiologic Responses to Head-of-Bed Manipulation. For the brain-injured cohort, ICP
changed significantly (P = 0.002) as the head-of-bed was lowered from 30o (11.2 ± 4.3
mmHg) to 0o (16.8 ± 9.5 mmHg), but CPP, PbtO2, MAP and HR did not. Measurements
of ICP, CPP, PbtO2, MAP and HR in the brain-injured cohort at each head-of-bed position
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Table 6.2: Effects of head lowering on cerebral and systemic vitals in brain-injured cohort.
Parameter Head-of-Bed Position Change from P-value
30o 0o 30o to 0o
ICP, mmHg 11.2 ± 4.3 16.8 ± 9.5 5.6 ± 8.1 0.002
(3.8 to 19.5) (3.3 to 49.7) (-8.1 to 30.2)
CPP, mmHg 95.1 ± 22.8 88.2 ± 25.5 -6.9 ± 12.9 0.218
(59.9 to 136.6) (42.0 to 137.8) (-44.5 to 23.3)
PbtO2, mmHg 47.5 ± 35.0 37.1 ± 19.8 -10.4 ± 18.0 0.142
(8.5 to 196.5) (19.4 to 101.6) (-94.9 to 11.5)
MAP, mmHg 106.7 ± 23.4 105.0 ± 23.3 -1.8 ± 8.3 0.738
(67.8 to 151.0) (64.0 to 144.3) (-15.5 to 26.9)
HR, bpm 84.3 ± 19.5 85.9 ± 18.7 1.6 ± 4.2 0.712
(54.2 to 118.4) (56.0 to 121.0) (-6.0 to 15.9)
Values listed as mean ± SD, with range in parentheses; P-values from one-way ANOVA test.
Table 6.3: Effects of head lowering on systemic vitals in healthy cohort.
Parameter Head-of-Bed Position Change from P-value
30o 0o 30o to 0o
SYS, mmHg 137.4± 11.4 134.6 ± 10.5 -2.8 ± 8.0 0.581
(117.8 to 157.3) (113.3 to 144.9) (-13.7 to 13.4)
DIA, mmHg 78.9 ± 9.9 75.8 ± 10.0 -3.0 ± 6.8 0.505
(63.5 to 93.7) (58.5 to 86.7) (-14.7 to 11.1)
MAP, mmHg 102.4± 9.8 99.4 ± 10.4 -3.0 ± 7.0 0.513
(88.5 to 119.3) (83.9 to 112.2) (-13.9 to 11.1)
HR, bpm 68.8 ± 9.6 68.5 ± 10.6 -0.2 ± 3.1 0.957
(53.3 to 82.7) (50.9 to 82.2) (-4.1 to 7.6)
Values listed as mean ± SD, with range in parentheses; P-values from one-way ANOVA test.
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Table 6.4: Effects of head lowering on rCBF , ∆HbO2, ∆Hb and ∆THC in brain-injured
versus healthy cohorts.
Parameter Brain-Injured Healthy P-value†, P-value†, Difference b/w
(n = 10) (n = 10) Brain-Injured Healthy Groups††
rCBF , % 0.3 ± 28.2 18.6 ± 9.4 0.938 <0.001 0.006
(-49.2 to 90.0) (2.1 to 34.0)
∆HbO2, µM 5.0 ± 4.5 2.3 ± 1.8 <0.001 <0.001 0.010
(-6.3 to 14.2) (-0.2 to 5.3)
∆Hb, µM 1.3 ± 1.8 0.5 ± 0.7 <0.001 0.005 0.059
(-3.0 to 7.1) (-0.6 to 2.1)
∆THC, µM 6.3 ± 6.0 2.8 ± 2.0 <0.001 <0.001 0.012
(-9.3 to 20.4) (-0.2 to 7.4)
Values listed as mean ± SD, with range in parentheses; †P-values from two-tailed Student’s t-test;
††P-values from one-way ANOVA test.
are summarized in Table 6.2. None of the systemic vital signs, including HR and MAP,
changed significantly for the healthy controls (Table 6.3).
The population-averaged DCS and DOS results for the healthy and brain-injured co-
horts are reported in Table 6.4. Positional changes in rCBF (18.6% ± 9.4%, P < 0.001),
∆HbO2 (2.3 µM± 1.8 µM, P < 0.001), ∆Hb (0.5 µM± 0.7 µM, P = 0.005), and ∆THC
(2.8 µM± 2.0 µM, P < 0.001) all reached significance for the healthy controls, with head-
of-bed lowering causing an increase in each physiological parameter. ∆HbO2, ∆Hb and
∆THC increased for the brain-injured group as well (P < 0.001); however, no net change
in rCBF was observed, and there was a large inter-subject variance (0.3% ± 28.2%, P
= 0.938). Figure 6.2 shows box plots comparing postural changes in rCBF and ∆THC
between the two groups.
All optical parameters except for ∆Hb showed a significantly different postural re-
sponse between the patient and healthy groups (P < 0.02). The most marked difference was
seen for CBF responses (P = 0.006). Correlation analysis of left versus right hemisphere
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Figure 6.2: Box plots showing (left) DCS-measured relative cerebral blood flow (rCBF )
and (right) DOS-measured total hemoglobin concentration changes (∆THC) in a group of
brain-injured patients versus gender-matched healthy controls during a head-of-bed low-
ering. Note, the large spread of values around zero for the patient group is qualitatively
different than the group response of the healthy subjects, e.g. a slight CBF increase. THC
increases in both groups, with the patients’ response again exhibiting significantly larger
variance, and, on average, a greater magnitude.
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responses to postural change also revealed a difference between the cohorts. Specifically,
left and right frontal cortex measurements showed strong correlation in healthy subjects for
rCBF (R = 0.94, P < 0.001), ∆HbO2 (R = 0.85, P = 0.002), and ∆THC (R = 0.75, P =
0.013). In contrast, optical measurements in the left and right frontal lobe cortices did not
correlate significantly for the brain-injured cohort (rCBF : R = 0.27, P = 0.146; ∆HbO2:
R = 0.22, P = 0.249; ∆Hb: R = -0.04, P = 0.817; ∆THC: R = 0.09, P = 0.639).
We also observed a moderate but significant correlation (R = 0.40, P < 0.001) between
change in CPP and rCBF , but no correlation with rCBF was seen for ICP (R = -0.15, P
= 0.213). Also, PbtO2 did not correlate with any DOS parameters. While the magnitude
(i.e. absolute value, disregarding sign) of rCBF change was found to have a negative
association with patient GCS score on the day studied (R = -0.42, P < 0.001), this was not
the case for the DOS parameters (∆HbO2: R = -0.19, P = 0.118; ∆Hb: R = -0.01, P =
0.907; ∆THC: R = -0.18, P = 0.152).
Similarly, as seen in Figure 6.3, rCBF was the only parameter that could differentiate
between SAH and TBI patients (P = 0.008). For patients with SAH (including the one with
AVM), there was a difference between rCBF responses measured on the side of ruptured
aneurysm versus the contralateral side (P < 0.001). In comparison, there was no difference
when comparing left and right rCBF responses for TBI patients. Also, the number of days
after injury inversely correlated with the absolute magnitude of rCBF change with head
lowering (R = -0.30, P = 0.012), but not with DOS parameters.
We present one case example of a 40-year-old male SAH patient (No. 4) studied over
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Figure 6.3: Box plots comparing relative cerebral blood flow (rCBF ) response of (left)
TBI versus SAH patients and (right) SAH patients’ hemisphere of aneurysm rupture versus
contralateral hemisphere. rCBF differed significantly between both sets of measurements,
but DOS-measured oxygenation parameters did not distinguish either.
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Figure 6.4: Case example data over three consecutive days (8, 9, and 10 days after injury)
for a 40-year-old male subarachnoid hemorrhage patient (No. 4) who suffered a ruptured
aneurysm in his anterior communicating artery. The vertical dotted line indicates the mo-
ment at which the patient’s bed was lowered from 30 degrees to flat. The Glasgow Coma
Scale was 7 on days 8 and 9, and 3 on day 10. Each figure shows the averaged result of
time-series data from three head lowering interventions for (a) rCBF , (b) ∆THC, and (c)
changes in ICP and CPP. 182
three consecutive days. Cerebral angiography identified a ruptured aneurysm in his anterior
communicating artery that was clipped on post-bleed day 1. Figure 6.4 shows time-series
results, averaged over three head-of-bed lowering events on each day, for three consecutive
days (days 8, 9 and 10). The patient’s GCS was 7 on days 8 and 9, and 3 on day 10.
On day 7, the patient had moderate right middle cerebral artery (MCA) and basilar artery
vasospasm, as well as mild left MCA vasospasm. On days 8 and 9, the patient had moderate
right MCA vasospasm and mild-to-moderate bilateral carotid siphon vasospasm. On day
9, the patient also had mild bilateral posterior cerebral artery (PCA) vasospasm. rCBF
(Figure 6.4a) in the left hemisphere decreased with position change to supine on all three
days, while rCBF in the right hemisphere did not change on days 8 and 9, and then
increased on day 10. Left frontal ∆THC (Figure 6.4b), on the other hand, showed no
change or even a decrease on days 8 and 9, but then sharply increased on day 10. These
THC findings are in contrast to the right frontal cortex, in which ∆THC increased with
head-of-bed lowering on all three days. Figure 6.4c shows ICP and CPP data for this case,
with an ICP increase and CPP decrease on days 8 and 9, and an ICP decrease and CPP
decrease of reduced magnitude on day 10.
6.1.3 Discussion
In this study, we employed a novel optical methodology that combines DCS and DOS to
measure cerebral hemodynamic changes during an intervention commonly performed in
the neurocritical care unit: head-of-bed manipulation. Our findings suggest that the effect
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of head-of-bed lowering on microvascular rCBF differs in brain-injured patients as com-
pared to healthy adults. Whereas frontal cortical rCBF consistently increased in healthy
subjects when lowering the head-of-bed from 30o to 0o, we found significant heterogeneity
in cerebral hemodynamic responses to posture change in patients with severe brain injury.
In addition, we observed substantial variation in hemispheric responses to posture change
in the brain-injured cohort, possibly due to the spatial heterogeneity in their disease. This
intersubject and intrasubject (i.e. hemispheric) variability in rCBF responses to posture
change suggests that optimization of cerebral perfusion for patients in the neurocritical
care unit may require an individualized approach to CBF management. Our results provide
also preliminary evidence that the DCS/DOS hybrid device is well-suited to provide non-
invasive, continuous hemodynamic monitoring that has the potential to optimize cerebral
perfusion on an individualized basis.
The observed difference between positional rCBF changes in the brain-injured ver-
sus healthy cohorts is consistent with prior studies of cerebral hemodynamics that have
demonstrated impaired cerebrovascular autoregulation in severely brain-injured patients
[172, 62, 45, 109, 127, 183]. Furthermore, the variability in frontal cortical cerebrovas-
cular responses to posture change observed in the brain-injured cohort is consistent with
similarly heterogeneous results in prior studies that examined the effect of head-of-bed
position on CBF.
Shenkin et al. measured absolute CBF via the Kety-Schmidt N2O technique at both 0o
and 20o in six patients with elevated ICP due to brain tumors, finding that CBF was lower
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at 20o by an average of 30% [209]. These findings suggested that the head-up position was
detrimental because of decreased cerebral perfusion. In contrast, Feldman et al. recorded
absolute CBF (also employing the Kety-SchmidtN2O technique), CPP, and ICP in 22 head-
injured patients at 0o and 30o, and found significantly lower ICP at head-of-bed 30o but no
overall change in CPP and CBF [67]. As in our study, they established that head-of-bed
angle did not have a significant effect on group-averaged CBF (47.8 ± 16.9 ml/100 g/min
at 30o, 48.9± 20.4 ml/100 g/min at 0o), and their subjects experienced heterogeneous CBF
responses ranging from increased to decreased perfusion. Specifically, five patients had
values of supine CBF that were 5 ml/100 g/min or more greater than their CBF at 30o,
and this subgroup had significantly different changes in CBF, cerebral metabolic rate of
oxygen, and cerebrovascular resistance than the other seventeen patients.
Lastly, Moraine et al. measured CBF with the continuous thermodilution method, CPP,
and ICP in thirty-seven comatose patients at head-of-bed angles 0o, 15o, 30o, and 45o [160].
CBF was higher at 0o (46.3 ± 4.8 ml/100 g/min) than at 30o (32.4 ± 2.8 ml/100 g/min),
which constituted a relative difference of 43%. ICP also decreased with raised head-of-
bed, but again with no change in CPP. Our study thus adds to prior evidence and suggests
that there may not be a single head-of-bed position that is optimal for maximizing cerebral
perfusion in brain-injured subjects in the neurocritical care unit. With regard to the healthy
cohort findings, several prior studies have similarly observed that CBF and cerebral blood
flow velocity via transcranial Doppler increase as the head of a healthy individual is lowered
[59, 26, 5].
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The heterogeneous frontal cortical rCBF responses to postural changes observed in
the patients in this study are also consistent with a prior DCS/DOS study in which patients
with acute ischemic stroke were found to experience variable changes in frontal cortical
rCBF during posture change [59]. In this prior study, a rCBF reduction after head-
of-bed lowering occurred in four out of seventeen acute stroke patients – a ”paradoxical
response” for which a definitive pathophysiological mechanism could not be determined.
One possible explanation for rCBF reduction after head-of-bed lowering is increased
ICP, but in the present study, we did not find a significant correlation between changes in
ICP and rCBF response. CPP changes, however, were moderately correlated with rCBF
responses. This observation is consistent with prior studies showing that CPP-guided man-
agement may be more effective than ICP-guided management at promoting tissue perfu-
sion, and thus improving clinical outcomes [259]. Yet the absence of a strong correlation
between CPP and frontal cortical CBF underscores the difficulty in predicting CBF from
CPP measurements and reinforces the need for direct monitoring of microvascular CBF to
guide therapies in the neurocritical care unit.
Similar to our study, Moraine et al. demonstrated that the correlation between CPP and
CBF is not always strong, but rather varies depending on head-of-bed position [160]. The
authors found that the slope of absolute CBF versus CPP calculated with least-squares lin-
ear regression analysis changed from 1.71 at 0o to 0.76 at 30o. Ultimately, determination of
which patients might experience predictable versus unpredictable changes in microvascular
CBF during head-of-bed related CPP changes could be an important factor for optimizing
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cerebral perfusion in individual patients.
In considering the individualized nature of rCBF responses to posture change, it is
also notable that the DOS-derived parameters for cerebral tissue oxygenation – HbO2, Hb,
and THC – did not display the heterogeneous responses seen in rCBF . Rather, HbO2,
Hb, and THC all significantly increased in the brain-injured cohort (P < 0.001) with head-
of-bed lowering. The observed increases may be the result of passive venous pooling that
increases cerebral blood volume when the head is lowered to the supine position. Because
of impaired autoregulation in some patients, this increase in cerebral blood volume could
contribute to an increase in ICP, and thus a decline in CBF. The fact that DCS and DOS re-
sults differed considerably in our study again highlights the advantage of hybrid DCS/DOS
instrumentation over DOS monitoring alone.
Spatial resolution remains a major limitation of the current DCS/DOS approach, since
measurements of rCBF , ∆HbO2, ∆Hb, and ∆THC are limited to approximately one
cubic centimeter of cerebral tissue under the optical probes. This limitation could possibly
explain any deviation from previous results in the literature, since CBF measurement tech-
niques such as those used in Moraine et al. [160] and Feldman et al. [67] measured CBF
more globally.
In addition, interfacing the optical probes to the patient’s head can be challenging and
can be hampered by hair or hair follicles; overcoming these technical barriers is an area of
active research. In the present application, flow measurements were limited to near the sur-
face of the frontal cortex due to placement of the optical probes on the forehead. However,
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most other bedside monitoring methods have similar limitations, and brain-injured patients
often have diffuse pathophysiological processes for which such measures remain useful.
Another challenge in optical monitoring of cerebral physiology is accurate localization of
signal changes measured by transcranial probes, which potentially detect signals from the
scalp and other intervening tissues as well as the brain. Recent findings suggest the likeli-
hood of some scalp contamination that can be suppressed by increasing probe pressure.
There are several further limitations of our study. First, timing of optical data acquisi-
tion ranged from day 2 to day 13 post-injury. As a result, patients were likely in different
stages of their disease processes, during which cerebrovascular autoregulatory function
may vary. For example, the data from the case example spanning three consecutive days
demonstrated a change in cerebral hemodynamic responses to posture change from day 9
to day 10 post-injury. These longitudinal changes in rCBF were associated with changes
in GCS and postural changes in cerebral perfusion pressure.
Second, our cohort included three different types of brain injury: TBI, aneurysmal
SAH, and AVM with associated ICH and SAH. Even within one of these injury categories,
there is large variability with regards to the severity and neuroanatomic distribution of
injury. Although our sample size was too small to determine the mechanisms that cause
variability in CBF responses to posture change, our preliminary observations suggest that
CBF responses may differ due to severity of injury (e.g. GCS score on day of study). We
found that GCS on the day of study was negatively correlated with rCBF , indicating that as
consciousness was more severely altered, postural changes in CBF were more pronounced.
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Also, preliminary analysis may suggest that CBF responses may differ according to
type of injury, hemisphere of aneurysm rupture, and number of days after injury. When
patients were grouped by type of injury, rCBF response differed between the SAH (n =
6) and TBI (n = 4) cohorts. This observation may be attributed to the diffuse hemodynamic
effects of traumatic brain injury as compared to the potentially more focal hemodynamic
effects of cerebral vasospasm after aneurysmal SAH [187, 181]. In addition, what may
superficially be called the ”injured hemisphere” (defined as the hemisphere containing the
aneurysm or the AVM) had a significant effect on postural rCBF changes in the patients
with SAH. The number of days after injury inversely correlated with absolute magnitude of
rCBF response with head lowering, saying that perhaps autoregulation was more impaired
earlier in the recovery stage, leading to greater changes in rCBF .
Finally, while studying individual patients on multiple days allowed for longitudinal
analyses, such measurements could introduce bias towards data from these patients who
were measured on more than one occasion. Nevertheless, the heterogeneity in our methods
suggests that the DCS/DOS protocol utilized in this study may be generalizable to multiple
patient populations within the neurocritical care unit, with the potential to improve patient
care by providing clinicians with the capability to monitor cerebrovascular hemodynamics
longitudinally at the bedside.
In conclusion, this study provides preliminary evidence that continuous, non-invasive
bedside monitoring DCS/DOS can be used to detect differences in cerebral hemodynamic
responses of brain-injured patients to posture change in the neurocritical care unit. These
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cerebrovascular responses are not easily predicted by postural ICP and CPP changes, high-
lighting the potential value of direct measurement of microvascular perfusion. The ob-
served variability in postural CBF responses also suggests that there may not be a single
head-of-bed position that optimizes cerebral perfusion in all patients. Larger studies are
needed to reproduce these findings, to further validate transcranial monitoring of cerebral
perfusion and metabolism with diffuse optics, and to test whether bedside monitoring with
DCS/DOS can be used to optimize head-of-bed positioning for maximizing cerebral perfu-
sion in individual patients.
6.2 Induced Hyperoxia
After severe TBI, ischemia and subsequent lowered levels of oxygen delivery can have dire
consequences such as mitochondrial dysfunction and hypometabolism [192]. The injured
brain has been found to develop diffusion barriers to the cellular delivery of oxygen that
prevents an increase in oxygen extraction that normally follows hypoperfusion, or lowered
CBF [151].
Hyperoxia, or excess oxygen, has been explored as a method of therapy for brain-
injured patients. Because patients are typically already intubated and on a respirator, in-
creasing the fraction of inspired oxygen (FiO2) to 100% at normobaric pressure is a simple
way to induce hyperoxia. It is known to increase partial pressure of brain tissue oxygen
[152]. For therapeutic uses, patients are typically put on 100% FiO2 for a duration of hours
[192].
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Short-term induced hyperoxia (for ∼2 minutes) is a commonly used intervention in
the neurocritical care unit. For instance, after suctioning and clearing the patient’s airway
from a blockage, the nurse will give 2 minutes of oxygen. It may also be used in times of
hemodynamic compromise, or as a simple way of testing the brain tissue oxygen partial
pressure monitor. In this study, we wanted to again test whether our hybrid DCS/DOS
monitor would be able to distinguish hemodynamic changes due to this simple intervention.
Also, we hypothesized that we would see similar trends between our non-invasive DOS
measurements and the invasive brain tissue oxygen monitor.
6.2.1 Methods
Patient Enrollment. Patients with traumatic brain injury or aneurysmal subarachnoid hem-
orrhage were recruited at the Hospital of the University of Pennsylvania (HUP) through
the Department of Neurology and the Neurosurgery Clinical Research Division. Written
consent was obtained by the subject or a legally authorized representative. Patients eligible
for enrollment included severe head trauma patients with post-resuscitation GCS scores be-
tween 3 and 8, or those with aneurysmal subarachnoid hemorrhage with clinical Hunt-Hess
classification grades III, IV, or V. All studies occurred in the patient’s hospital room, fol-
lowing protocols approved by the University of Pennsylvania Institutional Review Board.
Patient Monitoring. A continuous brain tissue oxygen partial pressure (PbtO2) monitor
(Licox R©CMP; Integra NeuroSciences, Plainsboro, NJ, USA) was placed on most study
patients prior to enrollment. The Licox sensor consists of a polarographic Clark-type elec-
191
trode placed into the white matter. A ventriculostomy was performed on many study pa-
tients to continuously measure ICP and to drain cerebrospinal fluid, if necessary; for pa-
tients without an intraventricular drain, ICP was monitored by a fiberoptic intraparenchy-
mal catheter (Camino-MPM1; Integra NeuroSciences, Plainsboro, NJ, USA). CPP data
was calculated from the difference between mean arterial pressure (MAP) and ICP. For
some patients, a multi-modality monitoring system (MobiusTM; Integra NeuroSciences,
Plainsboro, NJ, USA) was used to continuously record PbtO2, ICP and CPP for analysis.
Before the introduction of this new technology, the variables were typed once per minute
into a spreadsheet by study staff.
The diffuse optical instrument (Joel’s Instrument, see Section 3.1.1) was placed unob-
trusively outside the patient’s room. The optical fibers extended from the instrument to
the patient’s forehead and were held in place at the probe end with a rectangular piece of
black foam. A source-detector separation of 2.5 cm was used for this study. A similar
sized disposable Duoderm was used to secure the probe and the surrounding foam to the
subject’s forehead. Two optical probes were positioned on each side of the forehead, in
front of the poles of the left and right frontal lobes. A black cloth rested on top of the
probes to shield ambient light and improve signal-to-noise ratio. Once adequate signal
was confirmed, the study began with induced hyperoxia interventions. Neurointensive care
physicians reviewed all study interventions and confirmed their safety on a case-by-case
basis prior to study initiation.
Study Protocol. Subjects began the hyperoxia protocol in the typical position at which
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most neuro-ICU patients are kept, with head elevated at 30o. Baseline FiO2 level was
recorded at this head-of-bed position. FiO2 was then increased to 100% for 2 minutes,
followed by recovery for 5 minutes at baseline FiO2 level. This intervention was repeated
up to three times for each patient.
Data Analysis and Statistics. We used a portable hybrid DCS/DOS instrument that was
built in our lab (see Section 3.1.1). DCS employs a narrowband continuous-wave laser
(785 nm, 40 mW), four photon-counting fast avalanche photodiodes, and an four-channel
autocorrelator board. Temporal autocorrelation functions of the reflected light were used
to derive relative CBF.
For DOS, 3 mW of light from amplitude-modulated (70 MHz) lasers operating at 690,
785, and 830 nm were fiber-coupled onto the tissue surface. Photons transmitted into the
brain were detected in reflection at the surface of the scalp. These wavelength-dependent
photon reflections were used to determine the oxy- and deoxyhemoglobin concentrations
by near-infrared (NIR) spectroscopic analysis.
DCS/DOS data was treated the same as described in Section 6.1. To assess the sig-
nificance of changes in parameters due to the induced hyperoxia intervention, we uti-
lized a linear mixed effects model. We used the library nlme in statistical software R
(http://www.rproject.org). The threshold for significance was a p-value less than
0.05.
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Figure 6.5: Bar plot showing cohort-averaged response of DOS/DCS quantities to induced
hyperoxia. ∆HbO2 and ∆Hb changes were in opposite directions, but overall THC saw a
decrease that is in agreement with the trend of rCBF .
6.2.2 Results
We induced hyperoxia in eleven brain-injured patients. Nine of the eleven patients pos-
sessed a continuous brain tissue oxygen partial pressure (PbtO2) monitor, while the re-
mainder did not have any PbtO2 device.
Population-averaged results from DOS/DCS are shown in a bar plot in Figure 6.5, with
means and standard errors listed in Table 4. All DOS/DCS-measured quantities showed a
significant change with induced hyperoxia intervention. ∆HbO2 and ∆Hb changes were
in opposite directions, and rCBF and ∆THC saw decreases.
Table 4 outlines changes of all quantities, including Licox-measured PbtO2 and sys-
temic vitals, with significant changes identified. Induced hyperoxia caused significant
changes in heart rate, PbtO2, respiration rate, and arterial oxygen saturation as measured
by pulse oximetry.
Continuous timeseries from Patient 8, an 18-year-old male pedestrian hit by a car, is
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Table 6.5: Effects of induced hyperoxia on vitals and DCS/DOS parameters in brain-injured
patients (n = 11).
Parameter Mean ± SD P-value
SYS, mmHg -2.0 ± 5.0 0.202
DIA, mmHg -0.04 ± 2.3 0.957
MAP, mmHg -0.8 ± 4.0 0.529
HR, bpm -1.2 ± 1.7 0.018
PbtO2, mmHg 15.7 ± 17.9 0.004
RESP, bpm -1.8 ± 3.3 0.070
ICP, mmHg -0.4 ± 3.0 0.642
CPP, mmHg 0.07 ± 2.7 0.928
SpO2, % 1.1 ± 2.0 0.074
rCBF , % -4.4 ± 5.3 0.007
∆HbO2, µM 0.4 ± 0.3 0.006
∆Hb, µM -1.0 ± 0.3 <0.001
∆THC, µM -0.5 ± 0.7 0.009
Values listed as mean ± SD, with range in parentheses; P-values from two-tailed Student’s t-test
shown in Figure 6.6. He suffered from a TBI and had small evolving subarachnoid hemor-
rhaging in the right frontal lobe as a result. The patient also had subdural hemorrhage along
both frontal convexities and the interhemispheric fissure. Figure 6.6(a) shows changes
in the DOS-measured oxy- and deoxyhemoglobin concentrations against changes in the
Licox-measured PbtO2 during hyperoxia. ∆HbO2 and PbtO2 both begin to increase after
100% oxygen is administered, although temporally ∆HbO2 seems to increase and reach a
peak faster than PbtO2. Trends of ∆Hb and PbtO2 show stronger temporal (negative) cor-
relation. With the increase in fraction of inspired oxygen, it follows that blood and tissue
oxygenation both increase as expected. Relative CBF measured during the same hyper-
oxia event is shown in Figure 6.6(b). The intervention leads to steady decreases in CBF of
roughly 10% and THC of 2 µM in this patient.
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Figure 6.6: (top) Changes in ∆HbO2, ∆Hb (from DOS, left hemisphere probe shown)
and PbtO2 (from Licox R©monitor) during induced hyperoxia event. Fraction of inspired
oxygen (FiO2) was set at 100% for the 2-minute interval shown between the bars. Rises in
both ∆HbO2 and PbtO2 are seen, as both increase with a rise in oxygenation of the blood.
Negative correlation is seen between trends of ∆Hb and PbtO2. (bottom) Relative CBF
and ∆THC during the same hyperoxia event (left hemisphere probe only). Both rCBF
and ∆THC decrease with rise of FiO2.
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6.2.3 Discussion
Our hybrid optical monitor was tested during a period of induced hyperoxia, where the FiO2
was increased to 100% for 2 minutes. In the neurocritical care unit, this intervention is used
in times of respiratory distress or hemodynamic compromise, or as a simple way of testing
the brain tissue oxygen partial pressure monitor. During the 2-minute period of hyperoxia,
both the brain tissue oxygen and DOS monitors observed increases in oxygenation as a
population, but the relative changes differed. DOS found much smaller relative changes in
oxy- and deoxyhemoglobin than the brain tissue oxygen monitor’s changes in PbtO2. In
general, however, the two different quantities may not necessarily be well correlated due
to the inverse S-shape of the hemoglobin dissociation curve [2], and due to the fact that
different regions of the brain were probed by the two monitors. rCBF (and ∆THC) fell
an average of -4.4% (and -0.4 µM).
A study by McLeod et al. also measured blood oxygenation with NIRS in comparison
to brain tissue oxygen tension in eight patients with head injury [147]. They began at the
patient’s baseline FiO2 for 10 minutes, then increased to 100% for 30 minutes. Although
the duration of induced hyperoxia in their study was much longer (and therefore provides
an explanation for greater magnitudes of change), their results have a trend similar to ours:
2.80 µM increase in ∆HbO2, -5.2 µM drop in ∆Hb, -2.4 µM drop in ∆THC, 117.5 mmHg
increase in PbtO2, and no significant change in MAP or ICP.
Numerous studies on healthy subjects have found a varying magnitude of CBF decrease
with induced hyperoxia, ranging from -27% to -10.8% as reviewed by Johnston et al. [113].
197
Also on healthy individuals, Floyd et al. measured an even larger drop in rCBF (-33%)
with continuous arterial spin-labeled perfusion MRI [72]. For those with severe head in-
jury, the typical response is as yet unsubstantiated. Menzel et al. used stable xenon-CT
to measure six patients with severe traumatic brain injury, with 35% inspired oxygen for
baseline scan and 60% for second scan [153]. They found a global CBF decrease of -9%,
and for an undamaged region of interest (as determined by noncontrast CT), a regional de-
crease of -19.3%. This may support results found by DCS in that the magnitude of decrease
found in a head injured population is less than those reported in healthy subject literature.
However, caution must be taken in directly comparing results from DCS (where FiO2 was
increased from baseline value to 100%, not 35 to 60%).
Another study by Rosenthal et al. on fourteen TBI patients also observed a decrease
in rCBF (-22.6%) using a thermal diffusion probe, but with greater magnitude than that
found by Menzel et al. and by our study [195]. This differential may be explained by
the fact that they maintained 100% inspired oxygen for 20 minutes as compared to our 2
minutes.
The results of this pilot study suggest hybrid diffuse optical devices utilizing DCS/DOS
technology has the potential to be implemented as a bedside monitor of CBF and blood oxy-
genation in the neuro-intensive care unit. When brain-injured patients underwent periods
of induced hyperoxia, DCS/DOS detected changes in frontal cortical microvascular CBF
and blood oxygenation that were in general agreement with vitals measurements provided
by invasive intraparenchymal monitoring devices. Further studies are warranted to examine
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the utility of DCS/DOS continuous bedside monitoring in the neurocritical care unit.
6.3 Conclusion
In this chapter, we demonstrated feasibility of a hybrid diffuse optical device as a contin-
uous, non-invasive bedside monitor for severely brain-injured patients in the neurocritical
care unit. We had already shown that DCS measurements of relative CBF were shown to
correlate with relative CBF values measured by a ”gold-standard” CBF technique: xenon-
enhanced CT. Thus, following this validation, we demonstrated the hybrid diffuse optical
device can also monitor significant changes in CBF and blood oxygenation during two
common clinical interventions: head-of-bed elevation change and induced hyperoxia. This
opens the door for DCS/DOS add to the array of bedside monitors currently used in the
neurocritical care unit to give clinicians additional information on cerebral hemodynamics
during various interventions. Future studies include long-time monitoring (>24 hours) to
investigate the effects of other types of interventions such as drug administration or suc-
tioning.
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Chapter 7
Use of DCS at High Altitudes
High altitude has profound cerebrovascular effects on those that work, live, or are stationed
at heights greater than 2400 m (8000 ft above sea level). For them, high altitude cerebral
edema (HACE), or the swelling of brain tissue from fluid leakage, is a common cause
of death; the only treatment for HACE in current use is immediate descent. But because
edema is also found frequently in severe brain injury, it has been hypothesized that methods
proven to successfully treat patients in the neurocritical care unit could also help those
with altitude sickness, i.e., without forcing them to descend. For instance, treatments like
oxygen administration and some medications have proven themselves useful as temporary
relief until descent [86].
High altitude scientists would likely benefit greatly from a portable and continuous
monitor of CBF in order to investigate therapies and their effect on blood flow in such
an environment. Currently, near-infrared spectroscopy (NIRS) and transcranial Doppler
(TCD) are options, but these techniques are surrogate measures of CBF. Diffuse correla-
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tion spectroscopy (DCS) could provide a compact, continuous technique for monitoring
changes in CBF at high altitudes.
This chapter describes a first attempt to use DCS as a monitor of relative CBF at high
altitude. We utilize a hyperventilation intervention. Hyperventilation is the simplest of the
treatments for high intracranial pressure (ICP) used in the neurocritical care unit, but it is
also known to decrease CBF at sea level. Its use at high altitude could lead to possible
ischemia, since those at altitude already suffer from respiratory alkalosis (high blood pH)
[86]. However, we wanted to directly measure the effects on CBF of hyperventilation at
high altitude, to determine whether blood flow indeed decreases as a result, as it does at sea
level. Also note that this work is currently being prepared for publication.
7.1 Effects of High Altitude
Due to lower atmospheric pressure, high altitudes affect humans because of a lowered par-
tial pressure of oxygen. Acute exposure to high altitude hypoxia can cause pathophysio-
logical changes that manifest as a spectrum of disorders ranging from the relatively benign
high-altitude headache to life-threatening high-altitude cerebral edema. One study that
looked at trekkers in Nepal found that the incidence of HACE was 21%, and that there
were 8 altitude illness-related deaths for every 100,000 trekkers [129].
In addition, the potential long-term neurological sequelae from travel to high-altitude
are beginning to be appreciated with magnetic resonance imaging (MRI) evidence of cor-
tical atrophy, white matter changes and enlargement of Virchow-Robin spaces [66], and
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Figure 7.1: One possible train of effects of high altitude on humans. Ascent to altitude can
cause a number of disorders ranging from altitude sickness to life-threatening high-altitude
cerebral edema.
persistent cognitive impairment [29]. While these changes seem to be related to cerebral
hypoxemia [245], the underlying pathophysiology remains elusive with the cerebrovascu-
lar response to altitude incompletely characterized. Cerebral oxygenation is determined by
arterial oxygen content, oxygen consumption and CBF. In turn, CBF is subject to different
regulatory mechanisms than peripheral blood flow and is known to be particularly reactive
to changes in arterial carbon dioxide (CO2).
High altitude illness begins with mild to moderate acute mountain sickness (AMS),
characterized by symptoms such as headache, nausea, fatigue, and sleep disturbance [10].
Severe AMS, if left untreated, may develop into life-threatening HACE. The exact mecha-
nism causing these syndromes is unknown, but raised ICP found in those with moderate to
severe AMS has led to one proposed chain of events shown in Figure 7.1 [190, 85]. First,
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a subject ascends to high altitude (>2400 m) where the oxygen concentration is low due to
low atmospheric pressure. This causes cerebral hypoxia, or a reduced supply of oxygen to
the brain, which in turn then leads to a dilation of the blood vessels in the body’s attempt
to increase oxygen supply by increasing blood flow. It is also thought that the blood-brain
barrier decreases in permeability [10]. The increased CBF and blood volume in the brain
can lead to an increase in ICP, and can cause the brain to swell.
Severity of injury depends on rate of ascent (faster → more dangerous), maximum
altitude attained, and amount of physical activity at altitude. There also seems to be an
individual’s own susceptibility to altitude, i.e. some people are more susceptible to AMS
than others. Individual susceptibility is due, in part, to how familiar one is with being at al-
titude (e.g. sherpas, experienced trekkers, or those raised and living at high altitudes versus
visitors to high altitude). For instance, one study looked at over 3000 adult tourists who
traveled to the Rocky Mountains of Colorado and found that the biggest factor influencing
those who developed AMS was a permanent residence below 900 m (3000 ft) [99].
Another theory in line with the cascade of events shown in Figure 7.1 is that those who
have ”tight brains”, i.e., a smaller ratio of cranial cerebrospinal fluid to brain volume, are
more susceptible to AMS [85]. This is because they are less able to tolerate brain swelling
through the displacement of cerebrospinal fluid than those with higher ratios. Some recent
imaging evidence has supported this ”tight-fit” hypothesis [253, 116].
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Figure 7.2: Effects of hyperventilation on humans at sea level. Hyperventilation is the state
of breathing faster or deeper than normal, causing excessive explusion of carbon dioxide
and ultimately a decrease in cerebral blood flow.
7.2 Hyperventilation as Possible Treatment
As mentioned in Section 1.3, hyperventilation is one simple procedure that can be em-
ployed to decrease ICP in severely brain-injured patients. Hyperventilation is defined as a
state of breathing faster or deeper than normal. Hyperventilation can cause the excessive
expulsion of CO2. Figure 7.2 shows the cascade of events that result from hyperventilation
at sea level, and its cerebrovascular effects. The subject begins to breath faster and deeper
than normal, blowing out excessive CO2. This causes the blood pH to rise, making it more
alkaline, and leading to vasoconstriction and a drop in CBF. In the case of head trauma
management, this drop in cerebral blood volume would cause a subsequent and relieving
decrease in ICP, possibly reducing the risk for secondary injury.
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However, it is unknown what happens to CBF when humans hyperventilate at high
altitudes. One study used NIRS on 20 healthy subjects at sea level, 2770 m, 3560 m, and
4680 m [106]. They found that hyperventilation caused end-tidal carbon dioxide (EtCO2)
to reduce to approximately 50% of baseline level, while cerebral tissue oxygen saturation
(StO2) decreased with hyperventilation for sea level and 2770 m. However, interestingly,
StO2 remained unchanged at 3560 m and increased at 4680 m.
Other studies have used TCD-measured cerebral blood flow velocity as a CBF surrogate
during hyperventilation. One study looked at cerebral blood flow velocity (CBFV) in the
middle cerebral artery (MCA) of 43 subjects without AMS, 17 subjects with AMS, and
20 sherpas [110]. All were at an altitude of 4243 m, and after hyperventilation, all three
groups saw decreases in MCA flow velocity. But the AMS subjects saw a greater decrease
in flow velocity than the non-AMS subjects and the sherpas. There was no difference in
CBFV change between the non-AMS subjects and the sherpas. Another TCD study saw
a similar decrease of -34% in CBFV after being at an altitude of 4559 m for about a day
[138].
7.3 Study Motivation
Studies of cerebral hemodynamics at altitude have been hampered by the lack of an ef-
fective method to monitor intracranial microvascular perfusion. DCS has the ability to fill
this niche, as it provides a non-invasive, portable way to measure relative cortical blood
flow. Importantly, it does not rely on the principles of tracer clearance and is a continuous
205
measure of CBF changes. DCS modules are simple to build (see Section 3.2.5), and can be
made both compact and study enough to survive ascent to high altitudes.
Hyperventilation will naturally cause a decrease in CBF at sea level, but may cause an
increase in CBF after ascent. If this is the case, hyperventilation (or any physical activity
causing heavy breathing) could aggravate altitude-related illness rather than reduce it. If
this is not the case, hyperventilation could be explored as a method to help alleviate altitude-
related illness.
Using our lab-built DCS device with concurrent measurements of StO2 from a commer-
cial diffuse optical spectroscopy (DOS; otherwise known as near-infrared spectroscopy)
module, we sought to elucidate the effects of altitude and acclimatization on cerebral hemo-
dynamics and oxygenation during hyperventilation. We also used TCD measurements of
CBFV to see whether the microvascular changes in CBF seen by DCS would match com-
monly measured large-vessel CBFV.
7.4 Methods
Approval for this study was obtained from the ethics committees of the University of Turin
and University College London. All participants underwent medical screening and writ-
ten informed consent was obtained after the possible risks of the study were explained.
Twelve subjects ranging in age from 22 to 80 years, with varying degrees of experience at
altitude were recruited from the 2010 Xtreme Alps Medical Research Expedition. None
had traveled to altitude during the previous three months, nor had any history of cardio-
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vascular, respiratory or neurological disease. Subjects were initially studied in London,
UK at a baseline altitude of 75 m above sea level prior to the expedition. High altitude
measurements took place at the Capanna Regina Margherita1 at 4559 m.
The presence of AMS symptoms was collected using a self-reported Lake Louise scor-
ing system questionnaire at approximately 6 a.m. daily. Subjects with symptoms of AMS
severe enough to require treatment with dexamethasone or acetazolamide were excluded
from further participation in the study after they began treatment.
7.4.1 Optical Instrumentation
We used a house-built, two-channel multi-wavelength DCS module modified specifically
for this study (see Section 3.3.3). The module includes 785 nm and 830 nm long-coherence
length continuous-wave lasers, two single-channel avalanche photodiodes, and a 2-channel
hardware correlator. The probe had a source-detector separation of 2.5 cm, and we used a 2-
to-1 detector fiber bundle to increase signal-to-noise. Relative cerebral blood flow (rCBF )
data is calculated every 3 seconds.
A commercial DOS device, the Fore-sight Absolute Cerebral Oximeter (Casmed; Bran-
ford, CT, USA), uses 4 wavelengths of near-infrared light (690, 780, 805, and 850 nm) to
calculate absolute cerebral tissue oxygen saturation (StO2). The probe has two source-
detector separations, and measurements of absolute StO2 are obtained once every two sec-
onds. A wool cap was then placed over the probe to minimize interference from ambient
1The Capanna Regina Margherita is a hut built on the top of Punta Gnifetti (4559 m) in the Italian Alps
with an observatory for scientific studies beside it.
207
light and to apply a constant, even pressure.
The DOS device provided absolute StO2 at both baseline (resting) and during hyper-
ventilation, and those values were used in conjunction with measurements of intensity
changes from both lasers of the multi-wavelength DCS module. Using these intensity
changes, we used the differential pathlength method (see Section 2.1.4) to calculate changes
in oxy- and deoxyhemoglobin concentrations (∆HbO2, ∆Hb). With this information, we
could then find values of absolute oxy- (HbO2), deoxy- (Hb), and total hemoglobin con-
centrations (THC). Changes in absorption were calculated and used in fitting the temporal
intensity autocorrelation functions to extract blood flow index (BFI). Scattering was as-
sumed to remain constant.
7.4.2 Transcranial Doppler Ultrasound
Transcranial Doppler ultrasound was assessed using the Sonosite MicroMaxxTM (Sonosite;
Bothell, WA, USA), a handheld ultrasound device [252]. A 5-1 MHz transducer was used
to insonate the subject’s MCA via the right temporal window. The clinoid process of the
sphenoid bone, the Circle of Willis and the distal internal carotid artery were initially lo-
cated, and then the identification of the M1 segment of the MCA was characterized by flow
towards the transducer. An optimal portion of the MCA without branches and with laminar
flow was then selected and the depth recorded. Once identified, the center of the artery was
insonated resulting in values of peak systolic velocity (PSV). On subsequent studies, every
effort was made to insonate the same depth (to within 1 mm).
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Figure 7.3: Hyperventilation protocol. Subject lays supine with DCS/DOS probes attached
and relaxes. During this time, baseline values are recorded for 5 minutes. The subject then
hyperventilates until their end tidal carbon dioxide (EtCO2) level reaches 50% of baseline.
This EtCO2 level is maintained and a second set of data is taken.
7.4.3 Systemic Vitals
An in-line capnograph (EMMA Capnometer, Phasein Medical Technologies; Danderyd,
Sweden) was used to record end-tidal CO2 (EtCO2) values via a tight-fitting face mask
both at pre-study baseline and throughout the hyperventilation protocol. Peripheral arterial
oxygen saturation (SpO2) was monitored by a near-infrared pulse oximetry probe (Nonin,
Onyx model 9500; MN, USA) placed on the finger.
7.4.4 Hyperventilation Protocol
Figure 7.3 outlines the hyperventilation protocol. Subjects were positioned supine and
asked to relax. DCS/DOS probes (one per subject) were affixed above the brow overlying
the left/right hemispheres, being careful to avoid the frontal and superior sagittal sinuses.
Baseline values of PSV from the MCA were obtained by the TCD operator, and once
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Figure 7.4: Study protocol. The hyperventilation experiment is repeated at on the same
subjects at 3 different timepoints: 1) 75 m above sea level, 2) 4559 m above sea level after
2 days at altitude, 3) 4559 m above sea level after 7 days at altitude. Subjects ascended first
to 3611 m for two days, then proceeded to 4559 m.
proper DCS/DOS signal had been confirmed, rCBF and StO2 baseline data were taken for
5 minutes. Subjects were then asked to hyperventilate to 50% of their baseline EtCO2, with
verbal feedback and instruction given to the subject regarding depth and rate of respiration
based on readings from the capnograph. After achieving this target, the subject maintained
the level of EtCO2 for 3 minutes, an additional set of DCS/DOS/TCD measurements were
obtained.
This hyperventilation protocol was to be repeated on the same subjects at three different
time-points (see Figure 7.4): 1) 75 m above sea level, 2) 4559 m above sea level after 2
days of being at altitude, 3) 4559 m above sea level after 7 days of being at altitude. Ascent
was by cable car and on foot, with two days spent acclimatizing at 3611 m.
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7.4.5 Statistical Analysis
Mean changes in each cerebral and systemic physiological parameter due to hyperventi-
lation and each timepoint were computed from continuous time-series data by taking the
average (〈〉) during the 5-minute time period (tBL) of rest as baseline for comparison against
the 3-minute hyperventilation time period (tHV ). Periods were defined as those data mea-
sured after the optical signal had stabilized, with all data during the hyperventilation tran-
sition and all motion artifacts excluded from the analysis. Differential values for DOS data
as well as for systemic vitals were defined as
∆Y = 〈Y (t0o)〉 − 〈Y (t30o)〉, (7.1)
with Y representing the parameter of interest. For DCS/TCD data, a percentage change
from baseline was employed to compute rCBF /relative PSV (rPSV), as follows:
rCBF =
〈BFI(tHV )〉 − 〈BFI(tBL)〉
〈BFI(tBL)〉
, (7.2)
and
rPSV =
〈PSV (tHV )〉 − 〈PSV (tBL)〉
〈PSV (tBL)〉
. (7.3)
Data are expressed as mean ± standard deviation (SD). We wanted to test for four
different hypotheses. First, we used a one-way ANOVA test to determine whether there was
evidence of differences between baseline (resting) means of the physiological parameters
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Table 7.1: Number of subjects included in each timepoint.
Timepoint Altitude No. of Subjects
1 Sea Level N = 12
2 Day 2 at 4559 m N = 9
3 Day 7 at 4559 m N = 7
measured at each of the three timepoints: sea level, 2 days and 7 days at altitude. Second,
we again used a one-way ANOVA test to see if induced changes from hyperventilation
are different among the three timepoints. Third, a two-tailed Student’s t-test was used to
determine whether the induced changes themselves were significant. Lastly, correlations
between parameters were performed using Spearman’s correlation. Statistical significance
was defined as a P-value smaller than 0.05.
7.5 Results
Out of twelve initial subjects, data were collected on nine subjects at the second timepoint
(2 days at altitude) and seven at the third timepoint (7 days at altitude). Incomplete data
were a result of two subjects that had developed severe AMS before the second timepoint,
who then required treatment with dexamethasone or acetazolamide; these subjects con-
tributed data only to the sea level, or first, timepoint. One subject was left the study right
after the sea level measurement, and another was excluded prior to the third timepoint. Fi-
nally, a subject was unable to tolerate maximal hyperventilation on day 7 at altitude and
was thus excluded. Table 7.1 outlines the number of subjects included in each timepoint of
the study.
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Table 7.2: Baseline (resting) physiology at sea level, 2 days at altitude, and 7 days at
altitude.
Parameter Sea Level Day 2 at Day 7 at P-value
Altitude Altitude
EtCO2, kPa 4.5 ± 0.8 3.3 ± 0.4 † 3.2 ± 0.4 † <0.001
SpO2, % 98.0 ± 1.5 80.5 ± 4.3 † 84.4 ± 5.8 † <0.001
StO2, % 69.5 ± 4.4 65.0 ± 5.4 62.2 ± 4.1 † 0.005
THC, µM 71.4 ± 28.4 61.8 ± 13.1 63.9 ± 10.2 0.502
HbO2, µM 49.2 ± 18.5 40.0 ± 8.7 39.6 ± 6.0 0.172
Hb, µM 22.2 ± 10.5 21.9 ± 5.5 24.3 ± 5.3 0.779
PSV, cm/s 82.4 ± 15.6 100.9± 32.4 84.6 ± 27.8 0.203
Values listed as mean ± SD; P-values from one-way ANOVA test; † Significantly different from sea level; ‡
Significantly different from 2 days at altitude.
7.5.1 Effects of Altitude on Baseline Physiology
Baseline (resting) values of both systemic and cerebral parameters are shown in Table 7.2,
with significant differences between timepoints noted. EtCO2 decreased from 4.5 kPa ±
0.8 kPa at sea level to 3.3 kPa ± 0.4 kPa after 2 days at altitude. The change in EtCO2
between days 2 and 7 at altitude was not significant. Baseline SpO2 decreased from 98.0%
± 1.5% at sea level to 80.5% ± 4.3% at day 2 at altitude. At day 7 at altitude, baseline
SpO2 was 84.4%± 5.8% – still significantly lower than sea level, but not different than day
2.
In contrast to peripheral oxygen saturation, baseline cerebral oxygen saturation contin-
ued to decline throughout each of the three timepoints, although the drop was only signif-
icant between sea level and day 7 at altitude. StO2 decreased from 69.5% ± 4.4% at sea
level to 65.0% ± 5.4% after 2 days at altitude, and further to 62.2% ± 4.1% on day 7.
All the other baseline cerebral oxygenation parameters (THC, HbO2, Hb) did not change
among the three timepoints.
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Table 7.3: Effects of hyperventilation at sea level, 2 days at altitude, and 7 days at altitude.
Parameter Sea Level Day 2 at Day 7 at P-value
Altitude Altitude
∆SpO2, % 0.9 ± 1.4 15.9 ± 6.7 ?† 13.9 ± 5.2 ?† <0.001
∆StO2, % -5.1 ± 2.0 ? 5.2 ± 3.3 ?† 2.5 ± 5.4 † <0.001
∆THC, µM -5.1 ± 10.4 -3.1 ± 3.1 ? -1.5 ± 2.3 0.473
∆HbO2, µM -7.1 ± 6.2 ? 0.9 ± 3.3 † 0.3 ± 3.1 † 0.001
∆Hb, µM 2.0 ± 5.1 -3.9 ± 2.3 ?† -1.7 ± 4.0 0.006
rPSV, % -33.1 ± 12.8 ? -32.6 ± 21.4 ? -34.0 ± 9.7 ? † 0.980
rCBF , % -20.9 ± 13.2 ? -25.7 ± 16.3 ? -31.2 ± 24.9 ? 0.440
Values listed as mean ± SD; ? Significant change with hyperventilation; P-values from one-way ANOVA
test; † Significantly different from sea level; ‡ Day 7 significantly different from day 2 at altitude.
Baseline PSV also did not change significantly from sea level to either day at altitude.
7.5.2 Effects of Altitude on Response to Hyperventilation
Table 7.3 summarizes changes in systemic and cerebral parameters induced by hyperventi-
lation at all three timepoints.
The study cohort’s peripheral and cerebral oxygen saturation responses to hyperventi-
lation are shown in Figure 7.5. Hyperventilation increased SpO2 at altitude, but remained
unchanged at sea level. After 2 days at altitude, hyperventilation induced an increase in
SpO2 of 15.9% ± 6.7%, and after 7 days, 13.9% ± 5.2%.
Following hyperventilation, StO2 decreased -5.1%± 2.0% at sea level. But after 2 days
at altitude, hyperventilation resulted in an increase in cerebral oxygen saturation of 5.2%±
3.3%. After 7 days at altitude, hyperventilation did not induce a significant change in StO2.
Changes in total hemoglobin concentration were not affected by altitude, but changes in
oxy- and deoxyhemoglobin concentration at 2 days after being at altitude were different
from sea level. ∆HbO2 decreased -7.1 µM ± 6.2µM at sea level, but did not change with
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Figure 7.5: Bar plot showing peripheral and cerebral oxygen saturation changes with hy-
perventilation. The hyperventilation protocol was performed at three timepoints: 1) ap-
proximately sea level (SL), 2) 4559 m above sea level after 2 days at altitude, 3) 4559 m
above sea level after 7 days at altitude.
hyperventilation at either altitude timepoints. On the other hand, ∆Hb saw no change at
sea level or 7 days at altitude, but dropped -3.9 µM ± 2.3 µM after 2 days at altitude.
Figure 7.6 shows changes in PSV and CBF with hyperventilation, and the effects of high
altitude on cohort response. rPSV dropped with hyperventilation at all three timepoints,
with no significant difference in magnitude between sea level and high altitude. rPSV at
sea level decreased -33.1% ± 12.8%, -32.6% ± 21.4% after 2 days at altitude, and -34.0%
± 9.7%.
DCS measured a decrease in rCBF of -20.9% ± 13.2% at sea level, -25.7% ± 16.3%
after 2 days at altitude, and -31.2% ± 24.9% after 7 days. There was a trend towards more
pronounced decreases in CBF with hyperventilation with increasing time at altitude, but it
did not reach significance.
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Figure 7.6: Bar plot showing cerebral blood flow changes with hyperventilation. The hy-
perventilation protocol was performed at three timepoints: 1) approximately sea level (SL),
2) 4559 m above sea level after 2 days at altitude, 3) 4559 m above sea level after 7 days at
altitude.
7.5.3 Correlations Between Parameters
Baseline SpO2 was correlated with baseline StO2 (ρ = 0.52, P = 0.003). Baseline PSV
correlated significantly with baseline StO2 (R = -0.52, P = 0.003) as well as with SpO2
(R = -0.37, P = 0.039). However, as seen in Figure 7.7, no association was found between
changes in rCBF and rPSV with hyperventilation (ρ = -0.02, P = 0.91). rCBF was also
not correlated with changes in any of the DOS parameters.
7.6 Discussion
We have reported the changing, dynamic relationship between peripheral oxygenation,
cerebral oxygenation, and cerebral blood flow that occurs with hyperventilation after as-
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Figure 7.7: Scatter plot illustrating the correlation between rCBF (as measured by DCS)
and rPSV (as measured by TCD). The fit line has a slope of 0.13 and an offset of -20%. No
significant correlation was found between the two modalities.
cent to altitude and following partial acclimatization. There are several novel findings in
this study. Firstly, we have demonstrated the feasibility of using DCS to measure corti-
cal blood flow with a high temporal resolution in an austere environment. We have also
documented the effects of voluntary hyperventilation on cerebral oxygenation and cerebral
blood flow over time spent at high altitude. And lastly, on an instrumentation front, we
have successfully implemented multi-wavelength DCS in a compact, rugged module for
monitoring both cerebral blood flow and oxygenation changes simultaneously.
Peripheral oxygen saturation decreased after 2 days at altitude and then rebounded par-
tially after 7 days at altitude, but still remained lower than sea level. Cerebral oxygen
saturation, on the other hand, continued to decrease from 2 to 7 days, and the difference
from sea level reached significance after 7 days. This demonstrates a differential effect
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of acclimatization on peripheral and cerebral oxygenation. This divergence may be at-
tributable to the differences in the vascular response to arterial CO2 between the periphery
and the central nervous system. Interestingly, at simulated extreme altitudes, Hornbein et
al found a significant correlation between subjects with a more pronounced hypoxic venti-
latory response (HVR) and increased impairment on a variety of cognitive tasks [102].
This contrasts with other reports demonstrating improved climbing performance in sub-
jects with a higher HVR [144, 167, 202]. This dichotomy between athletic and cognitive
performance parallels the divergence between peripheral and cerebral oxygenation seen in
the present study. Subjects with a more pronounced HVR are better able to increase periph-
eral oxygenation. However, this also results in hypocapnia which leads to cerebral vaso-
constriction, exacerbating cerebral hypoxia. Thus, those travellers to very high altitudes
that are most adapted to deal with the physical rigors of altitude may be most susceptible
to cerebral hypoxia and the associated structural and functional changes.
This study is the first of its kind to utilize the absolute cerebral oximeter in the assess-
ment of cerebral oxygen saturation. Previous studies have relied on examining regional
cerebral saturation trends making direct comparisons with peripheral saturation difficult.
However, the inherent weakness of cerebral DOS technology remain [174]. DOS monitors
measure the saturation of oxy- and deoxyhemoglobin in all biological material beneath the
probe (arterioles, capillaries, tissue, and veins) and assumes a stable ratio of arterial-to-
venous compartment volumes. Therefore, relative changes in these compartment volumes
could also lead to changes in StO2 [94]. This is particularly relevant given the putative role
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of venous hypertension in the in the pathogenesis of AMS/HACE [254, 250, 252].
Hyperventilation on day 2 at 4559 m caused both peripheral and cerebral oxygen sat-
uration to return to sea level values. In the non-acclimatized subject, the normalization
of peripheral oxygenation probably overcomes the negative effects of hypocapnic cere-
bral vasoconstriction to increase cerebral oxygenation. The situation after acclimatization,
however, is harder to explain. After hyperventilation on day 7 at 4559 m, peripheral oxy-
gen saturation again returned to its sea level value whereas cerebral oxygenation did not.
Thus, acclimatization abolished the initial improvement in cerebral oxygenation seen with
hyperventilation.
The ideal modality to measure CBF at high altitudes would provide a real-time, non-
invasive, portable quantification of absolute blood flow. While various techniques have
been used to approximate cerebral blood flow at altitude, all have important shortcomings
[180]. Severinghaus applied the Kety-Schmidt nitrous oxide technique [119] at altitude,
demonstrating an initial increase in CBF of 24% 6 to 12 hours after ascent, declining to 13%
above baseline after 3 to 5 days of acclimatization [207]. However, this modality requires
that CBF be at steady state and is not appropriate for dynamic studies as the temporal
resolution is poor.
Transcranial Doppler ultrasound is currently the most common method for estimating
CBF at altitude. The accuracy of this measurement is predicated on the assumption that
MCA diameter remains constant at altitude and assumes no regional variation. An increase
in measured CBFV may reflect either a decrease in MCA diameter and thus a net decrease
219
in CBF, or an increase in diameter of smaller arteries and arterioles downstream from the
MCA and thus a net increase in CBF. Although several studies have demonstrated that
MCA diameter changes less than smaller intracranial vessels with small, acute changes in
blood pressure or CO2 [76, 206], a more recent study demonstrated that MCA diameter
changes significantly with altitude [251]. More recently, it has been shown that intact or
partially intact cerebral vascular responses to CO2 are associated with poor correlation
between CBFV and CBF [200].
Diffuse correlation spectroscopy was successfully used for the first time in a high alti-
tude environment. We modified a module specifically for this study – added an additional
wavelength of laser, made the instrument rugged and portable, and used our DCS device
in conjunction with a commercial DOS device to get absolute optical properties of tissue.
Both probes and software were made user-friendly – enough so to be operated solely by a
medical doctor with no prior training in optics for use on all this study’s experiments. Fu-
ture versions of the device could be improved in various ways for further implementation
at high altitudes.
In this study, DCS measured a consistent reduction in CBF with hyperventilation at all
timepoints. There was a trend towards a larger drop in CBF with hyperventilation with
increasing time at altitude, but it was not significant. This potential exaggeration of the
hypocapnic vascoconstrictive response with increasing time at altitude is in agreement with
the findings of Lucas et al [135]. It also may explain why the initial improvement in
cerebral oxygen saturation via hyperventilation is abolished with increasing time at altitude.
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The larger decrease in CBF overcomes the increase in peripheral oxygen saturation, leading
to an overall no change in cerebral oxygenation.
Although DCS signals consistently demonstrated the expected reduction in rCBF fol-
lowing hyperventilation, there was considerable inter-subject variability that may reflect
physiological differences in reaction to altitude and acclimatization (see Section 7.1). Larger
studies and further refinements in technique are necessary to reduce inter-subject variabil-
ity.
There was no correlation between relative changes in CBFV as measured by TCD and
CBF as measured by DCS. The two techniques differ considerably in what they are mea-
suring, and thus this lack of correlation is not completely surprising. TCD measures flow
velocity through the MCA and thus is a global indicator of changes in flow dynamics, re-
flecting changes to a large region of the concerned hemisphere and measures velocity of
flow rather than flow. It is thus susceptible to misinterpretation when the diameter of the
measured vessel changes. DCS measures regional cortical perfusion in a small portion of
tissue and reflects changes in a focal region of brain parenchyma.
7.7 Conclusion
Hyperventilation induced lowered cerebral blood flow and velocity both at sea level and at
altitude. Diffuse correlation spectroscopy was shown to be a promising technology with
the potential to increase our understanding of changes in cerebral blood flow at altitude.
Larger studies and further refinements in technique are necessary to reduce inter-subject
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variability.
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Chapter 8
Conclusions and Future Work
This dissertation has emphasized the translation of hybrid diffuse optics, i.e., the combi-
nation of diffuse optical spectroscopy (DOS) and diffuse correlation spectroscopy (DCS),
to the neurocritical care unit. Prior to this work, hybrid diffuse optics had been tested on
animal brain and to some extent in human applications (e.g. healthy subjects, neonates,
ischemic stroke patients). But DCS/DOS had not been used to investigate a severely brain-
injured population before.
Neurocritical care patients could benefit from a continuous cerebral blood flow and oxy-
genation monitor. They are in danger of secondary injury while residing in the intensive
care unit, e.g., following a severe primary insult such as traumatic brain injury or ruptured
aneurysm. Clinicians now routinely monitor intracranial pressure (ICP), which has lead to
lower mortality rates, but ICP can only serve as a surrogate measure of perfusion. Addi-
tional information about the state of their cerebral physiology could help prevent further
brain damage and even death. My work suggests that DCS/DOS should add significantly
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to the existing monitoring tools.
In Chapter 4, we described the first successful validation of DCS-measured cerebral
blood flow in adults, against gold-standard method stable xenon-enhanced computed to-
mography. This experiment showed good agreement between the two techniques, and since
the study cohort was comprised of brain-injured patients, it took first steps towards estab-
lishing that DCS could serve as a blood flow monitor in the neurointensive care unit.
The study outlined in Chapter 5 stemmed from the need to understand the normative
response of head-of-bed manipulation. We had looked at the response of brain-injured
patients, and wanted to know what DCS/DOS would measure in healthy controls. From
that need, it was decided that an entire study could be born out of this idea – the effects of
age on normative responses to not just head-of-bed manipulation, but a supine-to-standing
posture change. Results showed that healthy subjects across the age spectrum experience
significant postural declines in frontal cortical blood flow. This study also showed that
hybrid diffuse optics is easily implemented for studying cerebral hemodynamics in healthy
subjects across the age spectrum.
Chapter 6 explored experiments done with DCS/DOS monitoring during two simple
and common interventions performed regularly in the neurointensive care unit: head-of-
bed manipulation and induced hyperoxia. This was an exercise in identifying what issues
might fall upon us while monitoring cerebral hemodynamics in this type of patient popu-
lation. We also wanted to see if hybrid diffuse optics could provide additional information
about patient condition. DCS/DOS was able to detect differences in cerebral hemodynamic
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responses of brain-injured patients versus healthy controls during posture change. During
induced hyperoxia, both the invasive brain tissue oxygen and DOS monitors observed in-
creases in oxygenation, but the relative changes differed. Overall, knowing real-time, con-
tinuous, unpredictable trends in blood flow and oxygenation gives clinicians extra valuable
information, particularly in situations and interventions by the bedside where they would
ordinarily be somewhat steering blindly.
Lastly, we took our lab-built instrumentation to the heights of the Italian Alps for a
unique opportunity to measure cerebral hemodynamics on adults at high altitude. Many
of the issues seen in those afflicted by severe altitude-related illness are similar to those of
neurocritical care patients. Thus, we investigated whether hybrid diffuse optics could help
those in danger of high altitude cerebral edema, which can lead to death if left untreated.
This represented the first time DCS was used in such an environment, and its successful
implementation led us to believe that it could be used as a much-needed high altitude blood
flow monitor.
The use of DCS continues to spread outside of our group, e.g., as other laboratories find
even more applications and uses. The main hurdles that prevent its eventual widespread
acceptance by clinicians include: 1) need for better probe interface engineering, 2) issues
with going though hair, 3) relative rather than absolute blood flow measurements. Groups
including ours are in the midst of tackling these challenges.
The trend in neurocritical care continues to move towards individualized medicine, and
to do so, clinicians must utilize multimodal monitoring. DCS/DOS, being non-invasive
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and relatively inexpensive, has the ability to easily fit in with other monitoring techniques
with little cost and potentially great benefit to patient outcome. Future work should involve
long-term (>12 hours) monitoring and looking at possible vasospasm detection.
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